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ABSTRACT 
Several lines of evidence obtained in a variety of human tumours support the 
theory of cancer stem cells (CSCs). The aim of this thesis was the isolation and the 
biomolecular characterization of the tumorigenic subpopulation of melanoma cells. 
Melanoma cells growing in stem cell medium as non-adherent colonies, here 
named 'melanospheres', were successfully isolated from melanoma specimens or 
from melanoma cell lines. Melanospheres displayed a self-renewal capacity and 
multipotency in vitro and were highly tumorigenic in vivo. Remarkably, 
melanosphere-derived xenografts maintained tumorigenic potential in subsequent 
recipients and mirrored the original melanoma of the patient. 
Melanospheres expressed a heterogeneous assortment of stem cell markers, 
and no direct and unique correlation between any of their phenotypes and in vivo 
tumorigenicity was found. 
Conversely, melanoma cells cultured in the presence of fetal calf serum 
displayed a lower tumorigenicity in SCID mice with limited engraftment capacity in 
secondary recipient animals. Moreover, adherent cell xenografts displayed a 
homogeneous phenotype for the expression of melanoma associated markers and 
contained cells with markers of full differentiation. 
Taken together our data provide further evidence on the heterogeneous nature 
of human melanomas and show that melanospheres and their xenografted 
tumours represent a useful model to investigate melanoma biology. 
The parent-to-progeny relationship between CSCs and tumour bulk does not 
necessarily reflect the well conserved and predictable rules operating in normal 
tissue development. CSCs may thus not be a static compartment but rather 
6 
sternness features can be acquired by tumour cells in response to environmental 
signals. Thus, in this thesis, experiments have been performed to define the role of 
tumour environmental factors produced by melanoma cells themselves or by cells 
composing the tumour stroma in modulating the acquisition of sternness properties. 
The results provided in this thesis indicated that melanospheres display an 
extensive secretory capacity quantitatively and qualitatively different from that of 
melanoma cells growing as adherent monolayer. The roles of these immune-
related factors in shaping melanoma heterogeneity, plasticity and tumour 
maintenance are discussed. 
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CHAPTER 1: INTRODUCTION 
1.1 STEM CELL AND CANCER 
1.1.1 Normal adult Stem Cells 
Normal adult stem cells (SCs) reside in most somatic tissues, where they are 
responsible for the maintenance of tissue homeostasis. These SCs are relatively 
rare and usually they do not express differentiation markers and they do not 
display other morphological features specific for the mature cells of the tissue they 
belong to. SCs are instead endowed with the ability to self-renew and to generate 
transit amplifying progenitors committed to differentiate. 
Self-renewal is defined as the ability of stem cells to go through numerous 
cycles of cell divisions maintaining constant their number for virtually unlimited 
period of time.· Stem cells, through asymmetric division, originate cells that 
maintain all the features of stem ness, and progenitor cells that instead will undergo 
progressive differentiation thus supporting both tissue and stem cell homeostasis 
(Reya et ai, 2001) (Figure 1.1). 
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Fig. 1.1 . Scheme of stem cell location and progeny. S: Stem cells; eT: early Transit 
amplifying cell ; T: transit amplifying cell ; M: mature cell. 
/ M -
<3 ~ / .. .. M 
eT ~ , M 
<3 
M. 
\. Stem Cell Niche J 
In conditions such as a serious tissue damage that affects SC compartment, 
SCs can divide symmetrically, thus generating cells and recovering the stem cells 
compartment. Stem cells can also remain in quiescent status and re-start 
proliferation needed only to maintain tissue homeostasis. 
Despite the importance of stem cell self-renewal, we are only beginning to 
understand how it is regulated . The coordinate activities of multiple pathways are 
required for a stem cell to self-renew. Wnt, Notch, Hedgehog as well as genes 
regulating chromatin structure such as Bmi-1 are crucial for the self-renewal of 
different adult stem cells (Molofsky et ai, 2004). The balance between self-renewal 
and differentiation is maintained by the interplay between these pathways and the 
differentiation signals received by the stem compartment from cells and other 
tissue components (cellular matrix, blood vessels), altogether constituting the" 
stem cell niche" (Morrison and Kimble, 2006). The main characteristics defining 
stem cells are summarized in Table 1.1. 
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Table 1.1 Stem cell features . (Adapted from Potten and Loeffler, 1990). 
Features Stem cells Transit cells Maturing cells 
1. Differentiation markers No Onset Yes 
2. Proliferation Yes Yes No 
3. Self-renewal Yes No No 
4. Generation of committed Yes Limited No 
progeny 
5. Tissue regeneration Yes (long term) Temporarily No 
6. Flexibility in options Yes Yes No 
1.1.2 Human Cancer Stem Cells 
1.1.2.1 The Cancer Stem Cells hypothesis 
Tumours differ from physiological tissues because they lose homeostatic 
mechanisms (Leong and Karsan, 2006); moreover tumour cells proliferate 
extensively, exhibit a heterogeneous phenotype and are composed by cells with 
varying clonogenic capacity and displaying some degree of plasticity (Hendrix et 
aI., 2003). 
Traditionally two models have been proposed to explain tumour heterogeneity: 
the stochastic (or clonal evolution model) and the hierarchical model. The 
stochastic model assumes that some mutant tumour cells with a growth advantage 
are selected and expanded. The stochastic event that governs tumour-initiating 
capacity can be intrinsic, such as the activation of critical molecular pathways or 
extrinsic, such as the requirement of the appropriate microenvironment. This 
indicates that genetically divergent clones of tumorigenic cells can arise and 
maintain malignant potential independently, also providing a basis for 
Understanding genetic mechanisms of therapy resistance acquired by cancer cells. 
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The stochastic model states that all cells with the same genetic alteration have 
equal potential to regenerate the tumour, thus, according to this model, the 
prospective isolation of tumour initiating cells is unfeasible. 
In contrast, the hierarchical model postulates that only a subset of cells 
composing the tumour mass is endowed with the ability to initiate and regenerate 
the tumour, suggesting the possibility to isolate tumour cells into fractions that are 
tumour initiating and non-tumour initiating, with only the former capable of 
sustaining tumour development. The tumour initiating cells have the capacity to 
self-renew, maintaining and also expanding the tumorigenic subpopulation of cells, 
but they are also able to differentiate into heterogeneous, non tumorigenic cancer 
cells that constitute the tumour bulk (Figure 1.2). 
11 
Figure 1.2 Models of cancer heterogeneity. According to the stochastic model , tumour cells are 
biologically equivalent, and their different behaviour is subjective to intrinsic and extrinsic factors . 
Therefore, tumour-initiating activity cannot be enriched by sorting cells based on intrinsic 
characteristics. The hierarchy model assumes the existence of biologically distinct classes of cells 
with differing functional abilities and behaviour. Some cancer cells possess self-renewal ability and 
are uniquely responsible of tumour initiation and progression, also giving rise to non-tumorigenic 
progeny that make up the bulk of the tumour. In this perspective, tumour-initiating cells can be 
identified and purified from the bulk nontumorigenic population based on intrinsic characteristics 
(adapted from Bonnet and Dick, 1997). 
Extrinsic ~ factors 
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A hierarchical relationship in normal and neoplastic tissues was first 
demonstrated by experiments taking advantage of radiolabeled leukemic cells . 
This technique enabled the precise measurement of proliferation and lifespan 
of cancer cells. The results clearly showed that human leukemic cells comprised 
two distinct cellular fractions each displaying different proliferation capacity: a fast 
cycling subset and a smaller, slow cycling fraction with a dormancy estimated to 
last from weeks to months. Moreover, the slow cycling fraction was able to 
generate the fast cycling cells thus suggesting that the slow cycling cells had 
similar properties to those observed for normal haematopoietic stem cells (HSCs). 
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Indeed, they were responsible for tumour maintenance and the concept of "cancer 
stem cells" (CSCs) was thus introduced for the first time. The "CSCs model" 
implies a hierarchical organization of tumour heterogeneity and in this perspective 
the tumour is viewed as a caricature of normal tissue development that retains a 
hierarchical even if aberrant organization with CSCs at the apex (Wang and Dick, 
2005). 
The currently accepted definition of CSC is a functional one. In fact, CSCs are 
identified as self-renewing cells that display in vivo tumorigenicity and that are able 
to generate phenotypic diverse progeny. When injected at low dose in 
immunocompromised animal CSCs are able to re-form tumours with the same 
features and heterogeneity of the tumour from which they were derived (Clarke, 
2005). Tumours generated by stem cells in primary host should be transplantable 
and maintained over serial in vivo passages. This concept led to the alternative 
definition of putative CSCs as Tumour Initiating Cell (TICs) (Figure 1.3) 
Figure 1.3. The gold standard assay for the study of CSCs. The gold standard assay that fulfils 
the functionally definition of CSCs (S) is the serial transplantation of cancer cell subpopulation in 
immunocompromised mice. In these assays, cells from mice bearing primary tumours are reisolated 
and re-injected into secondary recipients and so on . CSCs multipotency is confirmed by their 
capacity to generate a tumour that mirrors the cellular heterogeneity of the patient original tumour. 
(Adapted from Schatton and Frank, 2010). 
Dissociation eO 
• Oe~OO - ~ Isolation 0 --... 
NO TUMOR 
Observation 
Injection Dissociation 
t 
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Importantly, the CSC model makes no inferences on the cellular origins of 
cancers, and it does not require that tumorigenic cells are similar phenotypically, 
genetically, epigenetically or functionally to the normal stem cells of the same 
organ. How CSCs are generated is still an open issue. It has been proposed that 
CSCs may arise by genetic alteration of long-lived normal SCs (Reya et aI, 2001) 
as recently suggested for certain type of lung cancer (Kim et aI, 2005). 
Nevertheless, recent studies on haematopoietic malignancies indicated that 
CSCs may arise through oncogenic transformation of progenitors or of even more 
differentiated cell types (Jamieson et aI, 2004; Krivtsov et aI, 2006). In addition, 
CSCs could also originate because of epigenetic transformation occurring in a 
normal stem cell by a dysfunctional environmental niche (Houghton et aI, 2004). 
1.1.2.2 Human Cancer Stem Cells: definition of their phenotype 
Different approaches, previously used in haematological malignancies, have 
been employed to select putative CSCs from solid human cancers. CSCs have 
been selected exploiting their ability to form non-adherent colonies when seeded at 
clonogenic number in a suitable medium lacking serum but enriched in growth 
factors (EGF and bFGF). Sphere forming ability as a method to measure and 
isolate CSCs has proved successful for normal tissue and tumour of the brain 
(Singh et aI, 2003; Galli et aI, 2004), and for other solid tumours such as mammary 
and colon carcinomas (AI-Hajj et aI, 2003; Singh et aI, 2003; Galli et aI, 2004; 
Singh et aI, 2004; Ponti et aI, 2005; O'Brien et al 2007; Ricci-Vitiani et aI, 2007). A 
Second approach to selectively isolate CSCs is based on their prospective isolation 
from the tumour bulk using pre-defined-markers. Putative CSCs are directly sorted 
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out from the whole tumour mass using a combination of cell surface markers and 
the selected populations are then assayed in vivo for their ability to form tumours. 
This method has been successfully applied to tumours of haematological origin 
and more recently it has also been applied for solid tumours (Bonnet and Dick, 
1997; Matsui, et ai, 2004; AI-Hajj et ai, 2003; Singh et ai, 2004; Ma et ai, 2007; Li et 
ai, 2007; Prince et ai, 2007; Dalerba et ai, 2007; O'Brien et al 2007). Concerning 
solid tumours, the prospective identification of TICs is a challenging task because 
in most of the cases, little information is available on the hierarchical organization 
of the corresponding normal tissue and therefore the selection of markers 
potentially associated with the stem cell compartment becomes a difficult guess. 
For some solid tumours such as mammary and colon carcinoma, (AI Hajj et ai, 
2003; Ponti et aI., 2005; Ricci-Vitiani et aI., 2007) the application of the two 
methods for CSC isolation, direct isolation using pre-defined markers and in vitro 
expansion of sphere-forming subpopulation, leads to the identification of the same 
sUbset of cells further validating the notion that TICs can be pulled out from solid 
tumour by selecting in vitro a population of cells with sphere-forming capacity. 
Starting by single-cell suspensions obtained from human breast cancer specimens 
and using flow cytometry-assisted cell sorting, AI-Hajj and colleagues succeed in 
the isolation of a CD44+CD24- subset of breast cancer cells that exclusively 
possessed the capacity to generate tumours, when injected at low doses in 
immunocompromised mice. The xenografted tumours, mirrored the phenotype of 
the patient's tumour from which they were derived (AI-Hajj et aI., 2003). This same 
cell subset CD44+CD24- was also defined as TICs using the sphere forming assay 
(Ponti et aI., 2005). CD44, either alone or in combination with other markers, has 
also been proposed to identify the CSC subset in a variety of tumours including 
15 
colon (EpCAM+CD44+CD166+) (Dalerba et aI., 2007), pancreas 
(ESA+CD44+CD24+) (Li et aI., 2007), prostate (CD44+a2p1integrinhiQhCD133+) 
(Collins et aI., 2005; Patrawala et aI., 2005), head and neck (CD44+) (Prince et aI., 
2007) and ovarian cancer (Zhang et aI., 2008a). 
CSCs in human brain tumours expressed the cell surface antigen CD133 
(human prominin-1) (Singh et aI., 2003). CD133, identified as a cell surface antigen 
present in HSCs (Yin et aI., 1997), is a human five-transmembrane domain 
glycoprotein whose function is not well understood. With an experimental approach 
similar to that used in identifying breast CSCs, the injection of CD133+ but not of 
CD133- brain tumour cells resulted in xenograft formation. As few as 100 CD133+ 
cells produced serially transplantable xenografts that were phenotypically and 
histologically similar to the patients' tumour from which the CD133 cells were 
derived. Besides brain cancer, CD133 has been also investigated as marker for the 
CSC population in a variety of human cancers, including colon (O'Brien et aI., 
2007; Ricci-Vitiani et aI., 2007) and lung (Eramo et aI., 2008) cancers, 
hepatocellular carcinoma (Song et aI., 2009) and Ewing's sarcoma (Suva et aI., 
2009). CD133 expression has been also explored in melanoma, with evidence for 
an enhanced expression of CD133 (associated also to CD166 and of NGFR) in 
metastatic lesions (Klein et aI., 2007). Monzani and colleagues (Monzani et aI., 
2007) although examining a very limited number of cases, showed that CD133+ 
cells, isolated from melanoma samples, exclusively displayed the ability to grow as 
melanospheres and possessed enhanced in vivo tumorigenicity as compared to 
the CD133 negative counterpart. 
In pancreatic cancer, CD133 not only identifies CSCs but when coexpressed 
With CXCR4 it defines CSCs capable of initiating metastatic disease. Thus, while, 
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both the CD133+ CXCR4- and the CD133+ CXCR4+ fractions initiate disease at the 
primary site, only CD133+ CXCR4+ cells were capable to produce metastasis 
(Hermann et aI., 2007). Although CD133 enriches for CSC, it is not yet proved that 
every CD133+ cell represents a CSC, and the identification of additional CSC 
specific markers is still needed. 
It is probably reasonable to speculate that CSCs should be defined by a 
combination of several markers. The whole amount of data currently available for 
colon CSCs, goes in this direction and a recent paper seem to indicate that a 
combination of CD133, CD44 and CD26 will potentially identify colon CSCs also 
displaying metastatic capacity (Pang et ai, 2010). 
Another approach to identify tumorigenic fractions is based on the use of the 
side population (SP) assay. This assay exploits the inherent feature of stem cells to 
extrude cytotoxic dyes such as Hoechst33342. This phenotype is due to the efflux 
pump of the (ATP)-binding cassette (ABC) transporter protein family present on the 
plasma membrane in diverse cell types. CSCs, extruding Hoechst more rapidly, 
appear less fluorescent in flow cytometry analysis than the non stem cell 
counterpart. Hoechst-excluding SP cells sorted from many human established 
cancer cell lines (Patrawala et aI., 2005) were shown to be endowed with 
enhanced tumour formation capacity in vivo. Tumorigenic SP+ cells were also 
Sorted directly from human tumours. In primary musculoskeletal tumours, ranging 
from benign to high-grade sarcomas, SP+ but not SP- cells showed tumour-
initiating capacity; moreover, the percentage of SP+ cells detectable in the primary 
tumour was directly correlated with its aggressiveness (Wu et aI., 2007). SP+ cells 
with tumour initiation capacity and self-renewal ability have been also identified in 
primary human ovarian cancers (Moserle et aI., 2008). 
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Studies by Schatton and colleagues further support the tumorigenic role of SP in 
melanoma (Schatton et aI., 2008). Instead of studying the SP+ cells, they looked at 
the expression of ABCB5, one of the chemoresistance-mediating ABC proteins on 
the surface of melanoma cells. They showed that ABCB5+ melanoma cells were 
enriched in tumour-initiating cells as compared with their ABCB5- counterpart. 
Moreover, the systemic administration of specific anti-ABCB5 antibodies, led to in 
vivo reduction of tumour mass (Schatton et aI., 2008). 
ALDH1, a member of the ubiquitous aldehyde dehydrogenase (ALDH) family is 
indeed a functional marker useful for the enrichment of breast cancer stem cells. 
ALDH1 mediates the conversion of retinol to retinoic acid, a crucial pathway for 
proliferation, differentiation and survival (Ginestier et aI., 2007). In colon cancer, 
the activity of ALDH1 was responsible for the resistance to cyclophosphamide and 
the cells expressing ADLH1 were also positive for the colon cancer stem cells 
markers ESA and CD44 thus confirming that ALDH 1 is a functional marker for 
cancer stem cells (Dylla et aI., 2008). Recently, ALDH1 has been reported to select 
thyroid carcinoma cells with CSC properties and endowed with high metastatic 
activity (Todaro et aI., 2010). As for the CD133+ cells, the ALDH1+ cells are 
heterogeneous and the expression of other markers identifies a subpopulation of 
ALDH1+ cells with enhanced tumorigenic capacity. This is the case for CXCR1, the 
receptor for the IL-8 cytokine, whose expression further defines the breast 
carcinoma CSCs. inside the ALDH1+ subpopulation (Ginestier et aI., 2010). 
Conversely, conflicting results have been reported on the possible role of ALDH1 in 
defining tumour initiating cells for human melanoma. Recently published results 
indicate this marker as useful to select melanoma cells with enhanced tumorigenic 
activity (Boonyaratanakornkit et aI., 2010). These data have been only partially 
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confirmed by Prasmickaite and colleagues. In fact, while they showed that ADLH1+ 
melanoma cells efficiently generate xenografts which contain both ADLH1 + and 
ALDH1 negative cells, nevertheless in their system, the ALDH1+ and ALDH1-
melanoma cells displayed similar tumour initiation capacity in vivo (Prasmickaite et 
al,2010). 
Melanoma is a very aggressive tumour, often clinically detectable only in their 
metastatic forms. Moreover, the rules governing the differentiation pathways of 
melanocytes from their precursor, namely melanoblasts, are not yet defined. While 
some results have cast doubts on the hierarchical organization of human 
melanomas and thus on the existence of a subset of cells selectively endowed with 
tumorigenic potential (Quintana et aI., 2010), other investigators, using prospective 
isolation of CSCs and FACS sorting or exploiting the sphere formation capacity of 
CSCs, have provided evidence for the presence of classically defined CSCs in 
human melanoma (Monzani et aI., 2007; Schatton et aI., 2008; Roesch et aI., 2010; 
BOiko et aI., 2010) and as also shown by results presented in this thesis. However, 
a consensus on the cell surface markers defining cells with tumorigenic capacity 
for melanoma has still not been reached. CD20 was firstly proposed to be 
expressed preferentially on melanoma cells with increased tumourigenicity (Fang 
et aI., 2005), and more recently it has been reported that melanoma CSCs can be 
isolated as a highly enriched CD271+ population (Boiko et aI., 2010). 
By analogy with SCs of normal tissues, CSCs are thought to remain quiescent. 
Thus it has been proposed that CSCs could be isolated from solid tumours using 
labels that, because of their irreversible binding to the lipid bilayer on cell 
membrane get equally apportioned between the daughter cells resulting from cell 
diVision. Slow cycling CSCs will retain the label and will appear as a subpopulation 
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with higher fluorescence intensity than the population of dividing cells that lose the 
dye faster. 
Following this approach, PKH67/PKH26 dyes were first used to isolate CSCs 
from human ovarian cancer and pancreatic adenocarcinoma (Kusumbe and 8apat, 
2009). For this last tumour, the slow-cycling CSCs were found to be enriched in 
CD44 +CD24 + CD133+ ALDH+ as compared to the total population or to the rapid 
dividing cells (Dembinski and Krauss, 2009). Most recently it has also been shown 
that the PKH26high fraction of human breast cancer is enriched in tumorigenic 
cells expressing a6 integrin and high level of Delta/Notch-like EGF-Related 
receptors (DNER) and Delta-Like Ligand (DELL) (CD49tDLLhighDNERhigh) 
(Pece et aI., 2010). 
The same experimental approach was applied to human melanoma and led to 
the identification of a slow-cycling subpopulation of cells required for continuous 
tumour growth. These slow cycling cells responsible for tumour maintenance in 
vitro, express the H3K4 demethylase JARID18 (Roesch et aI., 2010). Although the 
JARID18+ cells self-renew and give rise to rapidly proliferating progeny, the 
capacity of melanoma cells to initiate new tumours in immunocompromised mice is 
independent of JARID18 expression. Interestingly, JARID18 expression is 
dynamically regulated and it does not follow a rigid hierarchical model. 
Markers associated with tumour initiating cells in different malignancies are 
sUmmarized in table 1.2. 
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Table 1.2. Markers used to isolate CSCs from human solid tumours. 
Tumour Marker Minimal Matrigel Transplantation Mouse strain Ref. 
type number site 
of cell for 
tumour 
formation 
Breast CD44+CD24-IIOW 200 + Mammary fat pad NOD-SCID 5-
167 
ALDH+ 500 +' Mammary fat pad NOD-SCID 66 
ALDH+CXCR1+ 100 + Mammary fat pad NOD-SCID 67 
Label retainin~ (PKH26hIQh) 500 Mammary fat pad NOD-SCID 159 
Brain 
(CD49fDLLhi9 DNERhigh) 
CD133+ (GBM) 100 Brain NOD-SCID 199 
Colon CD133+ 3x10J Subcutaneous SCID 180 
EpCAMhi/CD44 + ICD 166+ 200 + Subcutaneous NOD-SCID 36 
CD26 1x10J + Subcutaneousl SCID 155 
cecal wall 
Head&Neck CD44+ 5x10J + Subcutaneous NOD-SCID 170 
EWing's CD133+ 2.5x10J + Kidney NOD-SCID 211 
sarcoma 
Pancreas CD44+CD24+ ESA+ 100 + Subcutaneous NOD-SCID 125 
CD133+ 500 Subcutaneous NMR-nu/nu 81 
Label retaining (DiI4) 5x10J + Subcutaneous SCID 39 
Lung CD133+ 104 Subcutaneous SCID 50 
liver CD90+ 5x10J Liver SCID/Beige 130 
ihyrOid ALDH+ 5x10J Subcutaneous NOD-SCID 220 
carCinoma 
Sarcomas Side Population 100 Subcutaneous NOD-SCID 239 
Prostate CD44+/a2~ 1 integrinhigh/CD133+ 100 + Subcutaneous NOD-SCID 158 
Ovarian 
Side Population 100 + Subcutaneous NOD-SCID 157 
CD44+ CD117+ 100 + Subcutaneous/i.p£ Nude 253 
Side Population 500 +J Kidney capsule Nude 143 
PKH26hlgh 5x10J Subcutaneousl NOD-SCID 113 
Melanoma 
i.p. 
CD20+ 2x105 + Subcutaneous NOD-SCID 53 
CD133 3.5x1 05 Subcutaneous NOD-SCID 140 
ABCB5+ 10° Subcutaneous NOD-SCID 191 
CD271+ 2x104 Subcutaneous Rag2-'-"(C-'- 22 
NOD-SCI D/IL-
2rfull 
Label retaining (PKH26h,gh) 1 _ +5 Subcutaneous NOD/USscid/IL- 183 
JARIDB1 + 2R-yull 
'1 . 
nJected with fibroblasts; 2 Intra peritoneum; 3 Rat tail collage gel; 3 Vybrant_ Dil cell-labeling solution 5 serial 
transPlantation. GBM= glioblastoma multiform; MB=medulioblastoma_ 
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1.1.2.3 Challenging issues of cancer stem cell model 
As outlined in 1.1.2.2, CSCs have been indentified and isolated from human 
tumours mainly by taking advantage of two alternative experimental procedures. 
One of these approaches directly sorts the putative CSCs from the whole tumour 
mass using a combination of cell surface markers. The selected populations are 
then assayed in vivo for their ability to form tumours. The application of flow 
cytometry to stem cell purification is still challenging because of the presence of 
crucial technical issues that need to be carefully evaluated. 
Although flow cytometry offers a sensitive method for cell isolation and 
purification, occasionally cell aggregates or doublets could interfere with the 
process of sorting and the sorting conditions chosen for a given cellular subtype 
could be not well tolerated by other cells of the same organs. In addition, the 
definition of the cells as high, middle or low regarding the expression of a marker is 
Subjective and can vary depending on the method used for cell and antibody 
preparation or it could be influenced by the gate setting. 
An alternative way to select CSCs is based on their ability to form non-adherent 
colonies when seeded at clonogenic density in a suitable medium and non-
adherent sphere assays are increasingly being used to evaluate stem cell activity 
in normal tissues as well as in tumours. "Neurospheres" have been widely used to 
investigate neurogenesis and this approach, extended to the tumours of the entire 
nervous system, was considered a valuable model subsequently applied to many 
other solid tumours. Briefly, cells obtained from human cell lines or from surgical 
specimens by mechanical and enzymatic digestion are plated at low density in 
sPecific culture media characterized by the absence of serum and the presence of 
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growth factors, namely Epidermal Growth Factor (EGF) and basic Fibroblast 
Growth Factor (bFGF). Clonal density during in vitro culture as well as the 
appropriate concentration of growth factors is crucial for the maintenance of cells 
with feature of self-renewal. Due to the repeated in vitro replications, cells may 
clearly acquire additional genetic aberrations and this is a drawback of the sphere 
forming approach in the identification of TICs. However it has been recently 
reported that neural stem cells propagated in vitro for long periods of time 
maintained a strikingly stable profile with regard to self-renewal, differentiation, 
growth factor dependence, karyotype, and molecular profiling (Foroni et aI., 2007) 
(Figure 1.4). 
Figure 1.4. Sphere assay for isolation of CSCs. Cells obtained from cell lines or from surgical 
Specimens are plated at low plating density in a serum free culture medium supplemented with 
stem-cell mitogens. Most of the cells die, except those that respond to stem-cell mitogens . These 
cells proliferate to form floating aggregates named spheres. These spheres can be dissociated into 
Single cells and then re-seeded in fresh medium giving rise to secondary spheres. This procedure 
can be repeated, resulting in an expansion in the number of cells originated at each passage. 
(Adapted from Vescovi et aI., 2006). 
Cell line 
Dissociation 
e! D il!J .. _  pr_oli_fer_ati_on_ 
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In xenotransplantation assay, cells are orthotopically engrafted into 
immunocompromised mice that are then assayed at various time points for tumour 
formation. Tumours engrafted in the primary recipients should be capable of self-
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renewal when grafted in subsequent animals. Several critical steps are inside this 
crucial and fundamental step of TICs identification. First xenotransplantation of 
viable single cells from solid tumours require modifications of the approaches used 
for haematological malignancies because of the need to dissociate solid tissues 
into single cells, thus requiring several manipulations that may affect cell viability or 
behaviour. Thus, the frequency of CSCs calculated in limiting dilution experiments 
can be markedly influenced by these parameters. 
In addition, the grafting site and the modalities of tumour cell injections, namely 
injection of tumour cell alone or mixed with Matrigel or with stromal cells of human 
or murine origin, may indeed affect the efficiency in tumour take. We should then 
consider wether some murine growth factors, crucial stimuli for stem and 
progenitor cells in multiple organs, can interact with their equivalent human 
receptors. Moreover, it is well known that co-injection of tumour cells together with 
normal fibroblasts increases latency and decreases tumour take, whereas the 
addition of carcinoma-associated fibroblasts has the opposite effect (Liao et aI., 
2010). Transplantation efficiency could also be influenced by the presence of 
residual immune effector cells in recipient mice since NOD-SCID mice retain some 
natural killer activity. This hindrance has been recently overcome by the 
introduction of the NOD-SCID-IL2Rvnull mice, which do not display any residual 
innate immunity. However, despite these concerns, data obtained with tumours of 
mOUse origin in· syngeneic models clearly demonstrated the existence of 
sUbpopulation of cells in at least some solid tumours, satisfying the functional 
criteria of CSCs. 
An integrated, multifaceted approach with the development of suitable ex vivo 
and in vivo models will allow better characterization of the CSCs. High-resolution 
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imaging technologies together with stromal markers will improve our understanding 
of the cellular niche for different CSCs and will facilitate refinement of 
transplantation models to more accurately recapitulate the niche for tumorigenic 
cells. 
1.1 .2.4 Translational relevance of Cancer Stem Cell Concept 
The CSCs theory posits that CSCs are self renewing cancer cells that drive 
tumour initiation and growth. Thus, it this subset of cells that need to be targeted 
and eliminated in order to achieve cure, and if a therapy fails to eliminate all self-
renewing CSCs, residual surviving CSCs will lead to tumour relapse (Figure 1.5). 
Figure 1.5 CSCs and drug resistance. Conventional anti-cancer therapies (e.g. chemotherapy 
and radiation) can often shrink tumours by targeting tumour bulk, but these therapies fail to target 
and kill CSCs (S) . CSCs subsequently re-drive tumour growth leading to treatment failure and 
relapse (Adapted from Stemline Therapeutics, Inc. Copyright 2008). 
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Unfortunately, normal stem cel ls have evolved multiple mechanisms to protect 
themselves from toxins and genotoxic stress, which make them relatively resistant 
to cell killing with cytotoxic agents. The analogies between normal SC and CSCs 
led to the hypothesis that CSCs may be relatively resistant to common therapeutic 
agents compared to their more differentiated non-tumorigenic counterparts. This 
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hypothesis has been confirmed and CSCs present in some established cell lines 
and long-term xenografts appear relatively resistant to cytotoxic drugs (Ho et ai, 
2007; Todaro et ai, 2007). Importantly this concept has been also verified in vivo in 
humans and frequency of CSCs in tumours of women receiving chemotherapy in 
the neo adjuvant setting for local advanced breast cancer is enhanced after 
treatment with cytotoxic agents (Li et ai, 2008). 
From a clinical perspective, it will be important to elucidate the mechanisms of 
chemoresistance and radioresistance operating in CSCs. There is also an 
additional need for tracking residual CSCs following treatment in order to monitor 
the efficacy of potential anti-CSCs therapies. 
CSC resistance to chemo- or radiotherapy can be ascribed to the intrinsic cell 
cycle kinetics of CSCs. Rapidly dividing cells are more sensitive to cytotoxic 
therapies than quiescent cells and quiescence is a typical feature of normal stem 
cells. Mirroring the physiological conditions, leukemic stem cells have been 
demonstrated to remain quiescent and insensitive to chemotherapy (Ishikawa et ai, 
2007). Recently, a two-step strategy has been proposed to target resistant 
leukemic SCs, consisting in priming tumours with activators of dormancy followed 
by chemotherapy or targeted therapies (Trumpp et aI., 2010). Whether this same 
strategy could be applied to solid tumour as well still remains to be investigated. 
Initial data on solid tumours have been achieved in glioblastoma multiform. In 
fact, it has been· demonstrated that glioblastoma CSCs could be induced to 
differentiate if exposed to bone morphogenic protein 4 (BMP4) thus attenuating 
their tumour forming capacity (Piccirillo et aI., 2006). These results show that the 
eSC fraction may still possess the ability to respond to biological cues for 
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maturation that may in the future lead to new non-toxic therapy driving 
differentiation of malignant tissues. 
An additional common mechanism of CSC drug resistance includes the 
expression of multiple drug resistance transporters (Dean et aI., 2005), such as 
ATP-binding cassette half-transporter proteins (ABCG2 and ABCG5) and multidrug 
resistance protein 1 (MDR1-ABCB1). Much effort has been devoted to the 
development of inhibitors of ABC transporters such as ABCB 1 and ABCG2 that are 
highly expressed on CSCs. Initial studies used ABC inhibitors in combination with 
standard therapies, but they did not produce convincing results (Dean et aI., 2005), 
probably due to the low activity of the inhibitors and their difficult in interacting with 
the chemotherapeutics or because of the presence of additional drug transporters 
not targeted by the inhibitors. Alternatively, CSC resistance to cytotoxic agents 
includes other crucially active pathways such as enhanced DNA repair capacity 
and the expression of specific drug detoxifying enzymes such as ALDH1 (Ginestir 
et ai, 2007). 
Reactive Oxygen Species (ROS) are critical mediators of radiation-induced cell 
killing but stem and early progenitor cells of different tissues contain lower levels of 
ROS than they their differentiated progeny, suggesting a possible cause of 
radioresistance. Human mammary CSCs contain lower ROS levels than more 
differentiated tumour cells, and accumulate less DNA damage upon irradiation 
(Diehn et aI., 2009). 
It is also likely that CSCs employ a combination of mechanisms that make them 
relatively resistant to therapies compared to their progeny, which could even vary 
between tumour types. The identification of the specific resistance mechanisms at 
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work on these cells will allow rational design of chemo- and radio-sensitization 
protocol that could lead to higher tumour control and cure rates. 
1.1.2.4.1 Targeting CSCs 
Surface markers used to isolate CSCs may represent suitable targets to develop 
monoclonal antibody based therapies specific for CSCs but sparing non-
tumorigenic cells. CD44 is a CSC marker shared by many different human tumours 
and although its role in CSC biology remains unclear, CD44 enriches for 
tumorigenic cells in breast (AI-Hajj et aI., 2003), prostate (Collins et aI., 2005), 
colon (Dalerba et aI., 2007), head and neck (Prince et aI., 2007), pancreas 
(Hermann et aI., 2007) and liver tumours (Yang et aI., 2008). Treatment of animals 
with anti-CD44 prevents serial tumour formation in mouse model of human AML 
(Jin et aI., 2006), but given the relatively diverse tissue and cell types expressing 
CD44, it remains unclear if this antigen will be useful in clinical settings. Similarly, 
targeting ABCB5+ melanoma cells with systemic administration of a monoclonal 
antibody inducing antibody-dependent cell mediated cytotoxicity led to a reduction 
of tumour mass in mice xenografted with human melanoma ABCB5+ (Schatton et 
aI., 2008). 
Although associated with the CSCs phenotype in many human cancers, CD133 
is not a reliable marker due to the technical limitation of its detection. CD133 
eXpressing cells have been isolated using the monoclonal antibodies CD133/1 
(AC133) and CD133/2 (AC141) recognizing different glycosylated epitopes that are 
still poorly characterized. Furthermore, CD133 expression might be regulated by 
environmental factors such as oxygen concentration (Bidlingmaier et aI., 2008). 
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The concept that cancer is a "developmental disease", in which normal 
developmental pathways have been altered by oncogenic processes, was firstly 
proposed several decades ago (Pierce and Speers, 1961). 
In recent years, it has been shown that embryonic signaling pathways such as 
Notch, Wntl~-catenin, and Hedgehog (Hh), regulate adult stem cell self-renewal 
and survival in the haematopoietic system, skin, nervous system and breast 
(Kopper et aI., 2004). More interestingly, these very same pathways are often 
abnormally activated in cancer. 
The Notch pathway is a short-range communication system in which contact 
between a cell expressing a membrane-associated ligand and a cell expressing a 
transmembrane receptor sends to the receptor-expressing cell (and possibly both 
cells) a cell fate regulatory signal. This signal takes the form of a cascade of 
transcriptional regulatory events that affect the expression of hundreds of genes, 
and has profound, context-dependent phenotypic consequences. Mature Notch-
receptors (in mammals Notch-1 through-4) are non covalent eterodimers consisting 
of an extracellular and a transmembrane subunit. 
In mammals Notch receptors (Notch1-4) interact with surface bound or secreted 
ligands (Delta like 1-3-4; Jagged 1-2). Upon ligand binding, Notch receptors are 
activated by serial cleavage events involving members of the ADAM protease 
family followed by intramembranous cleavage regulated by y-secretase. After 
Cleavage, the intracellular domain of Notch (D) translocates into the nucleus to act 
on downstream targets (Figure 1.6). 
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Figure 1.6 Notch signaling pathway. Notch signaling starts upon ligand-receptor interaction which 
induces successive proteolytic cleavages . Metalloproteases of the ADAM family mediate the first 
cleavage in the extracellular domain, and the subsequent second cleavage in the transmembrane 
domain is made by a y-secretase activity of presenilins (PS). This second cleavage frees the 
intracellular domain of Notch (NICO) that subsequently moves to the nucleus where it forms a 
binary complex with CSL, leading to transcriptional activation by dislodgment of co-repressor 
(CoRs) and synchronized recruitment of different co-activators (CoA), including mastermind like 
proteins (MAML) and p300. 011= delta-like ligand ; Jag= Jagged. (Adapted from ISREC research 
groups , Radtke 2010). 
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Notch signaling has been shown to playa pivotal role in cell fate determination 
in neural, haematopoietic and embryonic stem cells and it has been shown to be 
involved in the biology of several solid tumours (Allenspach et ai., 2002). In 
agreement with this central role of Notch signaling in the control of SC 
homeostasis, the Notch pathway is one of the most intensively studied putative 
therapeutic targets in CSCs, and several Notch inhibitors are being developed . y-
secretase inhibitors (GSls) capable of blocking Notch receptor cleavage and 
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pathway activation have been under clinical evaluation for the treatment of 
malignancies such as gliomas (Fan et aI., 2010) or T-cell acute lymphoblastic 
leukaemia (T-ALL) (Tammam et aI., 2009) (Table 1.3). GSls have been able to 
appreciably decrease breast CSC self-renewal in vitro, analogously to what is 
observed in these cells with treatments with a Notch-4 monoclonal antibody (Farnie 
et aI., 2007). More recently, at clinically relevant doses, GSls deplete glioblastoma 
stem cells in vitro and in vivo making them more sensitive to radiation (Wang et aI., 
2010; Fan et aI., 2010). Moreover, the use of a human specific blocking antibody 
(anti-hDLLA) to suppress Notch signaling in human colon cancer, dramatically 
reduce the proliferation of tumour cells (Hoey et aI., 2009). In animal model, the 
inhibition of human DLL4 in the tumour, either alone or in combination with the 
chemotherapeutic agent irinotecan, reduced CSC frequency (Hoey et aI., 2009). 
Recently, the use of a specific peptide to interfere with Notch transcription complex 
formation has been exploited with success in a mouse model of T -ALL (Moellering 
et aI., 2009). 
These encouraging results, suggest that the therapeutic regimens including 
Notch inhibitors may be used in the clinic to target CSCs and reverse or prevent 
chemo- or radio-resistance. Some of the now available investigational Notch 
inhibitors are already in the clinic (Table 1.3); GSls inhibitors have the advantages 
of relative ease of administration, oral bioavailability, and low cost. Whether 
intermittent Notch inhibition will be sufficient for effective CSCs targeting in patients 
is still an open question. If continuous inhibition is necessary for optimal results, 
systemically delivered GSls may be disadvantageous, because of their off-target 
effects mainly related to intestinal toxicity. 
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Table 1.3. Notch-targeting agents. (Adapted from Pannuti et aI., 2010). 
Agent Mechanism Targets Development 
Phase 
GSls Inhibition of final Notch All 4 Notch paralogs; Notch 1-2 
cleavage by y- ligands; multiple other O-secretase 
secretase substrates 
MAML 1-stapled Interference with Notch All Notch para logs; potentially Preclinical 
peptide nuclear co-activator other nuclear transcription factors 
MAML-1 that use MAML 1 
Notch mAbs Interference with ligand- Specific for individual Notch Preclinical 
induced Notch subunit receptors 
separation 
DLL4 mAbs Interference with ligand- Specific for Oelta-4 ligand Preclinical 
receptor interaction 
Notch soluble Interference with ligand- Relatively specific for Notch Preclinical 
receptors decoy receptor interaction paralogs potential pan-Notch 
inhibition 
siRNA, miRNA Interference with Specific for target mRNA Preclinical 
based expression of Notch 
therapeutics signaling components 
The Wnt signaling pathways have been conserved throughout evolution and 
they regulate cell proliferation , morphology, motility, and fate during embryonic 
development. These pathways also play important roles throughout adult life to 
maintain homeostasis of tissues including skin, blood, intestine and brain by 
regulating somatic stem cells and their niches. Aberrant regulation of these 
pathways leads to neoplastic transformation in the same tissue (Taipale and 
Beachy, 2001). 
Among the described Wnt signaling pathways the Wnt!~-catenin pathway is the 
best characterized. The activity of the Wnt!~-catenin pathway is dependent on the 
amount of ~-catenin in the cytoplasm. Normally cytoplasmatic ~-catenin is 
maintained at a low level through ubiquitin-proteasome-mediated degradation, 
Which is regulated by a complex containing axin, adenomatous polyposis coli 
(APe) and glycogen synthase kinase 3~ (GSK3~). Upon binding of Wnt proteins to 
a receptor complex comprised of Frizzleds/low-density lipoprotein receptor-related 
Protein (FzlLRP), the cytoplasmic disheveled (Ovl) is phosphorylated thereby 
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inhibiting GSK-3I3, resulting in the accumulation of non phosphorylated l3-catenin in 
the cytoplasm. Nonphosphorylated l3-catenin avoids degradation and translocates 
into the nucleus. In the nucleus, l3-catenin in the classical Wnt signaling cascade 
forms a complex with members of the T-cell transcription factor (TCF)/Iymphoid 
enhancer-binding factor (LEF) family of transcription factors. To generate a 
transcriptionally active complex, l3-catenin recruits the transcriptional co activators, 
cAMP response element-binding protein (CREB)-binding protein (CBP) or its 
closely related homolog, p300 as well as other components of the basal 
transcription machinery, leading to the expression of a host of downstream target 
genes. Secreted Wnt inhibitor factor 1 (WIF1) and secreted Frizzled-related 
proteins (SFRP), soluble Wnt receptors and competitors of Fz, respectively, are 
Wnt target genes that function as endogenous inhibitors of the Wnt Signaling 
pathway (Figure 1.7). 
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Figure 1.7. The canonical Wnt-p-catenin pathway signaling . A. In the absence of Wnt ligands, 
~-catenin is recruited into a complex with APC and the axins. Following phosphorylation of p-
catenin by the kinases casein kinase 1 a (CK1 a ) and glycogen synthase kinase 3p (GSK3P), and 
subsequent ubiquitylation , p-catenin is proteasomally degraded. Low cytoplasmic levels of p-catenin 
ensure transcriptional repression of Wnt target genes by recruitment of the corepressor Groucho to 
LEF (lymphoid enhancer factor)- TCF (T-cell factor) transcription factors . B. In the presence of Wnt 
ligands, LDL-related receptor protein 5 (LPR5) and LRP6 are phosphorylated by CK1 y and GSK3p, 
and Dishevelled (DVL) molecules are recruited to the plasma membrane to interact with Frizzled 
(FZD) receptors and other DVL molecules. These Interactions lead to the inactivation of the 
destruction complex and subsequently to the stabilization of p-catenin and its translocation to the 
nucleus . In the nucleus, p-catenin forms a transcriptionally active complex with LEF and TCF 
transcription factors by dislocation of Grouchos and HDAC and interactions with co-activators such 
as B-cell lymphoma 9 (BCL9), Pygopus (Pygo) and CREB binding protein (CBP). (Adapted from 
Klaus and Birchmeier, 2009). 
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The Wntl~-catenin pathway has been demonstrated to regulate pluripotency in 
embryonic stem cells (Sato et aI. , 2004) and it is critical for the fate decision in 
neural crest stem cells (Hari et aI. , 2002). This pathway plays an important role in 
the regulation of the haematopoietic stem cell self-renewal (Staal and Luis , 2010) 
and it is also involved in the maintenance of mammary (Lamb et aI., 2007) and 
epithelial stem cells (Gu and Watanabe, 2010). Because of the analogies existing 
between normal and CSCs, it has been suggested that the Wntl~-catenin pathway 
COUld also have a role in the regulation of CSCs. Initial evidence from epithelial 
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cancers pointed out that an abnormal activation of this pathway is associated with 
the acquisition of hyperproliferation and self-renewal by intestinal crypt progenitor 
cells (Radtke and Clevers 2005) and by luminal progenitor cells during 
oncogenesis (Zhang et aI., 2008b); moreover, Wnt Signaling has also been recently 
Shown to be essential for the renewal of chronic CML stem cells in vivo (Zhao et 
aI., 2007). 
Given the fact that multiple mutations lead to nuclear translocation of ~-catenin, 
the attenuation of the nuclear functions of ~-catenin is of particular interest. A 
number of drugs and natural compounds have been identified as inhibitors and/or 
modulators of Wntl~-catenin pathway (Takahashi-Yanaga and Kahn, 2010) (Table 
1.4). They could be divided into small molecule inhibitors and biologic inhibitors. 
Small molecule inhibitors include existing drugs such as nonsteroidal anti-
inflammatory drugs (NSAID) and mOlecular-targeted agents such as the CPB/~­
catenin antagonist ICG-001. Biologic inhibitors include antibodies, RNA 
interference (RNAi), and recombinant proteins. Some promising results have been 
achieved using the NSAID celecoxib in colon cancer cells (Takahashi-Yanaga et 
aI., 2008) and the ICG-001. These compounds are currently clinically tested. 
Additional encouraging evidence on the utility of monoclonal antibody directed 
against Wnt-2 is provided in preclinical models where treatments with this agent 
have led to tumour control in lung, melanoma, colon and hepatocellular 
xenografted human tumours (You et aI., 2004; Shi et aI., 2007; Wei et aI., 2009). 
However no data are available on the effects of this antibody treatment on the 
CSCs subpopulation. 
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Table 1.4. Wnt-targeting agents. (Adapted from Takahashi-Yanaga and Kahn, 2010). 
Agent Targets Development Phase 
NSAIDs ~-catenin/TCF Clinical (Calecoxib) 
Vitamins ~-catenin Clinical 
Poliphenoles Unknown Preclinical 
Molecular targeted drugs ~-cateninITCF Discovery-preclinical 
CBP Phase I 
Dvl Discovery 
Axin Discovery 
Porcupine Discovery 
Tankyrase 1 &2 Discovery 
Antibodies Wnt proteins Preclinical 
Recombinant proteins WIF1 and SFRPs Preclinical 
RNA interfering molecules Wnt proteins Preclinical 
Many human cancers have been shown to require the activity of the Hedgehog-
GLI (HH-GLI) signaling pathway for sustaining their growth (Ruiz et aI., 2007). 
Interestingly, HH-GLI not only controls the survival and the proliferation of the bulk 
of the tumour but it is also required for cancer stem cell survival in leukaemias 
(Dierks et aI., 2009), gliomas (Bar et aI., 2007), colon (Varnat et aI., 2009), breast 
(liu et aI., 2006) and pancreatic cancers (Li et aI., 2009). HH-GLI signaling is a 
complex pathway that involves multiple factors even though the core pathway has 
few components. Briefly, secreted HH glycoproteins bind and inactivate the 12-
transmembrane protein PATCHED1 (PTCH1), which itself normally inhibits the 
activity of the 7 -transmembrane G-protein coupled receptor-like protein 
SMOOTHENED (SMO). Thus, upon presence of the ligand, SMO is free from 
PTCH1 inhibition and it sends a signal leading to the activation of the GLI 
transcription factors. Upon HH-SMO signaling, the GLI proteins cease to act as 
repressors and turn into full-length activators of target genes (Figure 1.8). 
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Figure 1.8. The Hh-signaling pathway. A. In the absence of Sonic hedgehog (SHH), Patched 1 
(Ptc1) inhibits Smoothened (Smo). The Gli proteins are phosphorylated by protein kinase A (PKA), 
leading to their cleavage by the proteasome and the formation of carboxyl-terminus-truncated 
repressor Glis, which move to the nucleus and repress the GIi-dependent transcription of target 
genes. B. When Hh binds Ptc, its interactions with Smo are altered such that Smo is no longer 
inh ibited . The macromolecular complex that is associated with the microtubules (MT), and includes 
Su(fu) (Suppressor of fused) , Fu (Fused), PKA, the Gli proteins and other possible components acts 
to produce labile Gli activators. These are imported into the nucleus and transactivate target genes. 
This leads to Ci/Gli protein entering the nucleus and acting as a transcriptional activator for the 
same genes it represses when Ptc is free to interact with and inh ibit Smo. The regulation of Gli 
activity takes place at many levels, including nuclear export and the presence of positive or 
negative cofactors. In addition, SHH activates the transcription of Ptc1 , which , when overexpressed , 
attenuates the SHH response by preventing SHH from binding Ptc1 molecules within the receptor 
complex. (Adapted from Ruiz i Altaba et ai. , 2002). 
A 
Cell 
Cytoplasm 
Cytoplasm 
Nucleus 
Targeting Hedgehog-GLI signaling could be a very powerful anti-cancer strategy 
also because GLI integrates signaling not only dependent from Hedgehog, but it 
could also be regulated by major human oncogenes (e.g. RAS and AKT) or tumour 
sUppressors (e.g PTEN, p53) (Mas and Ruiz i Altaba, 2010). 
Some results have been recently achieved targeting HH-GLI on CSCs. Inhibition 
of Hh signaling has been shown to affect tumour initiation and systemic metastasis 
in orthotropic xenografts of human pancreatic cancer with minimal effect on the 
primary tumour volume, but leading to significant reduction of CSC fraction 
selected by ALDH expression (Feldmann et aI. , 2008). CSCs depletion by Hh 
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signaling inhibition has been also obtained from medulloblastoma (Rudin et aI., 
2009), glioblastoma (Bar et aI., 2008) and breast cancer (Tanaka et aI., 2009). An 
important downstream target of the Hh pathway is the bone morphogenic insertion-
1 (Bmi1), a member of the Polycomb group protein family of transcriptional 
repressors. Bmi1 targets genes such as p161NK4A and p14ARF preventing stem 
cell senescence. It has been claimed that Bmi1 is expressed in almost all Small 
Cell Lung Cancer (SCLCs) and antisense Bmi1 therapy reduces proliferation of 
lung cells in vitro (Yu et aI., 2007). Interestingly, Bmi1 is required for HSCs self-
renewal and loss of Bmi1 leads to a depletion of murine neural stem cells 
associate with upregulation of p161NK4A (Molofsky et aI., 2005). Bmi-1 is 
preferentially expressed in the pancreatic CD44+ tumorigenic subpopulation of 
head and neck cancer cells in comparison to the non-tumorigenic fractions (Prince 
et aI., 2007). 
In line with the HH-GU molecular pathway, treatment with cyclopamine that 
inhibits Hh signaling, blocks Bmi-1 and self-renewal of mammary malignant stem 
cells (Liu et aI., 2006). On the basis of these crucial data, several compounds 
Working as hedgehog pathway antagonists are currently being tested in the clinical 
Setting (Table 1.5). 
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Table 1.5. Hedgehog-GLI-targeting agents. (Adapted from Mas and Ruiz i Altaba, 2010). 
Agent Targets Development 
Phase 
GDC0449 SMOH Phase II 
BMS·833923 SMOH Phase I 
LDE225 SMOH Phase I-II 
IPI·926 SMOH Phase I 
Zerumbone Gli Discovery 
Starusporinone Gli Discovery 
Acryfalvin C Gli Discovery 
Physalin B-F Gli Discovery 
Robotnikinin Shh Discovery 
Components of PI3K pathway, including PTEN, Akt and mTOR are critical 
regulators of both normal SC function and tumorigenesis. Intriguingly, inactivation 
of some pathway components, like PTEN has an opposite effect on normal HSCs 
and CSCs. PTEN has an essential role in restricting the activation of HSCs, in 
lineage fate determination and in the prevention of leukemogenesis. In fact PTEN 
deletion leads to impair reconstitution of bone marrow after HSC transplantation. In 
Contrast, CSCs arise and expand in number after PTEN deletion in murine model 
of leukaemia. Furthermore, the CSCs were found to be sensitive to the mTOR 
inhibitor Rapamycin, while the normal HSCs were not (Yilmaz et aI., 2006). The 
PTEN/AktlmTOR pathways have also been described to confer resistance to 
ConVentional therapies and playa central role in the viability and maintenance of 
prostate epithelium progenitor cells (Zhang et aI., 2006b) and of CSCs in breast 
and prostate cancer (Zhou et aI., 2007; Dubrovska et aI., 2009). Using a murine 
lYmphoma model it was firstly shown that using the mTOR inhibitor Rapamycin in 
combination with standard chemotherapeutics (doxorubicin) it was possible to 
efficiently eradicate tumour cells (Wendel et aI., 2004). Moreover, combination 
therapy inhibiting Hh and mTOR signaling, together with standard chemotherapy 
39 
(gemcitabine), was effective in selectively eliminating CSCs in pancreatic cancer 
(Mueller et aI., 2009). 
There is increasing interest in the possibility of exploiting the putative CSC niche 
for drug targeting. The existence and the architecture of the CSC niche remain 
elusive although there is a substantial evidence for an instructive role of the tumour 
microenvironment. Nevertheless, aberrant stem cell niches may result in disease, 
as exemplified by an altered haematopoietic stem cell niche leading to the 
development of myeloproliferative diseases (Walkely et aI., 2007). Moreover, 
glioblastoma and medulloblastoma CSCs appear to be maintained by signals from 
an aberrant vascular niche that mimics the normal stem cell niche (8ao et aI., 
2006; Calabrese et aI., 2007). These studies suggest that brain CSCs have potent 
angiogenic activity. In fact, intraperitoneal administration of anti-angiogenic therapy 
with 8evacizumab, a vascular endothelial growth factor (VEGF)-neutralizing 
monoclonal antibody, markedly reduce CSCs tumourigenicity in vivo (Folkins et aI., 
2007). Recent evidence also suggest the possibility of using antibodies directed 
against molecules that could playa crucial role in mediating CSC drug resistance 
sUch as cytokines and chemokines. This in accordance to what has been observed 
in colon CSCs, that could became drug sensitive if treated with an IL-4 neutralizing 
antibody (Todaro et aI., 2007). 
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1.2 MELANOMA 
1.2.1 Epidemiology 
Cutaneous melanoma, also referred to as "malignant melanoma", represents 3-
7% of all skin malignanCies and is the most serious form of skin cancer because of 
its propensity for early invasion and widespread metastasis. With early detection 
and treatment, the cure rate of melanoma is about 95%, but advanced melanoma 
appears to be resistant to conventional therapies and, despite the overall advances 
in the fields of tumour biology and oncology therapies, prognosis for patients with 
Widely metastatic disease remains poor, with a median survival rate of 6 months 
and 5-year survival rate of less then 5% (Cummins et ai, 2006). 
The incidence of malignant melanoma is rapidly increasing, from 1975 to 2005, 
data from National Cancer Institute Surveillance Epidemiology and End Results 
(SEER) show that incidence of melanoma has nearly tripled in the United States. 
Based on the SEER data for 2001 to 2005, the median age at diagnosis for 
melanoma was 59 and the median age at death was 68. Additional breakdown in 
incidence and mortality by age group is shown in Table 1.6. Melanoma is several 
times more common in whites compared with more highly pigmented ethic groups 
and men are 1.5 times more likely to develop melanoma than women (Table 1.7). 
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Table 1.6: Incidence and death for melanoma by age. Data from National Cancer Institute. 
Surveillance, Epidemiology and End Results (SEER). (Cho and Chiang, 2010). 
Age Incidence (%) Deaths (%) 
<20 0.9 0.1 
20-34 8.1 2.9 
35-44 12.9 7.2 
45-54 18.9 15.0 
55-64 19.5 18.8 
65-74 17.8 21.3 
74-84 16.4 23.6 
>85 5.5 11.0 
Table 1.7: Incidence and death rates for melanoma by age and sex in the period 2001-2005. 
Data from National Cancer Institute. Surveillance, Epidemiology and End Results (SEER) (Adapted 
from Cho and Chiang, 2010). 
Incidence Rate by Race Deaths rates by Race 
Race or Male Female Male Female 
Ethnicity (per 100.000) (per 100.000) (per 100.000) (per 100.000) 
All races 24.6 15.6 3.9 1.7 
White 28.5 18.5 4.4 2.0 
Balck 1.1 0.9 0.5 0.4 
ASian or Pacific 1.6 1.3 0.5 0.3 
Islander 
American Indian 3.9 2.6 1.5 0.7 
or Alaska Naive 
Hispanic 4.8 4.9 0.9 0.6 
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1.2.2 Risk Factors 
The overall risk of developing melanoma during lifetime increases when multiple 
risk factors are present. Having one or two risk factors increase the risk of 
melanoma by two-to four-fold, and more than three risk factors can increase the 
risk by more than twentyfold (Cho et al 2005). 
1.2.2.1 Environmental Factor 
Risk factors can be divided into environmental factors and host factors. The 
main environmental risk is ultraviolet radiation (UVR); as reported in many studies, 
history of sunburns confers twice the risk of developing melanoma compared with 
no prior history of sunburns (Cho et ai, 2005). Moreover, aged people with a 
childhood history of sunburns are at even higher risk (Elwood and Jopson 1997). 
Australia and New Zeeland have the highest incidence and mortality rates for 
melanoma in the world with the estimated risk to develop melanoma over a lifetime 
of 3.3 and 5.7% respectively (Jones et ai, 1999) because at their latitudes sun is 
more direct and UVR levels are higher. 
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1.2.2.2 Host Factors 
Specific phenotypic characteristics such as red or blond hair, skin type, sun 
sensitivity and presence of freckles are associated to an enhanced risk of 
developing melanoma (Veierod et ai, 2003). Skin type is defined by the quantity 
and the type of melanin. Melanin, a pigment produced by the skin melanocytes 
naturally protects against UV damage, absorbing UV and neutralizing free radicals 
produced by the radiation. Two types of melanin exist in the skin: eumelanin and 
Pheomelanin. Eumelanin is responsible for gray, black, yellow colours found in hair 
and skin and confer greater UVR protection; pheomelanin is responsible for more 
pink and red colours. The ratio between eumelanin and pheomelanin is controlled 
by the melanocortin 1 receptor (MC1 R) that induces an increase in eumelanin 
production. People with red hair have diminished MC1 R function and in their skin 
Pheomelanin is the predominant form of melanin; impaired function of this receptor 
is Considered an independent risk factor for melanoma developing (Rees 2004). 
Family history is also strong risk for melanoma in fact, patients with a first-
degree relative with melanoma have a twofold higher risk of developing melanoma 
compared to patients with a non-family history of melanoma (Cho et ai, 2005). 
Familial melanoma represents about 10% of all melanoma cases (High and 
RObinson, 2007) and different susceptibility genes have been described including 
Cyclin-dependent kinase 4 (CDK4) alternative reading frame (ARF), cyclin-
dependent kinase inhibitor 2A (CDKN2A) and MC1 R (Table 1.8). A genetic 
predisposition to melanoma may also occur in a patient without a family history that 
may acquire a new mutation. 
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Melanocytic nevi are benign accumulation of melanocytes and may be 
congenital or acquired. The risk of developing melanoma increases with the 
number of nevi on the body. Having more then ten nevi greater then three 
millimetres on the arm can increase the risk of melanoma development up to 4.7 
fold on the trunk, shoulder, back or abdomen; 3.5 fold on the head and neck, 2.5 
on the upper extremity and 2 fold on the lower extremity (Cho et ai, 2005). Larger 
nevi are associated with a greater risk of melanoma (Watt et ai, 2004). Dysplastic 
nevi, that are melanocytic nevi with cytological atypia, are considered an 
independent risk factor for melanoma and it has been recently reported that 
individuals with five or more dysplastic nevi had six times the risk of developing 
melanoma compared to subjects with no atypical nevi (Gandini et ai, 2005). 
Tab. 1.8 Susceptibility genes in familial melanoma. (Adapted from High and Robinson, 2007). 
Gene Protein Chromosomal locus Melanoma risk Penetrance 
MC1R 
(high/low) 
MSH-u receptor 16q24.3 2- fold to 3.6-fold Low 
increased risk 
CDKN2A INK4a (p161NK4a) 9p21 (exons 1u,2,3) 67% lifetime risk; 35- High 
fold to 70-fold 
relative risk 
CDKN2A ARF (p14ARF) 9p21 (exons 1 ~,2,3) Unknown High 
CDK4 CDK4 12q13 Unknown High 
45 
1.2.3 Diagnosis and prognosis of melanoma. 
1.2.3.1 Diagnosis criteria and subtypes of melanoma 
Pigmented lesion need to be evaluated firstly considering the "ABCDE system", 
that simply evaluates Asymmetry (A), Border irregularity (B), Colour variation (C), 
Diameter (D) and Evolving (E) of the lesion, but a biopsy with a histopathologic 
evaluation is mandatory for the correct diagnosis. 
Melanoma could be divided into four main subtypes, distinguished by clinical 
and pathological growth patterns . 
• :. SuperfiCial spreading melanoma 
SUperfiCial spreading melanoma (SSM) is the most common type of melanoma 
in United States, accounting for about 70% of all diagnosed melanoma cases. This 
type of melanoma occurs slightly more often in females than males, it can arise at 
any age and it is the leading cause of death in young adults. SSM tends to occur 
on sun-exposed skin, and it appears most commonly on the legs in females and on 
the backs of males (Newell, 1988). In the early stages, SSM usually appear as a 
flat Spot similar to a freckle spreading sideways on the skin. Over time, the lesion 
grows acquiring the typical features of SSM lesions (irregular borders, various 
shades of black, brown, gray, blue, pink, red or white with possible variation in 
colour within the lesion). While, growing, the lesion may have areas of 
inflammation and the region around the lesion may begin to itch. 
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.:. Nodular melanoma 
Nodular Melanoma (NM), is the most aggressive kind of melanoma and 
accounts for about 15% of all melanoma diagnosed in the United States. It can 
appear anywhere on the skin and occurs more often in males than females, 
preferentially developing in people aged 50 and older. NM tends to growth more 
rapidly in thickness penetrating the skin than in diameter and can appear in regions 
lacking a previous lesion; NM is most often darkly pigmented and commonly 
present ulcerationing and bleeding lesions. The most common sites for NM are 
trunk, head and neck (Lens 2008) . 
• ++ L . 
• _entlgo Maligna Melanoma 
Lentigo maligna melanoma (LMM) typically occurs on sun-damaged skin in the 
middle aged and elderly, especially on the face and accounts 10% of the 
melanoma diagnosed in the United States. 
LMM begins as a spreading, flat, patch with irregular borders and variable 
shades of brown, for this reason, can be easily mistaken for an "age spot" or "sun 
Spot" in its early phases. As the lesion evolves, both the pigmentation and the 
margins become more irregular, with the possible appearance of irregular dark 
nOdules within the borders that represent the invasive tumour. Long-term 
cumulative rather than intermittent sun exposure is thought to confer the higher risk 
for developing LMM that appear almost uniquely on the sun-exposed skin of the 
head and neck (Lens, 2008). 
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.:. Acral Lentiginous Melanoma 
Acral Lentiginous Melanoma (ALM) counts for the 5% of the melanoma 
diagnoses in the United States but is the most common form of melanoma in 
Asians and in dark-skinned people among which it accounts for 50% of 
melanomas. Its appearance does not seem to be associated to sun exposure. ALM 
is sometimes referred to as "hidden melanoma" because it often appears on part of 
the body not easily examined or not thought to be examined such as palms, soles, 
mucous membranes and underneath or near fingernails and toenails. ALM usually 
begins as an irregular shaped tan, brown or black spot; as ALM increases in size, it 
Usually becomes more irregular in shape and colour and the tumour invades 
deeply into the skin, even if the surface of the lesion remains flat. The median age 
of occurrence is 65 years, with an equal sex distribution (Lens, 2008) . 
••• N 
• _on-pigmented subtypes of melanoma 
While uncommon, melanoma also exits without brown or black pigmentation. An 
uncommon subtype is called amelanotic melanoma that usually appears as a pink 
Or red nodule. Desmoplastic melanoma (OM) is a rare melanoma that mostly arises 
on sun-exposed skin of the head and neck of people aged 60 or more. Myxoid 
melanoma (MM) is an uncommon melanoma variants that is characterized by an 
important myxoid change that can be seen in primary melanomas, recurrences and 
metastases even when absent in the primary tumour (Lens, 2008). 
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1.2.3.2 Pathological staging of melanoma 
In 2001 the American Joint Committee on Cancer (AJCC) Tumour-Nodes-
Metastasis (TNM) staging classification incorporated Breslow depth, Clark's level, 
ulceration and pathological micro-staging attributes. The TNM classification is 
Widely used to describe many human cancers. In general T refers to the primary 
tumour size, N describes the involvement of regional lymph nodes, and M indicates 
the presence or absence of distant metastases. Paralleling the staging system for 
other cancers, melanoma patients with localized disease are characterized as 
stage I or II, those with regional metastases are considered stage III, and those 
with distant metastases are considered IV. To characterize the primary tumour, T 
in melanoma uses Breslow Depth (Breslow, 1970), Clark's level (Clark et ai, 1969) 
and the presence or absence of ulceration. 
Breslow depth is measured in millimeters and can be divided in T1 «1.0mm), 
T2 (1.01 to 2.0mm), T3 (2.01 to 4.0mm), T4 (>4.0mm). Clark's level describes the 
depth of invasion and is useful for prognostic differentiation of T1 lesions. Level I is 
limited to the epidermis (in situ melanoma); Level II reaches the papillary dermis; 
Level III fills the papillary dermis; Level IV involves the reticular dermis; Level V 
Penetrates within the subcutaneous fat. Tumours that have a Breslow depth of less 
than 1mm and have a Clark's level of II or III without ulceration remain T1a 
melanomas; T1 b melanomas are ulcerated or have a Clark's level IV or V. A final 
Version of the 2009 AJCC staging and classification of melanoma included the 
Illitotic index as a prognostic factor in stratifying T1 melanoma. In addition, the 
Clark level is not included as a parameter of staging since is not any longer an 
independent prognostic factor when mitotic index is included in the analysis. 
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Proliferation of the primary melanomas, defined by the mitotic index, is a powerful 
and independent predictor of survival. As a result, primary tumour mitotic rate is 
now a required element for the melanoma staging system. This prognostic value is 
maintained when age, sex, location of the primary tumour, thickness and ulceration 
are introduced in the multivariate model. 
The N category considers the status of regional lymph nodes. Stages I or II do 
not include any nodal or metastatic involvement. For Stage III melanoma, the 
nUmber and dimension (micrometastasis versus macrometastasis) of nodal 
metastases or the presence of in-transit metastases (lesions that reside more than 
5 cm from the primary tumour) or satellite lesions (lesions that reside within 5 cm 
from the primary tumour) are the most significant predictors of outcomes (Table 
1.9). 
Distant metastases characterize Stage IV melanomas and can occur in skin and 
SUbcutaneous tissues, distant lymph nodes (M1a), lung (M1b), and other visceral 
organs (M 1 c). 
Approximately 81% of cutaneous melanomas are locally confined; 12% are 
diagnosed after a regional spreading; 4% are diagnosed with distant metastases 
and for the remaining 4% the staging is unknown. In the absence of nodal or 
distant metastases, tumour thickness and presence or absence of ulceration 
remain the best predictors of survival outcome (Balch et ai, 2009). Presence of 
Ulceration signifies a greater risk for metastases and thus the survival rate for 
Patients with a given T category with ulceration is nearly the same as patients of 
the next T category without ulceration; moreover ulceration upstages melanoma 
and Confers poorer prognosis when melanoma is locally confined. 
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Patients with an unidentifiable primary tumour location account for 2-6% of all 
melanoma patients. Among this group, patients with subcutaneous or in-transit 
metastases show a 5-year survival of 83%; 50% in individuals with lymph node 
metastases and a median survival of 6 months for patients with disseminated 
disease (Schlagenhauff et ai, 1997). (Figure 1.9) 
Figure 1.9. Melanoma survival. AJCC TNM stages and overall survival of patients with cutaneous 
melanoma. (Adapted from Balch et aI. , 2009). 
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Table 1.9: Integrated TNM staging. M: metastasis; Vic: ulceration; mM: micrometastasis; MM; macrometastasis; trM: in transit metastasis; sM 
satellite metastasis. Percentage indicated the 5-and 10-year survival rates. Adapted from Cho and Chiang, 2010 and Balch et ai, 2009. 
Tis T1 «O,1mm) II T2 (1.01-2.0mm) T3 (2.01-4.0mm) T4 (>4.0mm) 
a b a b a b A b 
No ulceration Ulceration or no ulceration no ulceration no ulceration 
level 11/111 levellVN ulceration ulceration ulceration 
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1.2.4 Biology of melanoma: molecular mechanisms of 
melanocytic transformation and melanoma progression. 
Melanoma is a complex genetic disease, whose management will require an 
in-depth understanding of the biology underlying its initiation and progression. 
Until recently, melanomas were thought to arise from normal melanocytes 
undergoing malignant conversion caused by the sequential accumulation of 
genetic and molecular alteration. Cutaneous melanocytes originate from highly 
motile neural-crest progenitors that migrate to the skin during embryonic 
development (Slominski et ai, 2004). In the skin, melanocytes reside in the hair 
follicles and in the basal layer of epidermis. Melanocyte survival, differentiation, 
prOliferation and motility are regulated by keratinocytes. 
Although the precise mechanisms underlying melanoma development are not 
completely clarified, recent studies have provided a better understanding of 
melanoma biology. Mutations in critical regulatory genes, the production of 
autocrine growth factors and the loss of adhesion receptors all contribute to 
disrupted intracellular signaling in melanocytes, allowing them to escape their 
regulation by keratinocytes (Haass et aI., 2004). Consequently, melanocytes can 
proliferate and spread, leading to formation of a nevus. Melanocytes proliferation 
can be restricted to the epidermis Uunctional nevus), the dermis (dermal nevus) 
Or overlapping components of both (compound nevus). Common nevi are 
generally benign but they can progress to the radial-growth-phase (RGP) 
melanoma, an intra-epidermal lesion that can involve some local microinvasion of 
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the dermis. RGP cells can progress to the vertical-growth-phase (VGP), a more 
dangerous stage in which the cells have metastatic potential, with nodules or 
nests of cells invading the dermis. Not all melanomas pass through each of these 
individual phases; RGP and VGP can both develop directly from isolated 
rnelanocytes or nevi, and both can progress directly to metastatic malignant 
rnelanoma. Of note, RGP melanoma cells are mainly confined to the epidermis, 
are not tumorigenic in animal models and unable to metastasize in patients. In 
Contrast, VGP melanomas deeply invade the skin, are highly proliferative and 
turnorigenic in experimental models and rapidly metastasize in patients (Hsu et 
ai, 2002) (Figure 1.10). 
By the usage of several genetic approaches, that included mutation analysis, 
sorne crucial cell-signaling pathways activated in this disease have been 
identified and they are described below. 
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Figure 1.10. Scheme of melanoma progression . Aberrant proliferation of normal melanocytes, 
results in the formation of benign or dysplastic nevi. Radial growth phase (RGP) melanoma 
exhibits the ability to grow intraepidermally, followed by invasion of the dermis in the vertical 
growth phase (VGP), and culminating with lymphatic invasion or extravasation leading 
respectively to lymph node or visceral metastasis. Progression from a rad ial growing phase 
(RGP) to vertical growing phase (VGP) melanoma is associated with profound changes in 
expression of adhesion receptors . In particular there is an upregulation of N-cadherin, integrin 
aV~3 and ICAM-1 expression and a downregulation of E-cadherin and integrin a6~ 1. 
Spontaneous DNA mutations (black) have been observed in several genes and are postulated to 
be. involved at different stages of melanoma progression. Recent studies have also provided 
eV~dence for the presence of several genes whose expression is altered in melanoma by 
epigenetic modulations (Red) . B: blood vessels . (Adapted from Zaidi et aI. , 2008). 
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1.2.4.1 Proliferative pathways 
The MAPK-ERK pathway (including the cascade of NRAS, BRAF, MEK1/2, 
and ERK1/2 proteins) is one of the major signaling cascade involved in the 
Control of cell growth, proliferation and migration (Davies et ai, 2002). The 
RAS/Raf/MEKIERK pathway regulates cell fate decision downstream of receptor 
tyrosine kinase, cytokines and heterodimeric G-protein-coupled receptors. In 
melanocytes, this pathway is activated by growth factors such as stem-cell factor 
(SCF), fibroblast growth factor (FGF) and hepatocyte growth factors (HGF). 
MAPK-ERK pathway is a key regulator of melanoma cell proliferation, with 
ERK being hyperactivated in up top 90% of human melanomas (Cohen et ai, 
2002). In melanoma, ERK can be activated by the production of autocrine growth 
factors or in rare cases by mutational activation of growth-factor receptors such 
as c-Kit. A more common mechanism is through gain-of function mutations in 
NRAS, one of three Ras genes in humans (the others being HRAS and KRAS). 
NRAs is mutated in between 15% and 30% of melanomas and the most common 
sUbstitution is leucine for glutamine at position 61 (Q61 L) (Table 1.10). 
However, in melanoma, the most commonly mutated component of this 
pathway is BRAF, BRAF is mutated in 50% to 70% of melanomas (Table 1.10), 
and the most common mutation is a glutamic acid for valine substitution at 
POsition 600 (V600E) (Davies et ai, 2002). V600EBRAF supports constitutive ERK 
Signaling," thus promoting tumour proliferation and survival. V600EBRAF also 
COntributes to neoangiogenesis by stimulating autocrine secretion of vascular 
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endothelial growth factor (VEGF). Recent studies have identified several genes in 
melanoma that function downstream of V600EBRAF such as BRN-2 (POU domain 
class 3 transcription factor) , the cell cycle regulators cyclin 01 and p161NK4a, the 
tumour maintenance enzymes matrix metalloproteinase-1 and inducible nitric 
oxide synthase. Activating BRAF mutations have been detected in melanoma 
Patients only at the somatic level and in common cutaneous nevi. The presence 
of BRAF mutation in nevi strongly suggests that BRAF activation is necessary but 
not SUfficient for the development of melanoma. 
liable 1.10 Selected genetic alteration in malignant melanomas (Adapted from Gray-Schopfer et 
a., 2007). 
Gene lype Gene Chromosomal Alteration frequency Type(s) of alteration 
Oncogenes 
location in melanoma (%) 
BRAF 7q34 50-70% Mutated 
lUlllour 
NRAS 1p13.2 15-30% Mutated 
CDKN2A 9p21 30-70% Deleted, mutated, silenced 
SUppressor PTEN 10q23.3 5-20% Deleted or mutated 
APAF-1 12q23.1 40% Silenced 
Others 
p53 17q21 10% Lost or mutated 
CylinD1 11q13 6-44% Amplified 
MITF 3p14.1-p12.3 15.20% Amplified 
The different regulatory functions of MITF are associated to the level of 
eXpreSSion of the MITF protein. In particular, high level of MITF protein exerts an 
anti-proliferative activity in melanoma cells. High levels predispose to cell cycle 
arrest and differentiation, presumably by controlling cell cycle regulators (such as 
P161NK4a, cyclin-dependent kinase 2 (Cdk2) and p21 CiP \ whereas critically low 
levels lead to cell cycle arrest and apoptosis; only intermediate level favors 
prOliferation. The presence of oncogenic BRAF and low level of MITF protein 
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Were found in invasive melanoma cells and have been associated with poor 
prognosis and clinical disease progression. Of note, MITF resides downstream of 
the ERK and the PI3K pathways, suggesting that MITF could integrate 
extracellular pro-survival signals. In particular, MITF is targeted for degradation 
after its phosphorylation by ERK. Indeed, constitutive activation of ERK by 
VeoOE 
BRAF results in constant down-regulation of MITF. It has recently been 
Shown that MITF is amplified in a small percentage (10-16%) of metastatic 
Illelanomas in which BRAF is mutated (Table 1.10) (Gray-Schopfer et al. 2007) 
(Figure 1.11). 
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Figure 1.11 MITF signaling pathway. MITF is master regulator of melanocyte-specific 
transcription. Several pathways affect the level of MITF expression by acting on the MITF 
prOmoter. Specifically, a-MSH binds to the G protein- coupled MC1 R, which acts through 
~denYlate cyclase (AC) to stimulate binding of CREB1 to the MITF promoter thus inducing the 
ranscription of MITF target genes: genes involved in melanin production (TYR, TRP1, and OCT), 
~enes important for survival (BCL2), and numerous melanoma markers (Mart-1, MCR1, and 
liver). (Adapted from Sekulic et a!., 2008). 
AC 
Another Signaling pathway that has emerged as important in melanoma is the 
PhoSPhoinositide-3-0H kinase-AKT (PI(3)K) pathway (Figure 1.12). Activated 
Ii . 
Pld kinase phosphoinosite-3-kinase (PI(3)Ks) converts through hyper-
PhOSPhorylation, the lipid second messenger phosphatidylinositol (4,5) 
b' 
ISPhosPhate (PIP2) into phosphatidylinositol (3,4,5) triphosphate (PIP3), which 
recruits and activates phosphatidylinositol-dependent kinase 1 (PDK1). PDK1 in 
turn h P OSphorylates and activates AKT (also known as protein kinase B (PKB), 
59 
The AKT protein is a serine/threonine kinase and belongs to the AKT protein 
kinase family {AKT1, AKT2, and AKT3} that is overexpressed in up to 60% of 
melanomas {Stahl et aI., 2004}. AKT inhibits the activities of the forkehead 
(FOXO) transcription factors {which are mediators of apoptosis and cell-cycle 
arrest}, resulting in cell proliferation and survival. The tumour-suppressor 
PhosPhatase with tensin homology (PTEN) negatively regulates PI3K signaling 
by dephosphorylating PIP3, converting it back to PIP2. PTEN somatic mutations 
are found in 10-20% of primary melanoma and its function is lost in between 5% 
and 20% of late-stage melanomas (Table 1.10) (Tamura et aI., 1998). 
Under physiologic conditions, the PI3K1PTEN/AKT pathway is triggered by 
paracrine/autocrine factors (e.g., insulin-like growth factor-IGF). AKT activation 
stirnulates cell cycle progression through the down-regulation of the cyclin-
dependent kinase inhibitor p27 as well as trough the upregulation and 
stabilization of cyclin 01. In human cancer cells genetic inactivation of PTEN 
leads to constitutive activation of this AKT pathway and mediates 
turnourigenesis. Notably, in melanoma, NRAS and BRAF mutations are mutually 
eXclu . Slve, as are NRAS and PTEN mutations, whereas BRAF and PTEN 
mutations are coincident in about 20% of cases {Tsao et ai, 2004} (Figure 1.12). 
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Figure 1.12 Crucial pathways involved in melanoma progression. Within the MAPK pathway, 
activated receptors lead to SHC-mediated activation of RAS and propagation of signaling through 
RAF, MEK (also known as MAP2K), and MAPK (also known as ERK). Activated MAPK 
transduces signals that regulate multiple cell processes including proliferation, differentiation , 
angiogenesis, and survival. The second essential signaling pathway is the PI3KJAKT pathway. 
PI3K, a lipid kinase, catalyzes the phosphorylation of phosphatidylinositol (PI). Triple 
PhosPhorylation of PI is necessary for the association of AKT with the cell membrane and its 
SUbsequent activation by PDK1 . The key regulatory component is PTEN, a phosphatase that 
regulates PI3K and SHC phosphorylation. RAS may also regulate PI3K activity. Through 
activated AKT, several processes are activated including inhibition of apoptosis, survival gene 
~anscription , cell cycle progression , protein translation , and cell growth and proliferation . The 
alance between AKT activation and PTEN regulatory activity is a key determinant in cell cycle 
progression . FGF = fibroblast growth factor; HGF = hepatocyte growth factor; IGF = insulin like 
growth factor; P = phosphate; VEGF = vascular endothelial growth factor. (Adapted from Sekulic 
et aI. , 2008). 
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1.2.4.2 Senescence and apoptotic pathways 
Senescence is a form of irreversible arrest of cell proliferation. In normal cells 
it can occur due to telomere shortening (replicative senescence), oncogenic 
activation (oncogene-induced senescence, OIS), and/or cellular stress due to 
intense proliferative signals. OIS is emerging as a potent cancer-protective 
response to oncogenic events, serving to eliminate early neoplastic cells from the 
proliferative pool. In human, naturally occurring OIS is exemplified by nevi that 
represent benign aggregations of non-proliferative melanocytes often carrying 
activating mutations in BRAF (up to 80% of acquired nevi) or NRAS (up to 80% 
of Congenital nevi) genes. Intriguingly, activating mutations in the same genes 
Were detected in several types of malignant melanomas, even if at lover 
frequency (see Table 1.10). Thus, malignant melanomas have to develop some 
Illechanisms that allow escape from OIS. The INK4/ARF locus on chromosome 
9p21 has been shown to be involved in mediating OIS phenotypes. This locus 
enCOdes for two proteins with an overlapping but very distinct proteins: p161NK4a 
and P14ARF 
This is achieved by the selective use of an alternative first exon (exon E1a in 
P161NK4a . ARF . and exon E1 b In p14 ). Although structurally very different, both 
protein products act as negative regulators of cell cycle progression. The tumour 
sUppressor protein p161NK4a binds the cyclin-D-dependent protein kinases 
CDK4 and 6, blocks their activity thus preventing Rb phosphorylation and leading 
.' 
to . 
Cell cycle arrest (Serrano et al,·1993). In contrast, p14ARF regulates tumour 
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protein 53 (p53) activities by inhibiting HDM2. HDM2 is an ubiquitin ligase that 
targets p53 for degradation by the proteasome. High levels of p14ARF stabilize 
P53. The p53 protein arrests cell division at the G1 phase to allow DNA repair or 
to induce apoptosis of potentially transformed cells. Impairment of the p14ARF_ 
HDM2-P53 cascade, whose final effectors are the baxlbcl2 proteins, results in an 
aCCumulation of genetic damage in cells which promote tumour formation (Figure 
1.13). In human melanoma, CDKN2A inactivation by deletion, mutation or 
promoter silencing (through hypermethylation) generally affects p161NK4a alone 
Or P161NK4a and p14ARF simultaneously and its lost could be one possible 
meChanism overriding RAF-RAS induced senescence. An additional alternative 
mechanism suppressing senescence relies on C-MYC. C -MYC is a transcription 
factor frequently upregulated in human malignancies including metastatic 
melanoma (Bansal and Nikiforov, 2010) that regulates the expression of multiple 
genes involved in many cellular processes including promotion of proliferation. 
ihe observation that senescence can be induced via autocrine/paracrine 
pathways has been confirmed by the finding that BRAFv600E activates an 
inflammation-specific transcriptome in normal human melanocytes. Furthermore, 
some cytokine and chemokine expression declined during 015 bypass. In 
particular, some experiments revealed a causal relationship between the 
indUction of IL-6 and IL-8 and the ability of cells to undergo 015. In response to 
Oncogenic stress, IL6 and IL8 genes were activated by the transcription factor 
C/EBP~, upon its recruitment to the promoter. C/EBP~ depletion enables cells to 
effectively bypass 015. Escape of 015 is correlated with the lost of expression of 
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both cytokines. Since IL-6 depletion was followed by a strong decline in the levels 
of both C/EBP~ and IL-8, IL-6 could act as a positive feedback network regulating 
OIS (Kuliman et aI., 2008). These findings are supported by the positive 
correlation between increased IL-8 expression and p161NK4A positivity in growth 
arrested cells in human colorectal carcinoma thus sustaining a connection 
between senescence, inflammation and inflammation. 
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Figure 1.13 CDKNA pathways. The CDKN2A locus on chromosome 9r21 has an unusual 
~tructure because it encodes for 2 overlapping proteins: p161NK4A and p14AR using an alternative 
Irs~ exon (exon E1a in p161NK4A and exon E1b in p14ARF). The p161NK4A protein inhibits the 
activation of CDK4 and CDK6 by cyclinD1 (CCND1). thereby preventing the subsequent 
PhoSPhorylation of RB 1. Underphosphorylated RB 1 sequesters the transcription factor E2F and 
pre~~nts them from inducing the progression from G1 to S phase of the cell cycle In contrast. 
P14 F regulates tumour protein 53 (p53) activity by inhibiting MDM2. a ubiquitin ligase that 
otherwise targets p53 for degradation by theproteasome. H\&h levels of p14ARF stabilize p53 
~errnittin~ it to induce p21 . In the absence of functional p1 4A ' uncontrolled ubiquitination and 
h egradatlon of p53 removes this important cell cycle brake. leading ultimately to 
f yperphosphorylation of RB1 and cell cycle progression . P = phosphate; U= ubiquitin. (Adapted 
rom Sekulic et al. . 2008), 
E1b E1a E2 E3 
p14ARF 
I I 
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1.2.4.3 Novel signaling pathways involved in melanoma biology 
Notch proteins are a family of single-pass transmembrane proteins (Notch 
1-4) that act as membrane receptors activated by specific transmembrane 
ligands through a direct cell-cell interaction. The Notch signaling pathway plays a 
Pivotal role in self-renewal of adult stem cells, as well as in the differentiation of 
precursor along a specific cell lineage (Artavanis-Tsakonas et aI., 1999). 
Melanomas have a significantly higher Notch activity as compared to normal 
ll1elanocytes (Massi et ai, 2006). More specifically, Notch1 and Notch2 and their 
ligands are significantly upregulated in atypical melanocytic nevi and melanomas. 
In melanoma, Notch signaling exerts its oncogenic effect on primary melanoma 
Cells through positive regulation of ~-catenin (Balint et aI., 2005). Moreover, in 
earlY-Phase melanoma cells, Notch upregulates the expression of N-cadherin 
(Sanders et aI., 1999) and in human melanoma cell lines, ectopic expression of 
the active Notch1 intracellular domain regulates the MAPK and PI3K-Akt 
Pathways (Pinnix and Herlyn, 2007). 
The additional developmental signaling pathway sonic-hedgehog (SHH)-GLI, 
has been also found to be activated in human melanomas. Recently it has been 
ShOWn that SHH-GLI signaling is active in human hair follicles and required for 
normal in vitro proliferation of melanocytes (Rittie et aI., 2009). SHH-GLI is also 
invOlved in proliferation and survival of melanoma as evidenced both in vitro and 
iff Vivo 'In 
melanoma xenografts (Stecca et aI., 2007). More recently an 
a. 
ssoClation between GLl2 and melanoma invasion and metastasis has been 
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described in a series of human melanoma cell lines by in vitro and in vivo assays 
(Alexaki et aI., 2010). The molecular aspects of these pathways as well as their 
involvement in stem cell biology have been discussed in the section 1.1.2.4.1. 
1.2.4.4 Melanocyte development and melanoma 
Melanocytes are specialized melanin producing cells, and are responsible for 
skin, hair and eye pigmentation in vertebrate organisms. Melanocytes synthesize 
Pigment melanin within special organelles termed melanosomes. Once 
synthesized, melanin is deposited in melanosomes to form melanin granules. 
"hese melanin granules are transferred from melanocytes through their dendrites 
to adjacent keratinocytes, where melanin is accumulated to generate pigmented 
skin or hairs. The principal function of melanocytes is to protect skin from 
genotoxic stress of UV radiation but melanocytes also play an essential role in 
the hearing system. 
Melanocytes are derived from a group of highly pigmented migratory 
embryonic cells called neural crest cells. The neural crest is induced at the time 
of gastrUlation. in the zone between the neural and non-neural ectoderm and it 
gives . 
rise to a number of cell types, including osteocytes, chondrocytes and 
sensory neurons. Cell labeling studies indicate that neural crest cells are initially 
rnultiPotent but gradually become lineage-restricted in development potential 
(D .. 
orsky et aI., 1998). In most cases, this potential is determined by its anatomic 
10car 
Ion with melanocytes originating from the trunk neural crest together with 
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adrenal cells and sensory ganglia. The development of a multipotent neural crest 
stem cell into mature melanocytes involves a bipotent glial-melanocyte lineage 
progenitor that develops into unpigmented precursor cells called the 
rnelanoblasts (Dupin et aI., 2000). Early neural crest induction depends in part on 
intact BMP signaling together with a pivotal role of Snail/Slug family of 
transcription factors that stimulate neural crest progenitor cells to undergo an 
epithelial-mesenchymal transition (EMT) (Cano et aI., 2000). The Notch family of 
proteins plays an essential role in fate decision of early progenitors preventing 
cells in the premigratory neural crest from taking on a neural fate and instead 
becOming unspecified neural crest precursors (Kelsh et el., 2006). Commitment 
to the melanoblast stage usually occurs in the neural tube or after migration has 
started. Wnt signaling is important in promoting a cell fate decision towards 
rnelanoblasts and mature melanocytes as suggested by the study in Wnt 
der . 
rcrent mice (Ikeya et ai, 1997). However, recent data suggest the existence of 
an additional distinct origin of melanoblasts. According to these new findings, 
Skin melanoblasts originate from Schwann cell precursors that are positioned 
along the developing nerves (Adameyko et ai, 2009). 
Once melanoblasts arise, they migrate along the dorsolateral pathway and in 
rnammals most of the melanoblasts further invade the overlying epidermis, where 
they . . 
prolrferate and migrate extensively to distribute throughout the entire 
epidermis. The number of melanocytes in the epidermis is tightly controlled and 
this . 
. rs primarily due to their interaction with local keratinocytes. A major 
hOllleost "t' 
. a rc factor in the adult skin is Stem Cell Factor (SCF). Epidermal 
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keratinocytes produce SCF in both a membrane bound and soluble form and 
SCF stimulation or inhibition has been shown to drive proliferation or loss, 
respectively, of melanocytes in human skin (Grichnik et aI., 1998). 
In the hair follicle, melanoblasts are segregated into two popUlations: the hair 
ll"Iatrix melanocytes, which are responsible for pigmentation of the initial hairs; 
While the second population consists of melanocyte stem cells, which are 
lOcalized at the lower permanent portion of the hair follicle (the bulge region) and 
are responsible for the maintenance of the hair follicle pigment system in the 
SUbsequent hair cycles (Nishimura et aI., 2002). Hair growth occurs in alternating 
Phases of proliferation (anagen), regression (catagen) and quiescence (telogen). 
Melanoblasts appear at the onset of anagen phase in the hair matrix where they 
actively proliferate and differentiate into mature melanocytes. During catagen, 
these melanocytes are depleted from the follicles by apoptosis, and finally 
Illelanocytes become absent in telogen hair follicle until the next melanogenesis 
int 
I lated in the subsequent anagen phase. It is thought that at least one 
Illelanocyte stem cell remains in the bulge region during the entire hair cycle, 
enSUring the production of melanocytes at the beginning of a new cycle while 
transit amplifying melanocytes go out of the niche and migrate to the epidermis, 
were they can further differentiate into pigmented melanocytes. 
In non hair region of the human skin, melanoblasts stay immature and reside 
on the basement membrane of the interfollicular epidermis where they playa role 
~n formation of skin pigmentation (Osawa et aI., 2005). Whereas the origin of the 
hlJll"Ian .. 
. epidermal melanocytes has not been determined yet, it has been 
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hypothesized that these melanocytes may also arise from the bulge melanoblasts 
in the hair follicle as suggested by the observation that repigmentation process of 
Vitiligo, a condition where the epidermal melanocytes are lost from the skin, is 
initiated in a perifollicular manner (Falabella and Barona, 2009). Hence, these 
Observations indirectly provide evidence for a role of human follicles as reservoir 
also for the epidermal melanocytes. 
Furthermore, using in vitro culture conditions suitable for human embryonic 
stern cells, multipotent adult stem cells have been recently isolated from human 
h . 
air follicles. These cells do not express melanocytic markers, but express neural 
crest and neural stem cell markers as well as the embryonic stem cell 
transcription factors Nanog and Oct4. These precursor cells are self-renewing 
and rnultipotent in vitro acquiring lineage differentiation markers under specific 
Culture conditions and they also demonstrate appropriate functions in ex vivo 
Conditions (Yu et ai, 2006). 
"Through the extensive studies of mutant animals, a number of key genes for 
Illelanoblast development have been identified: examples of these genes include 
PaX3 (paired Box 3), Sox10 (Sex-determining region V-box 10), MITF 
(lllicrOPhtalmia-associated transcription factors), Edn3 (endothelin 3), Ednrb 
(endothelin receptor B), kit (c-kit tyrosine kinase receptor), Kitl (kit ligand, also 
Called 
as SCF or steel factor) and Snai2 (also called Slug) (Bennett and 
lam 
oreux, 2003; Hou and Pavan 2008) . 
. PaX3 plays a key role in neural crest development as well as muscle and 
cardio-va'sculature formation. Mice with loss of functional Pax3 exhibit a white 
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Spotting phenotype suggesting a role of Pax3 in melanoblasts development 
(Moase and Trasler, 1992). 
MITF is a melanocyte lineage-specific gene that encodes a transcription factor 
particularly important in melanocyte development. MITF regulates the 
Illelanocyte lineage by activating several pigment-producing genes, such as 
tyrosinase-related protein-2 or TRP-2 and tyrosinase and also melanoblasts 
survival depends on MITF (Hornyak et aI., 2001). A direct influence of Pax3 in 
antagonizing Mitt signaling has been demonstrated, suggesting a possible role of 
Pax3 in maintaining a balance between undifferentiated and differentiated status 
of Illelanoblasts (Lang et aI., 2005). 
Sox10 is expressed in pre-migratory neural crest cells and its expression is 
gradually restricted in glial and melanocyte lineages (Hou and Pavan 2008) with 
an indispensable role in promoting survival, migration and differentiation of 
ll1elanocytes. The downstream targets of Sox1 0 are not completely clarified, but 
SOX10 preferentially enhances expression of MITF and tyrosinase (Murisier and 
Seerrnann, 2006). Endothelin signals are essential for survival and migration of 
ll1elanocytes in their early stage of development (Lee et aI., 2003). 
'he type III receptor tyrosine kinase c-Kit is essential for melanocyte 
developrnent. It is involved in the molecular process of pigmentation. In fact 
h . 
Ull1ans heterozygous for a mutation in the c-KIT gene have a pigmentation 
disorder called piebaldism and mouse mutants for the c-kit gene or its ligand 
~~eel/stern cell factor, also demonstrate varying degrees of pigmentation 
ab ... 
, ,orrnalities. 
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Molecularly, melanocyte stem cells can be distinguished from their more 
differentiated progeny by a Pax3+, Tyr-, Tyrp1 -, Kit-, MITF-, Sox10- phenotype 
(Osawa et aI., 2005). Expression or absence of Pax3, Sox10 and MITF has been 
shown to be critical for melanocyte SC maintenance, differentiation and 
qUiescence. Importantly, elevated levels of Wnt signaling molecules antagonize 
the regulatory balance of Pax3, Sox10 and MITF towards terminal differentiation 
(Nishikawa and Osawa, 2007) (Figure 1.14). 
m rigure 1.14 Scheme of melanocyte development. During mouse embryogenesis, 
m:lanOblasts emerge in the neural crest at embryonic day (E) 9.S-1 O.S. These earl iest stages of 
ari ~noblasts are characterized by the expression of Oct, Kit , Mitf, Pax3, Sox10, and Si . After 
theSlng from neural crest, melanoblasts migrate to the developing dermis. Then, at E12.S- 13.S, 
en/ enter the epidermis where they actively migrate and proliferate to be distributed over the 
ex~re bOdy. In addition to the pre-migratory melanoblast markers, these migratory melanoblasts 
mo:e~s several melanosomal proteins including Tyr and Tyrp. Upon initiation of ha ir follicle 
POP~I o.genesis, the melanoblasts enter the newly developing hair and are segregated into two 
the atlons. In the hair matrix, melanoblasts differentiate into mature melanocytes and acquire 
to ~xpression of Mc1 rand Oa . In the bulge region melanoblasts are restricted in a resting status 
inClu~?ome melanocyte stem cells gradually downregualting several melanoblast markers 
Ing Kit , Mitf, Pax3, Sox10, Tyr, andTyrp1 (Adapted from Osawa et aI. , 200S). 
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Melanocyte stem cells appear to be maintained in a quiescent status in the 
niChe 
and the fact that melanocyte stem cells are randomly scattered within the 
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bulge region without forming into cell clusters led to the hypothesis that the bulge 
region itself serves as a niche for the melanocyte stem cells (Figure 1.15). 
Figure 1.15 Localization of the melanocytes stem cells from the hair follicle. The hair follicle 
is divided into two portions: a transit portion that completely reforms itself over the hair cycle; and 
a permanent portion of the follicle that is maintained throughout hair cycling that includes the hair 
bulge. The bulge is thought to contain melanocyte stem cells that are responsible for the 
formation of the new hair follicles during hair cycling and repair the epidermis upon injury. The 
bulge acts as a specialized niche, surrounded by other cell types, which together provide cues 
that maintain melanocytes stem cells in an undifferentiated state. The hair follicle melanocytes 
reside in the lower part of the hair bulb among the matrix keratinocytes. The matrix is in the 
deepest portion of the follicle that envelops the dermal papilla. (Adapted from Hoffman 2000; 
Fuchs 2007). 
Dermal papillae 
The existence of self-renewing and differentiation-capable melanocytes stem 
cells in humans has yet to be conclusively proven, however, the repigmentation 
processes in vitiligo, a depigmentation disorder resulting from the destruction of 
functional melanocytes, strongly suggested the presence of an immature pool 
that replenishes the skin with functional melanocytes upon disease control (Yu, 
2002). Moreover, different melanocyte phenotypes are distinguishable in the 
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human epidermis and hair follicle, including amelanotic, non-proliferative cell 
types, and pigmented more proliferative melanocytes (Grichnik et aI., 1996). 
1.2.4.4.1 Origin of me/anocytic nevi 
Nevi are benign clonal proliferations of cells expressing the melanocytic 
phenotype. In congenital nevi, it is presumed that a precursor cell is mutated and 
that by uncontrolled proliferation it gives rise to an excessive number of daughter 
cells. The migrating cells populate subcutaneous, dermal and epidermal 
structures, as they attempt to complete normal migration to the skin surface. 
B-Raf-activating mutations are commonly seen in acquired nevi and N-Ras 
mutations are commonly seen in congenital nevi (Bauer et aI., 2007). N-Ras not 
only activates a number of pathways, including PI3K, but also activates B-Raf, 
leading to an activation of MAPK and ERK pathways. In in vitro cultures, nevus 
cells are also less dependent on growth factors when compared to normal 
melanocytes (Alanko et aI., 1999), suggesting that although the underlying 
mutations are not sufficient to drive malignancy, they are sufficient to allow some 
independence from the normal homeostatic mechanisms. 
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1.2.4.4.2 Role of nevi in melanoma development 
Melanomagenesis is commonly described as the results of a de-differentiation 
process of transformed, mature melanocytes through nevus and dysplastic nevus 
stages to in situ and eventually invasive melanoma (Clark et ai, 1984). According 
to the traditional model, during melanoma development, tumour cells escape 
keratinocyte control by various mechanisms that include down regulation of E-
cadherin and upregulation of N-cadherin and MCAM. This shift in the expression 
of adherent proteins favours interactions of melanoma cells with endothelial cells 
and fibroblasts surrounding the tumour while disrupting the binding with 
keratinocytes (Haas et ai, 2005). Upon specific activation, cells composing the 
malignant microenvironment promote these processes by secreting proliferative 
growth factors such as Insulin-like growth factor (IGF), Transforming Growth 
Factor beta (TGF~), Basic Fibroblast Growth Factor 2 (bFGF) or Vascular 
Endothelial Growth Factor (VEGF) (Lee and Herlyn, 2007). Despite the five 
different stages of melanoma progression distinguishable histologically (benign 
nevi, dysplastic nevi, radial-growth phase (RGP), vertical growth phase (VGF) 
and metastatic melanoma (Figure 1.10), approximately three-quarters of 
melanomas develops in normal skin and less than one-half of the nevi associated 
with melanoma are· dysplastic (Bevona et aI., 2003). Thus, it is not clear whether 
it is more likely for a dysplastic nevus to develop in melanoma than any other 
type of nevus, and it is clear that a nevus precursor is not required for the 
majority of melanomas. 
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This phenomenon is difficult to explain, but in light of the esc concept, an 
alternative hypothesis has been proposed. It can in fact be foreseen that 
melanocytes stem cells or immature progenitor cells present in the skin following 
the accumulation of malignant mutations will potentially give rise then to 
melanoma without progressing through intermediates. In addition, the tumour 
microenvironment composed of surrounding and/or recruited fibroblasts and 
endothelial and inflammatory cells contribute and support metastasis 
(Zabierowski and Herlyn, 2008) (Figure 1.16). The identification of molecularly 
defined melanoma SC should shed light on the cellular events driving 
melanomagenesis and may provide experimental systems for the discovery of 
novel melanoma therapies. 
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Figure 1.16 Schematic model of the potential relationship between melanocyte SC (MSC) 
and putative malignant melanoma SC (MMSC) in context of distinct physiological or 
malignant microenvironments. (A) The balance between Melanocyte SC (Pax3+, SOX10-, Mitf-
) self renewal and differentiation, quiescence and proliferation in the hair follicle is regulated by 
Notch and/or Wnt signaling molecules. The homeostasis of these SCs is supposed to be 
maintained through the interaction with the physiological microenvironment, mainly composed of 
E-cadherin expressing keratinocytes). MMSX could arise by cumulative oncogenic mutation 
and/or loss of tumour suppressors. Surface marker associated with MMSC are ABCB5, CD133, 
CD20 and MMSC could secrete morphogens as Nodal or BMP4. Moreover, cleavages in the 
microenvironment may support MMSC formation and melanoma genesis. Mal ignant 
microenvironment is characterized by the production of proliferative growth factors such as bFGF, 
HIF, TGFp, VEGF. Moreover, MMSC might alter the microenvironment directly trough secreted 
factors (8). (Adapted from Schatton and Frank, 2008). 
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1.2.5 Systemic therapy for melanoma 
Surgical excision is the treatment of choice for melanomas, especially for early 
stages of disease, and systemic chemotherapy remains the most widely used 
treatment, especially when metastatic sites are not surgically accessible. Thus 
several studies investigating new drugs and exploration of mechanisms of tumour 
recognition by the patient's immune system are currently on-going with the final 
aim of offering to these patients new and more efficient therapeutic options. 
1.2.5.1 Chemotherapy of melanoma 
Traditional systemic chemotherapy has failed to significantly improve the 
survival of patients with non-resectable metastatic melanoma (Bajetta et ai, 2002) 
but chemotherapy continues to have a role in palliation of disease. Although 
many agents have been tested, single-agent chemotherapy is generally 
considered ineffective (O'Oay et aI., 2002). 
Oacarbazine (OTIC) is a pro-drug of the alkylating agent 5-(3-methyltriazen-1-
yl)imidazole-4carboximide (MITC) that is generally well tolerated. It is the only 
cytotoxic agent that has been approved for the treatment of advanced melanoma 
and it is the standard against which new treatment have to be tested. OTIC and 
its response rate as single agent ranges from 15% to 25%, but these responses 
have in general brief duration (3-6 months) and the complete response rate is 
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only 5% (Lee et ai, 1995). Because of this activity, OTIC has been tested alone or 
in combination therapy. 
Temozolomide (TMZ) is a relative new alkylating agent, it is a pro-drug that 
spontaneously converts to MTIC under physiologic conditions (Stevens et ai, 
1987). Moreover, TMZ has extensive tissue diffusion including penetration of the 
blood-brain barrier and the cerebral spinal fluid (Newlands et ai, 1992) and is 
commonly used as chemotherapeutic agent in the treatment of multiform 
glioblastoma (GBM) (Stupp et ai, 2005). TMZ was shown to have a slightly higher 
response rate (13.5% vs 12.1%) and median survival (7.7 vs 6.4 moths) than 
DITC, neither of which was statistically significant (Middleton et ai, 2000). TMZ 
cytotoxicity is mediate through methylation of DNA, and this adduct can be 
removed by methyl guanine methyltransferase (MGMT), a DNA repair protein 
that bypass the TMZ effects (Hegi et ai, 2005). Studies combining TMZ with 
Thalidomide demonstrated a 32% response rate (Perussia et ai, 1984), however 
the follow up study could not demonstrate a real improvement with this treatment 
(Clark et ai, 2010). 
The nitrosoureas are a group of alkylating agents that act by cross-liking DNA. 
Carmustine (BCNU) and lomustine have a response rate of 10-20%, similarly to 
DTCI, but are associated with more toxicity and their use is limited as single 
agents. Fotemustine is a nitrosourea that rapidly crosses the blood-brain barrier 
and it displays a 15% response rate that however was not associated woth 
survival advantage (Avril et ai, 2004). The platinum compound (cisplatin and 
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carboplatin) have a modest activity against melanoma with a response rate of 15-
20% (Gogas et ai, 2004). 
Microtubule toxins and microtubular disassembly have been demonstrated to 
have activity against metastatic melanoma. Vinblastine, a vinca alkaloid with 
modest activity and limited toxicity, has primarily been used in combination 
therapy. Vinorelbine did not demonstrate a significant effect alone (Jimeno et ai, 
2005; Whitehead et ai, 2004) and had 20% response rate in a study in 
combination with tamoxifen (Feun et ai, 2000). Paclitaxel and docetaxel are 
microtubule disassembly inhibitors with antitumour activity in a variety of 
neoplastic diseases. Paclitaxel has 12-16% response rate in previously untreated 
melanoma patients (Wiernik et ai, 1993) and a 26% response rate when used in 
combination to carboplatin (Rao et ai, 2006). Analogously, docetaxel alone 
showed a 12 % response rate (Bedikian et ai, 2003) and its effect in combination 
with TMZ and cisplatin has also been recently described (Kim et ai, 2009). 
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1.2.5.2 Target Agents in melanoma 
The advent of new cellular and molecular techniques led to a precise 
knowledge of the signaling pathway abnormally activated in melanoma thus 
paving the ground for the development of target therapies. Target therapies 
exploit the activities of biological agents/drugs designed to selectively block a 
given cell signaling, to disrupt angiogenesis, growth and proliferation pathway 
and to enhance tumour apoptosis. 
Vascular Endothelial Growth Factor (VEGF) has been implicated in tumour-
induced angiogenesis, and its inhibition can suppress the tumour growth in 
murine models. Bevacizumab is a humanized murine monoclonal antibody that 
binds to VEGF shown to have activity in colon, lung, and breast cancer (Van 
Meter and Kim, 2010). Bevacizumab has been used in combination with several 
agents. Bevacizumab plus Paclitaxel showed an overall survival at 12 months of 
43.3% suggesting some benefit from this treatment (Gonzalez Cao et aI., 2007). 
Another study combined Bevacizumab with carboplatin and taxol, with a 17% of 
partial response rate and 57% of patients displaying stable disease lasting for 8 
weeks (Perez et aI., 2009). 
Sorafenib is a tyrosine-kinase inhibitor with activity against the RAF 
serine/threonine kinas, although is also a multikinase inhibitor with activity 
against VEGFR-2 and-3. Sorafenib is FDA-approved for the treatment of renal 
cell carcinoma and hepatocellular carcinoma but in a melanoma study, no tumour 
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response was observed, although 19% of patient experienced stable disease 
(Flaherty et al. 2008). 
A number of other small molecule inhibitors, including Raf265, XL281 , AZ628, 
SB-590855 and PLX-4032 have been developed. These molecules are more 
selective than Sorafenib for RAF kinases, are much potent MAPK signaling 
inhibitors in vivo retaining good antitumour activity (Tsai et aI., 2008). In 
particular, PLX-4720 resulted in being highly selective for BRAFV600E and 
preclinical experiments demonstrated that PLX4032 (RG7204) selectively 
blocked the RAF/MEKIERK pathway in BRAFV600E mutant cells and caused 
regression of BRAF mutant xenografts. In a phase I-II trial PLX4032 induced 
complete or partial tumour regression in 81 % of patients who had melanoma, 
with progression free survival of more than 7 months and manageable side 
effects (Flaherty et aI., 2010). As expected, patients negative for the BRAFV600E 
mutation failed to respond to the treatment and no effect of PLX4032 was 
observed on nevi progression or regression. Although the number of patients in 
this trial was small, and eventually all patients experienced tumour relapse, 
nevertheless this study strongly suggests that selective targeting of early driver 
mutations can induce a substantial tumour regression in melanoma patients 
(Wellbrock and Hurlstone, 2010). 
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1.2.5.3 Immune-based therapy 
Several observations suggested that the host generates an immunogenic 
response to melanoma, leading to the interest in exploring therapeutic modalities 
to enhance such a response 
The most important therapeutic agent for melanoma treatment has been the T-
cell growth factor IL-2. IL-2 has not a direct antitumour activity, and exerts its 
function through its ability to stimulate an immunological response by 
lymphocytes. Initial studies reported an overall response rate of 16% with 6% 
complete response rate (Lotze et aI., 1986). Other studies reported overall 
response rate of 15-20% with durable responses (Atkins et ai, 1999). In light of 
these findings IL-2 has been approved by the FDA as treatment for metastatic 
melanoma but the toxicities associated with high-dose IL-2 have been the main 
obstacle to its widespread use in the treatment of patients. 
Interferons (IFN) are a complex family of proteins with immunomodulatory and 
antiangiogenic properties that are produced in response to viral infection or after 
T-cell activation. Their effects include upregulation of the Histocompatibility 
antigen expression on tumour cells and activation of various effector cells 
including natural killer (NK), T cells, monocytes and Dendritic Cells (DC). IFN 
was initially studied "in 1980s and was associated to an overall response rate of 
16%, with durable response generally achieved by patient with a small-volume 
cutane~us or soft tissue disease (Agarwala and Kirkwood, 1996). IFN-a has 
been used in combination with other agents, with higher response rates in the 
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IFN-a containing regimens (Hernberg et aL, 1999; Hwu et ai, 2006). Currently, 
IFN-a is used now in adjuvant therapy, in the treatment of patient after surgical 
resection of early stage melanoma, to prevent recurrences (Ascierto and 
Kirkwood,2008). 
New, innovative immune-based treatment strategies for melanoma include 
those that antagonize receptors that suppress the host immune response against 
the tumour (Cytotoxic T-Iymphocyte antige-4 CTLA-4, Programmed Death-1, PD-
1) and those that activate receptors that amplify the immune response (CD40 on 
antigen presenting cells, CD137 and OX40 on T cell). Human anti CTLA4 
antibodies (ticilimumab, iplimumab) have been tested in human clinical trials. 
Animal studies first provided insights into the ability of an anti-CTLA4 antibody to 
cause tumour regression. Early clinical studies defined ipilimumab 
pharmacokinetics and possibilities for combination therapeutic regimen. Phase II 
trials of ipilimumab in advanced melanoma showed objective reponses and, in a 
phase III trial, ipilimumab was the first agent to demonstrate an improvement in 
overall survival (10.1 months) in patients with advanced melanoma also 
comparing ipilimumab action with gp100 peptide vaccine alone (6.4 months) or in 
combination treatment of ipilimumab plus vaccine (10.0 months). In 10-15% of 
the treated patient severe immune related adverse events occurred, but most this 
treatment-related toxicity was reversible with appropriate care (Hodi et aL, 2010). 
Vaccines for melanoma are designed to boost immune reactions against a 
malignarlcy that is already established; the vaccine with the highest response 
rate (7.1 %) included DC or the addition of IL-2 to vaccines (Smith et aL, 2004). 
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Best response rate occurred in vaccinated patients with subcutaneous or 
cutaneous disease. Most vaccines were successful in generating easily 
detectable, vaccine-specific immune response. Several small studies have 
explored the efficacy of tumour-associated antigenic peptides (gp1 00, tyrosinase) 
with or without IL-2, DC or other adjuvant, with no relevant clinical efficacy, even 
if peptide-specific T cells were induced in most patients. 
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CHAPTER 2: AIM OF THE STUDY 
The cancer stem cells theory has changed our vision of how the human 
tumours are organized. Novel accumulating evidence support the idea that tumour 
cell heterogeneity is organized in a hierarchical mode and that a subpopulation of 
cells composing the tumour mass is responsible for the initiation and progression 
of tumour growth. The observation that the functional features of tumour initiating 
cells resemble those of stem/progenitor cells (proliferation capacity, self-renewal, 
and ability to sustain a differentiation program giving rise to a heterogeneous 
progeny) lead to the definition of tumour initiating cells as "Cancer Stem Cells" 
(CSCs). The isolation of cells required for tumour maintenance and progression is 
crucial to investigate new aspects of tumour biology. Furthermore, a molecular 
and phenotypic description of CSCs is essential for the identification of novel 
diagnostic and prognostic factors and to develop new therapeutic interventions 
targeting the CSC subpopulation within the tumour mass. One of the approaches 
to isolate CSCs exploits the ability of cells with stem cell properties to form non -
adherent colonies when seeded at low density in a suitable culture medium. 
Cutaneous melanoma is one of the most aggressive human tumours 
endowed with the capacity to metastasize very early in tumour pathogenesis and to 
disseminate to the draining lymph node/s and to the visceral organs by the 
haematogenous route. Melanomas are believed to arise from a mature 
differentiated melanocyte upon malignant transformation but in humans little 
information is available about the development of normal melanocyte, even if the 
existence of melanocyte precursors in a localized region of the hair follicle known 
as the hair bulge has been described. Experimental evidence suggests that 
melanomas display a high degree of heterogeneity and plasticity in vitro and in 
vivo, retaining the ability to differentiate into a wide range of cell lineages and 
suggesting a possible origin from a cell with multilineage differentiation abilities. 
Based on such considerations, it is now possible to foresee a CSC model also 
for human melanoma, and the present study is aimed at identifying and 
characterizing the putative CSCs in this human tumour. The following specific 
objectives have been addressed in this thesis: 
• Isolation of melanoma cells able to grow as floating melanospheres in 
medium suitable for stem cell in vitro maintenance. 
• Evaluation of the self-renewal capability of melanospheres, assessed as the 
ability to re-form spheres starting from one hundred or from a single cells. 
• Assessment of the multipotency, seeding melanosphere-derived cells 
culture media specific for mesenchymal lineage differentiation. 
• Evaluation of the melanosphere phenotype, with particular attention to the 
expression of melanoma and stem cell-associated markers. The expression 
of ABC drug transporter family was also studied considering the possible 
role of these proteins in melanoma drug resistance. 
• Estimation of the tumour initiating capacity of putative melanoma stem cells 
by .. serial injection into immunocompromised mice of low dose 
melanosphere-derived cells with subsequent histological evaluation of 
xenografted tumours. 
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• Immunological properties of the isolated putative melanoma stem cells 
To further highlight specific features distinguishing putative melanoma stem cells 
(melanospheres) from non stem-melanoma cells (adherent cells), the above listed 
analysis were performed on melanospheres and on the corresponding melanoma 
cells growing as an adherent monolayer in medium with the addition of FCS. 
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CHAPTER 3: MA TERIALS AND METHODS 
3.1 Melanoma cell cultures 
3.1.1 Establishment of melanoma cell lines from tumour specimens 
Lymph node melanoma metastases were collected upon patients' informed 
written consent according to the Internal Review and the Ethics Boards of the 
Istituto Nazionale Tumouri of Milan, Italy. Melanoma metastatic lesions were 
mechanically dissociated and live cells seeded in RPMI (Lonza) supplemented with 
10% FCS (PBI), penicillin/streptomycin (Sigma), HEPES buffer (Lonza), and 
maintained in 5% CO2 at 3]0 C at a the density of 1 E6 live cells per 75 -cm2 flask. 
Melanoma cells grew adherent to plastic forming confluent monolayers, and they 
were serially passed by trypsin disaggregation obtaining the melanoma cell lines 
named Me204ADH and Me14346ADH. The melanoma cell line MeJR8ADH was 
derived from a melanoma lung metastasis, and it has been kindly provided by Dr. 
G. Zuppi, Istituto Regina Elena, Rome. The fresh melanoma cell suspension 
derived from lymph node metastasis. Me15888 failed to establish an adherent 
melanoma cell line. 
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3.1.2 Selection of melanoma cells growing as non-adherent melanospheres 
Melanospheres Me204S and JR8S were derived from their corresponding 
adherent melanoma cell line adapted to grow in 10% FCS by plating at clonal 
density (2500-5000 cells/cm2) single melanoma cells grown as monolayer 
(Me204ADH and MeJR8ADH) into SCM consisting of Dulbecco's modified Eagle's 
medium/F-12 (Lonza) supplemented with 20 ng/ml epidermal growth factor (EGF, 
Peprotech) and 10ng/ml basic fibroblast growth factor (b-FGF; Peprotech), 
penicillin/streptomycin (Sigma). Melanospheres were maintained in 5% CO2 at 3r 
C by adding fresh medium every 2-3 days. Primary melanospheres were then 
mechanically dissociated into single cells and plated at clonal density in SCM. To 
generate Me 14346S and Me 15888S melanospheres, fresh melanoma cells 
obtained after mechanical dissociation of post-surgery specimens were directly 
seeded at the same clonal density in SCM, maintained and dissociated as Me204S 
and MeJR8S melanospheres. Alternatively, melanoma cells were cultured in 
mesenchymal stem cell medium STEMPRO® MSC SFM medium (Gibco) or in the 
Neural stem cell medium Neurobasal™ (Gibco) supplemented with N-2 
Supplement (Invitrogen) at the same density described above and following the 
same criteria for melanosphere dissociation. 
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3.2 In vitro assays 
3.2.1 Cytofluorimetric analysis of melanoma phenotype 
Cell phenotype was performed using the mouse anti-human primary antibodies 
reported in Table 3.1. For surface staining, 1-5E5 cells/sample were incubated with 
primary antibody for 30 minutes at 4'C except for C D126 and CD130 that were 
incubated at Room Temperature (R.T.). After washing in culture medium, cells 
stained with purified antibody were then incubated with secondary antibody anti-
mouse Alexa488 (Invitrogen). 
To analyze intracellular antigens, cells were fixed with 100Jll/sample of BD 
CytofixlCytoperm solution (Becton Dickinson, BD) for 20 minutes at 4'C. After 
fixing, cells were washed with Perm/Wash buffer 1 x (BD) and then incubated with 
primary mouse anti-human antibody and secondary anti-mouse Alexa488 antibody 
as described above. 
Nuclear antigens (Human Embryonic Stem Cell Marker Antibody Panel, R&D) 
were analyzed on cells fixed with 4% paraformaldehyde and permeabilized with 
TX-100 0.1 % in phosphate-buffer saline (PBS) for 30 minutes at R.T. Staining was 
performed following the manufacturer's instructions and anti-goat or anti-mouse 
Alexa488 (Invitrogen) were used as the secondary antibody. Stained cells were 
analyzed by flow cytometry (FACScalibur, BD) and analyzed using FlowJo, V 8.5.2 
(Treestar). Cells stained according to the protocol described above, were seeded 
on microscope slides by cytospin at 400rpm for 5 minutes and let them dry up for 4 
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hours. When spots were dry, cover slips were mounted with 20% Mowiol (Sigma) 
and cells were analyzed under fluorescent microscope (Nikon Elipse 600). 
Table 3.1 List of Antibodies used for FACS analysis. 
Anti-human Antibody Cellular localization Fluorocrome Host species Factory 
C09 Cell surface Purified Mouse R&D 
C020 Cell surface FITC Mouse BD 
C024 Cell surface FITC Mouse BD 
C044 Cell surface FITC Mouse BD 
C073 Cell surface Purified Mouse BD 
C080 Cell surface PE Mouse BD 
C086 Cell surface PE Mouse BD 
C0126 (IL-6Ra) Cell surface Purified Mouse BD 
C0130 (gp130) Cell surface Purified Mouse BD 
C0133/2 Cell surface PE Mouse Miltenyi 
C0146 (MCAM) Cell surface Purified Mouse BD 
C0152 (CTLA-4) Cell surface! Cytoplasm PE Mouse BD 
C0166 (ALCAM) Cell surface Purified Mouse BD 
C0181 (CXCR1) Cell surface APC Mouse BD 
C0182 (CXCR2) Cell surface APC Mouse BD 
C0192 (CCR-2) Cell surface APC Mouse BD 
C0271 (NGFR) Cell surface Purified Mouse BD 
C0274 (PO-L 1) Cell surface PerCP Mouse BD 
C0279 (PO-1) Cell surface FITC Mouse BD 
IL-10Ra Cell surface PE Mouse R&D 
SSEA-1 Cell surface Purified Mouse R&D 
SSEA-4 Cell surface Purified Mouse R&D 
Nestin Cytoplasm Purified Mouse R&D 
Mart-1 Cytoplasm Purified Mouse Kawakami 
(clone M-27) et ai, 1997 
Gp100 (HMB45) Cytoplasm Purified Mouse Dako 
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Anti-human Antibody Cellular localization 
Sox2 Nucleus 
Oct3/4 
Nanog 
Musashi-1 
Nucleus 
Nucleus 
Nucleus 
3.2.2 Cytokines Bead Array (CBA) 
Fluorocrome Host species Factory 
Purified Mouse R&D 
Purified Goat R&D 
Purified 
Purified 
Goat 
Mouse 
R&D 
R&D 
Cell culture supernatants were collected after elimination of cells trough 
centrifugation and stored at -20'C. Cytokines and c hemokine concentration in 
culture supernatants were analyzed using the Human Th 1 ITh2 cytokines 11 plex 
and the Human chemokines 6plex kits (Bender MedSystem) according to the 
manufacturer's instruction. Briefly, 25JlI of cell culture supernatants were added to 
25JlI of assay buffer and to 25JlI of the biotin-conjugated beads in polystyrene 
FACS tubes. Mixtures were incubated at R.T. for two hours. After washing, 50JlI of 
streptavidin-PE solution was added and incubated for 1 hour at R.T. After washing, 
samples were acquired using a FACSCalibur (BO). FACS raw data were analyzed 
with the specifically designed FlowCytomixPro Software (BenderMedSystem). 
3.2.3 Sphere forming assay and clonogenic assay 
For the Sphere Formation Assay (SFA), 100 single viable cells obtained from 
melanosphere dissociation were plated in 500JlI of SCM in a 48-well plate coated 
overnight with poly-Lysine (Sigma). C~lIs were fed every 2-3 days by adding fresh 
SCM; after 5-8 days melanospheres were counted. For the clonogenic assay, 
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100J.l1 of SCM containing 2.S cells/ml were seeded in 96-multiwell plate. After 2-4 
hours, each well was examined under the microscope and wells containing a single 
cell were then checked for sphere formation over the following days. In some 
experiments, viable melanoma cells were sorted according physical parameters 
thorough (FCSAria, BD) and seeded one cell/well into a 96 well plate. 
3.2.4 Differentiation assay 
Melanoma cells were induced to differentiate into adipocytes, chondrocytes and 
osteocytes according to the culture condition and staining procedures indicated in 
the Human Mesenchymal Stem Cell Functional Identification Kit (R&D). 
For Melan-A staining 60.000 viable cells/cm2 were plated in Lab-Tek chamber 
slides (Nunc) in RMPI+10%FCS for 2-4 days, until they were sub-confluent. 
Culture medium was removed and cells fixed with 4% PFA for 10 minutes at R.T. 
After washing with PBS containing O.S% of Bovine Serum Albumin (PBS-BSA 
O,S%), cells were incubated with a PBS-BSA 2% solution for 20 minutes at R.T. 
and subsequently incubated with 100J.lI/weli primary anti-Melan-AlMart-1 antibody 
for 60 minutes at R.T. After washing, cells were incubated for 60 minutes at R.T. in 
the dark with 300J.lI/weli of a PBS-BSA 2% solution containing the anti-mouse 
Alexa488 secondary antibody diluted 1 :300 (Invitrogen); nuclei were stained for 10 
min in the dark with 3 OOJ.lI/we II of a PBS-BSA 2% solution containing 
Hoe'chst33342 at final concentration of Sug/ml (Sigma). After washing, cover slips 
were mounted with 20% Mowiol in _ H20 (Sigma) and cells analyzed under a 
fluorescence microscope (Nikon Elipse 600). 
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3.2.5 Real Time PCR 
3.2.5.1 RNA extraction 
RNA extraction and digestion with DNase were carried out with the 
RNAqueous®-4PCR Kit (Ambion Europe LTD, Huntingdon, UK), according to the 
manufacturer's instructions. Obtained RNA was quantified by NanoDrop 
(Thermoscientific). RNA purity and integrity were assessed loading 500ng of 
extracted RNA on gel 1 % agarose gel in TBE Buffer1 x and running samples for 
about 30 minutes at 80V. Extracted RNA was then stored at -80CC. 
3.2.5.2 cDNA synthesis 
cDNA synthesis was performed with the High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems). 1Jlg of RNA was mixed with the 2x master 
mix (10xRT buffer; 25x dNTP mix 100mM; 10x RT random primers; MultiScribe™ 
Reverse Transcriptase; RNase inhibitors; Nuclesae-free H20) into each sample. 
The reaction mixture was incubated at 25CC for 10m inutes, followed by 120 
minutes at 37CC and then by heat inactivation of th e enzyme at 85CC for 5 sec in a 
GeneAmp® PCR System 9700 Thermal Cycler (Applied Biosystems). 
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3.2.5.3 Real Time peR 
The real-time PCR reaction was performed by taking advantage of TaqMan® 
Human ABC Transporter Arrays (Applied Biosystems), containing assays for 50 
human ABC transporter family genes in addition to 14 endogenous controls in 384-
well arrays. For the detection of immune-related genes the TaqMan® Human 
Immune Array (Applied Biosystems) was used. 
Briefly, in every port of the array cDNAs (2~1), TaqMan Universal PCR Master 
Mix (Applied Biosystems, 50~1) and nuclease-free water (48~1) were loaded. The 
reactions were performed using the ABI 7900HT instrument (Applied Biosystems). 
The relative levels of templates in each sample were determined through 
Relative Quantitation (RQ) using comparative CT (LlLlCT) assay configuration 
(RQ=ZMcT, where ~CT=CTtarget genes - CT GAPDH, and MCT=~CTsample -
~CT calibrator). 
The GAPDH gene was used as endogenous control. Data analysis was 
performed with SDS (Sequence Detection Systems) 2.2.2 software (Applied 
Biosystems). 
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3.2.6 Molecular characterization of melanospheres and adherent cells 
3.2.6. 1 Cellular extraction DNA 
The cells (2E6 - 4E6) were centrifuged at 1800 rpm for 5 minutes. The obtained 
pellet was washed with PBS and DNA extracted with the kit Qiamp DNA Blood Mini 
Kit (Quiagen) following the protocol for purification of DNA from Blood and Body 
Fluid. DNA was been eluted in 200~1 of Buffer AE (in the Kit) and stored at 4° C. 
The quantity and quality of DNA were measured by assessment of absorbance at 
260 and 280 nm (Nanodrop, Labtech International). 
3.2.6.2 Homozygous Deletion Analysis 
To assay for homozygous deletions of the CDKN2A gene, a comparative 
multiplex polymerase chain reaction technique was used. Globin was amplified as 
a control gene, and three exons of CDKN2a gene and the first exon of p14 gene 
were amplified. Primers, temperature annealing (TA) and length of fragments 
obtained by PCR are reported in Table 3.2. We used SOng of genomic DNA in final 
volume of 20~1 Mix containing 1 X of Buffer 10X, 0.1 mM dNTP 2mM, 1,5mM di 
MgCb 25 Mm, 0.2pM oligo1 10pM, O.4pM oligo2 10pM and 1 unit Ampli Taq 5 U/~I. 
PCR reactions were set with an initial denaturation of 5 minutes at 95CC and 
subsequent denaturation for 30s at 95CC, annealing for 30 seconds at 57CC and 
extension for 30 seconds at 72CC. Thirty-five cycle s were used to amplify the PCR 
products that were separated by electrophoresis on 3% agarose gels and 
visualized under ultraviolet light by ethidium bromide staining. 
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Table 3.2 List of primer pairs and peR conditions for homozygous deletions analysis. 
AMPLICON OLIGO SEQUENCE EXON TA LENGTH 
NAME NAME 
GLOBINA GLOFW 5'-CTT CTG ACA CAA CTG TGT TCA CT- 3' 5r 120bp 
GLORW 5'-TCA CCA CCA ACT TCA TCC ACG T-3' 
p14 18 FW 5'-TCC CAG TCT GCA GTT AAG -3' 113 5r 488bp 
IBRV 5'-GTC TAA GTC GTT GTA ACC CG -3' 
p16/CDKN2A P1611F 5'-CAG AGG ATT TGA GGG ACA GG-3' 10 5r 403bp 
P1613R 5'-AGAATC GAA GCG CTA CCT GA-3' 
p16/CDKN2A P1622F 5'-AGC TTC CTT TCC GTC ATG C-3' 2 5r 410bp 
P1625R 5'-GGA AGC TCT CAG GGT ACA AAT TC-3' 
p16/CDKN2A P1632F 5'-GCA GTG GAC TAG CTG CTG CTG GA-3' 3 5r 388bp 
P1632R 5'-TTA CGG TAG TGG GGG AAG G-3' 
3.2.6.3 BRAF Mutational Analysis 
Mutant allele-specific PCR was used to detect the BRAFv600E mutation as 
previously described (Pollock et aI., 2003). Briefly, two different forward primers 
with a single base substituted at the end of the primer, were used to amplify the 
wild-type allele and the BRAF mutation, respectively. The reverse primer used for 
both reactions was common. Temperature annealing (TA) and length of fragments 
obtained by PCR are reported in Table 3.3. Both PCR reactions were done 
separately in a 25IJL reaction volume containing 1 X of Buffer 10X, 1.5mmoliL 
MgCb, 0.1 mM dNTP 2mM, 1,5mM di MgCb 25mM, 50ng of genomic DNA, 0.2pM 
oligo 10pM, and 0.25 units of Ampli Taq 5 U/IJI . Both PCR reactions were set with 
an initial denaturation of 7 minutes at 95'C and su bsequent denaturation for 30 
seconds at 95'C, annealing for 30 seconds at 60'C, and extension for 30 seconds 
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at 72'C. Forty cycles were used to amplify the PCR products that were separated 
by electrophoresis on 3% agarose gels and visualized under ultraviolet light by 
ethidium bromide staining. Two controls, one mutated and one wt were included in 
PCR amplifications. 
Table 3.3 List of primer pairs and peR conditions for BRAF mutational analysis. 
AMPLICON OLIGO SEQUENCE EXON TA LENGTH 
NAME NAME 
Brafwt Brafwt fw 5'-ACAGT AAAAA TAGGTGA TITTGGTCT AGCTACAGT - 3' 15 60° 198 bp 
Brafwt rw 5'-CTATGAAAATACTATAGTTGAGACCTTCAATGACTT-3' 
Braf mut Braf mut fw 5'- ACAGTAAAAATAGGTGATTTTGGTCTAGCTACAGA -3' 15 60° 198 bp 
Brafwt rw 5'-CTATGAAAATACTATAGTTGAGACCTTCAATGACTT-3' 
3.2.7 Western Blot analysis 
3.2.7. 1 Protein extraction and quantification 
Melanospheres were collected and dissociated as indicated in section 3.2.1 and 
4E6 cells were centrifuged to obtain a pellet. Cell pellets were washed twice in cold 
Phospahte Buffer Saline (PBS) and lysed for 30 minutes on ice in Ripa-Like buffer 
(50nM Tris, 250mM NaCl , 0.1 % SDS, 0.5% NP40, 2mM DTT) containing the 
protease inhibitor Pepstatin 5mg/ml (USB), Leupeptin 10mg/ml, Aprotinin 1 mg/ml 
and PMSF 10mM (Sigma). After lysing, samples were centrifuged at 12000 rpm for 
15 minutes at 4'C to recover the protein fraction i n the supernatant. Protein 
quantification was calculated using the BCA colorimetric assay (Bio-Rad). Briefly, 
equal volu~e of samples and serial dilutions of a solution containing a known 
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concentration of Albumin from Bovine Serum (BSA) were seeded in a 96 well plate 
and subsequently copper sulphate and bicinchoninic acid (BGA) were added to the 
samples. After 15 minutes of incubation at R.T. absorbance at 550nm of wave 
length was read at the spectrophotometer; a calibration line obtained measuring 
absorbance with known concentration of the BSA sample, was used to calculate 
the protein concentration of each sample. 
3.2.7.2 Electrophoresis 
For Western Blotting, 60~g of proteins were denaturated for 10 minutes in a 
solution containing 0.5M OTT and LOS sample buffer (SOS, bromophenol blue, 
glycerol, Invitrogen) and separated on 4-12% Bis-Tris precasted gels (Invitrogen) in 
Running Buffer (MOPS-SOS 20x: MOPS 1M, Basic Tris 1M, SOS 69.3mM, EOTA 
20.5mM) using a vertical electrophoresis apparatus (Novex mini cell; Invitrogen) at 
120V for about 2 hours. 
3.2.7.3 Protein Transfer and signal detection 
After electrophoresis, protein were transferred to Nitrocellulose membrane 
(Hybond, Amersham) and embedded with Transfer Buffer (Bicin 500mM, Bis-Tris, 
500mM, EOTA 20.5mM) using a semidry apparatus (Hoefer semiphor, Amersham) 
at 45mA for about 1 h. Membranes previously saturated with PBS-milk 5% solution, 
were probed with human primary antibody (see Table 3.4) diluted in PBS-milk 
0.5% O.N at 4'C. After washing in PBS Tween 0.1% mi Ik 0.5%, the signal was 
detected using peroxidase-conjugated anti mouse antibody (BO) or anti-rabbit 
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secondary antibodies (Amersham) for 1 h at R.T., washed and developed using the 
ECl Plus Western Blotting Detection System (Amersham). Photographic plates 
were developed using a developing machine (Curix 60, AGFA). As loading control , 
all membranes were also hybridized with a anti-vinculin antibody. 
Table 3.4 List of primary antibodies used in WB analysis . 
Anti-human Antibody Host species Concentration Factory 
PTEN mouse 1:500 A.G. Scientific 
AKT mouse 1:500 Cell Signaling 
pAKT (serin4fJ) mouse 1:500 BO 
ERK1,2 rabbit 1 :10000 Sigma 
p-ERK1,2 (Thr' tlJ and Tyr'tlb in ERK-2) mouse 1 :10000 Sigma 
Vinculin mouse 1:10000 Sigma 
3.3 In vivo assays 
3.3.1 Evaluation of tumorigenic potential 
Seven week old SCIO mice (Charles River) were intradermally injected with 
either 104 , 103 or 102 melanosphere-derived cells or melanoma adherent cells 
resuspended in PBS and mixed with Matrigel (BO) at a 1:1 ratio. Viability of the 
injected cells was determined using the Trypan Blue exclusion test. Experiments 
were approved by the Ethics Committee for Animal Experimentation of the Istituto 
Nazionale Tumori of Milan according to institutional guidelines. Mice were followed 
for up to 200 days or sacrificed when ·tumour mass was >1.5g. To perform serial 
transplantati~ns, mice bearing tumours of about 500mg were sacrificed, their 
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tumour mechanically dissociated as reported for human tumour specimens and 
viable single cells were re-injected into SCID mice with the same modality as the 
first injection. 
3.4 Ex-vivo assays 
3.4.1 Immunoistochemistry 
25 human tissue samples consisting of 11 primary melanomas, 14 metastatic 
melanomas and 70 xenograft tumours were analyzed by indirect 
immunohistochemistry. Formalin-fixed, paraffin-embedded tissue sections (1-2IJm) 
were incubated in methanol plus 0.3% H20 2 for 30 min to quench endogenous 
peroxidase activity, rinsed with water several times, and incubated with one of the 
monoclonal mouse anti-human primary antibodies listed in Table 3.5. 
Antigen retrieval was performed in 0.05 molll sodium citrate (pH 6) for 6 min at 
95'C in an autoclave for Melan-A, HMB45 and Nestin; 0.05 molll sodium citrate 
(pH 6) for 15 min at 95'C in an autoclave for NGFR; 0.05 molll sodium citrate (pH 
6) for 30 min at 95'C in an autoclave for CD133 and MITF; EDTA 6 min for CD166, 
followed by cooling to room temperature and final rinses in PBS. Nonspecific 
binding sites were blocked by incubation with Ultra V Block (lab Vision) for 10 
minutes at RT. A secondary biotinilated anti-mouse antibody was incubated for 30 
minutes at RT. diluted 1 :100 (Dako Cytomation). After washing, tissues were 
incubated 30 minutes at RT. with peroxidase-conjugated streptavidin diluted 1 :300 
(Horseradish Peroxidase, Dako Cytomation). The peroxidase enzyme reaction was 
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developed with 3,3'-diaminobenzidine (Oako Cytomation). For negative controls, 
primary antibody was omitted. 
Table 3.5 List of primary antibod ies used in immunohistochemistry analysis . 
Anti-human Antibody Host Cellular Dilution Factory 
species localization 
Anti-Human Melanosome mouse Cytoplasm 1:50 Dako 
(gp100) clone HMB45 
Melan-A (Mart-1) mouse Cytoplasm 1:50 Dako 
Clone A103 
M ITF Clone 34CA5 mouse Nucleus 1:200 Novocastra Laboratories 
Nestin mouse Cytoplasm 1:200 Chemicon 
CD133/1 clone AC133 mouse Cell membrane 1 :25 Miltenyi 
CD166 (MCAM) clone MOG/O? mouse Cell membrane 1 :10 Novocastra Laboratories 
CD271 (NGFR) clone ?F1 0 mouse Cell membrane 1 :50 Novocastra Laboratories 
3.4.2 Masson-Fontana staining for melanin detection 
6IJm thick deparaffinised and hydrated sections were cut and stained with Silver 
Nitrate solution for 1 hour at 56'C. When sections were light brown, they were 
rinsed with distilled water and then stained with gold chloride solution 0.2% for 10 
minutes at R.T. After washing , sections were incubated with sodium thiosulfate 
solution 5% for 5 minutes at R.T. Washed sections are then dehydrated with xylol 
and observed under a light microscope (Nikon). 
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3.4.3 Transmission Electron Microscopy (TEM) analysis 
11 tumours were fixed with 4% paraformaldehyde and 2% glutaraldehyde in 
phosphate buffer 0.12M. The samples were post-fixed with 1 % Os04 in cacodylate 
buffer, dehydrated in ethanol and embedded in epoxy resin. Ultrathin sections 
(60nm), obtained with ultra microtome Ultracut E Reichert-Jung, were doubly 
stained with uranyl acetate and lead citrate and examined with a transmission 
electron microscope eM 10 Philips. 
3.4.4 Statistical analysis 
The differences in tumourigenicity (tumour take and latency) and in the tumour 
mass of the xenografts generated by melanospheres and adherent cells were 
statistically evaluated. For all the analyses, multiple regression models were used: 
a log-normal model for "time-to-event" data to evaluate differences in the 
tumorigenicity, and a generalized linear model for normal data in the case of 
tumour mass. The statistical assumptions were verified, and the log-normal model 
was chosen as being the best fit among a number of parametric alternatives 
(exponential, Weibull, and log-logistic models). The model predictors were 
treatment (melanospheres and adherent melanoma cells), cell line (Me204, 
MeJR8, and Me14346), and dose (104, 103, and 102). When treatment was the 
factor of experimental interest, cell line and dose represented study design related 
covariates. Ail these factors were categorical, and thus coded within the models by 
indicator (0-1) dummy variables. A search for interactions between treatment and 
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cell line or dose was also performed. Analyses were performed with SAS (Cary, 
NC); two-sided P-values of 00.05 were considered statistically significant. 
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CHAPTER 4: RESULTS 
4.1 Melanoma cells form anchorage-independent, self-renewing 
and multipotent spheres in stem cell medium. 
Normal and cancer stem cells can be selected in vitro by exploiting their ability 
to organize into anchorage-independent, three-dimensional spherical structures 
when cultured in serum-free medium supplemented with specific growth factors. In 
the present thesis, this same strategy has been applied with the aim of testing the 
hypothesis that cells with stem cell properties are indeed present in human 
metastatic melanoma and that these cells can be isolated in vitro either from 
melanoma cell lines already adapted to grow as an adherent monolayer or directly 
from fresh cellular suspension obtained by tissue processing of post surgery 
specimens. 
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4.1.1 Selection of cells growing in Stem cell medium (SCM) 
For the purpose outlined above, 18 lymph node melanoma metastases were 
processed as described in materials and methods and viable melanoma cells 
obtained after mechanical and enzymatic digestion were seeded in SCM. SCM 
supported the selection of cells growing as melanospheres in 8 of these lesions 
with a success rate of 44%. A similar success rate of melanosphere formation 
(32%) was achieved when melanoma cell lines, previously established as adherent 
cells in FCS, were used as the source of melanoma cells to be seeded in SCM. 
Melanospheres were also obtained using commercial media for neural stem cells, 
while media for mesenchymal stem cells was less efficient in supporting 
melanosphere generation and growth (Table 4.1). 
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Table 4.1. Selection of melanospheres using different culture media. 
Cell type Origin of cells SCM Mesenchymal Neural 
SC medium SC medium 
Me204S Adherent cells + + + 
MeJR8S Adherent cells + + + 
Me14346S Fresh suspension + + + 
Me15888S Fresh suspension + + + 
Me104B Adherent cells + + + 
Me304 Adherent cells No spheres No spheres Short term spheres 
Me8146 Adherent cells Short term spheres No spheres Short term spheres 
Me1 Adherent cells No spheres No spheres No spheres 
Me8 Adherent cells No spheres No spheres Short term spheres 
Me5127 Fresh suspension Short term spheres No spheres Short term spheres 
Me7902 Fresh suspension Short term spheres No spheres Short term spheres 
Me5988 Fresh suspension Short term spheres No spheres Short term spheres 
Me2179 Fresh suspension Short term spheres No spheres Short term spheres 
Me1390 Fresh suspension No spheres No spheres No spheres 
Four of these melanosphere cultures, two derived from adherent melanoma cell 
lines, namely melanospheres MeJR8S and Me204S, and two derived directly from 
lymph node melanoma metastasis, namely Me15888S and Me14346S, were kept 
in vitro by sequentially dissociating and re-seeding at low density in SCM medium 
for several passages (> than 30) and used in this thesis. 
Viable melanoma cells obtained after mechanical and enzymatic digestion of 
metastatic lesion Me14346 were also seeded in medium supplemented with 10% 
of FCS and thus the corresponding adherent cell line, named Me14346ADH was 
also established. The fresh melanoma cell suspension derived from melanoma 
Me15888 failed to establish an adherent melanoma cell line and thus the adherent 
counterpart of Me15888S was not available for analysis. 
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4.1.2 Self-renewing capacity 
Stem cells usually display an undifferentiated status and have the crucial 
features of self-renewal and multilineage differentiation. The self-renewing 
capacity of tumour spheres was evaluated by sphere formation and clonogenic 
assays. Both tests gave consistent results showing that all the melanospheres 
displayed a quite high frequency of self-renewing cells when seeded in SCM both 
at clonal density (SFA) or as single cells (clonogenic assay) (Figure 4.1). 
Figure 4.1 Clonogenic assay. One single cell seeded in a well of a 96well-plate and, after 
subsequent cell divisions, gives rise to a melanosphere. Numbers indicate time (h=hours) in culture 
in SCM after single cell seeding. 
To test whether cells endowed with self - renewal were also detectable inside 
melanoma cell lines growing as a monolayer, SFA and clonogenic assays were 
also performed with melanoma cells obtained by melanoma adherent cell lines 
after trypsin digestion. As reported in Table 4.2, self-renewing cells were also 
present in adherent melanoma cell lines but their frequency was significantly lower 
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than in the corresponding melanosphere-derived counterpart. These data suggest 
a strong enrichment of the self-renewing cells in melanospheres (Table 4.2). 
Table 4.2. Self-renewal of melanospheres (S) and melanoma adherent cells (ADH). 
Cell Type SFA1 Clonogenic as sal 
Me204 S 54 ±7.15:3 52.7 ± 5.6 
ADH 10.7±8.2 4.4 ± 0.3 
MeJR8 S 25.6 ± 1.1 18.5 ± 2.1 
ADH 8.2 ± 3.8 6.4 ± 0.2 
Me14346 S 26.9 ± 4.1 11.8 ± 4.2 
ADH 0.9±1.1 0 
Me1S8884 S 14 ± 8.2 5.8 ± 1.8 
1 Percentage of melanospheres per 100 cells 
2 Percentage of clones per total single cells seeded 
3 Mean ± SD (Standard Deviation) calculated on the basis of three independent experiments 
4 Me15888 failed to establish an adherent melanoma cell line, thus the adherent counterpart of 
Me15888S was not available for analysis. 
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4.1.3 Multilineage differentiation capacity 
Melanocytes derived from the pluripotent cells of the neural crest, that give rise 
also to cells of the mesenchymal lineage. In view of the fact that multipotency is 
one of the main features defining stem cells, in this thesis melanosphere-derived 
cells or their adherent counterpart were tested for the ability to differentiate into 
cells of mesenchymal origin by withdrawal of growth factors and culture in 
differentiating media specific for the cells of mesenchymal lineage. Differentiation 
was monitored by detecting the acquired expression of markers specific for each 
lineage, namely Osteocalcin for osteocytes, Fatty Acid Binding Protein-4 (FABP4) 
for adipocytes and Aggrecan for chondrocyte differentiation. 
Canonical melanoma differentiation was assessed seeding melanosphere-
derived cells into the medium for adherent melanoma cell lines, namely RPMI 
supplemented with 10% FCS and testing the expression of the Melan-AIMART-1, a 
marker for melanocytic lineage differentiation. 
As shown in Figure 4.2, Me204S was able to differentiate in all the 3 cell types 
of mesenchymal origin with similar efficiencies, and it also expresses Melan-
AlMART-1 upon seeding in 10%FCS. Conversely, the adherent counterpart 
Me204ADH did not display differentiation capacity for any of the mesenchymal 
lineages tested, while keeping a high expression of MelanAlMart-1, supporting the 
notion that melanospheres are enriched in self-renewing multi potent cells. 
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Figure 4.2 Mesenchymal differentiation of melanospheres and melanoma adherent cells . 
(Me204S (A) and Me204ADH (8) cells were induced to differentiate in osteogenic, adipogenic 
chondrogenic media . Differentiated cells were then stained for Osteocalcin (green , Alexa 488), 
FA8P4 (red, TRITe) or Aggrecan (red, TRITe), and with Hoechst33342 (upper and lower row in A 
and 8). Melan-AiMART-1 staining was also performed after culturing Me204S and Me204ADH in 
medium with serum. (e) Histogram shows the percentage of Me204S (grey columns) and 
Me204ADH (black column) cells expressing the indicated differentiation marker counted in ten 20x 
random fields . Data reported mean ± SE (Standard Error) of three independent experiments were 
performed and each experiment was performed in triplicate. Scale bar = 100 11m . 
A 
(j) 
~ 
o 
N 
Q) 
~ 
B 
I 
o 
<{ 
~ 
o 
N 
Q) 
~ 
c 
Osteocalcin FABP4 
Osteocalcin FABP4 Aggrecan Melan-A/MART-1 
Aggrecan 
o Me204S 
_ Me204ADH 
Melan-AlMart-1 
112 
4.2 Phenotypic characterization of melanospheres 
To better characterize the growing melanospheres, the presence of the most 
common mutations associated to melanoma was checked by taking advantage of 
PCR-based techniques and, subsequently, the activation status of melanoma-
associated proliferative pathways was analyzed by western blot. In addition, it is 
well known that melanoma is a tumour highly resistant to standard chemotherapy, 
and ABC transporter expression has been associated with cancer stem cell 
properties. Thus real time PCR analysis for the expression of ABC transporter 
mRNA was also included in this thesis. 
Finally, the surface expression of melanoma differentiation and cancer stem cell-
related markers was evaluated on melanospheres and on their corresponding 
adherent cell lines as well. 
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4.2.1 Mutational analysis and activation status of melanoma proliferative pathways 
on melanospheres and adherent cells 
As reported in Table 4.3, the mutational status of melanospheres was variable 
and as absence of mutation in BRAF was associated with CDKN2A deletion. 
Table 4.3. Melanoma common genetic alteration in melanospheres and adherent cells lines used in 
this study. S= melanospheres; ADH=Adherent cells; WT= Wild Type; MUT= mutated; POS= 
positive; HD=homozygous deletion. 
Cell Type BRAF V600E CDKN2A 
Me204 S wt HD 
ADH wt HD 
MeJR8 S MUT pos 
ADH MUT pos 
Me14346 S wt HD 
ADH wt HD 
Me15888 S MUT pos 
Conversely, as evidenced by western blot all the melanospheres lacked PTEN 
expression, consequently showing an enhanced level of activated AKT (p-AKT) as 
compared to mela.nocytes that instead were enriched in PTEN. PTEN deficiency is 
known to be associated with constitutive activation of AKT, which lead to enhanced 
proliferation and a more aggressive behaviour. Moreover, the ERK pathway was 
also activated in melanospheres as confirmed by the positive staining for p-ERK, 
the activated form of ERK (Figure 4.3). _ 
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Figure 4.3 WB analysis of signalling pathway activated in melanospheres. All the analyzed 
melanospheres express total (t-ERK) and activated ERK (p-ERK). Moreover, melanospheres 
express AKT (t-AKT) and its active form (p-AKT) while lacking PTEN that is widely expressed on 
melanocytes. 
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4.2.2 Expression of ABC transporters on melanospheres and adherent cells 
ABC transporters have been implicated in conferring resistance to multiple 
antitumor drugs and they are likely to be involved in the drug-resistant phenotype 
of CSCs of different tumour types. Thus, we used a genome-wide approach to 
examine the expression level of such transporters in our melanoma models. The 
TaqMan microfluidic cards were chosen for this analysis because they allow 
simultaneous assessment of all 50 known ABC transporters. 
Cultured melanocytes were also examined and used as a calibrator for data 
analysis In Table 4.4. ABC transporters upregulated or downregulated in 
melanoma cells compared to melanocytes are reported in red and in blue 
respectively. The melanoma tumour initiating cell markers ABCB5 (green boxed in 
Table 4.4) was expressed at high level on melanocytes in accordance to published 
data (Heimerl et aI., 2007). Me14346S melanospheres displayed an enhanced 
level of ABCB5 with respect to their adherent counterpart (Me14346ADH) (Figure 
4.4). Different components of the ABCC subfamily -recognized as crucial for the 
multidrug-resistant phenotype (Gatti et aI., 2009) - displayed enhanced levels in the 
three melanosphere models as compared to the corresponding adherent cells 
(ABCC1, ABCC2, ABCC4, pink-boxed in Table 4.4), whereas ABCG2 (yellow 
boxed in Table 4.4), a well known marker for CSC of different tumour types, was 
not up-regulated. 
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Table 4.4. Detection of ABC transporter mRNA in melanospheres and adherent cells . Melanocytes 
were used as calibrator. 
Me14346 Me204 MeJR8 Me15888 1Melanocytes 
ADH S ADH S ADH S S ADH 
2RQ RQ RQ RQ RQ RQ RQ RQ 
ABCA1 0,12 0,19 0,05 0,36 2,39 0,09 0,05 1 
ABCA2 0,74 5,7 3,79 8,94 4,02 3,02 6,65 1 
ABCA3 0,06 1,68 33 ,71 6,94 12,17 0,62 243,97 
ABCA4 3081 ,38 3 683,95 1860,63 
ABCA5 0,64 5,74 0,5 5,01 0,89 1,57 3,35 1 
ABCA6 0,07 0,16 0,19 0,16 0,06 0,61 1 
ABCA7 0,14 1,21 0,72 0,63 0,56 0,25 5,73 1 
ABCA8 0,01 36,89 0 0,06 0,02 
ABCA9 0,49 1,93 0,74 0,27 0,68 1 
ABCA10 0,37 2,36 3,31 0,63 0,7 3,7 
ABCA11 0,64 2,67 0,57 0,49 0,44 0,22 0,71 1 
ABCA12 0,63 0,58 113,96 1 
ABCA13 392,35 0 1,12 
ABCB1 1,55 0,1 0,3 0,66 0,03 0 107,35 
ABCB4 0,48 0,13 0,01 0,01 0,16 0,01 1,3 
ABCB5 0,02 0,21 0 0 0 0 0 
ABCB6 0,59 1,91 0,61 1,36 0,6 0,63 1,12 
ABCB7 0,82 2,53 0,63 1,9 0,87 0,59 2,63 
ABCB8 0,25 1,54 0,27 0,57 0,45 0,39 1,13 
ABCB9 0,33 0,58 0,56 0,1 0,57 0,69 1,29 
ABCB10 0,49 1,93 0,36 0,02 0,73 0,86 4,4 
ABCB11 
ABCC1 0,58 2,32 0,54 1,4 1,01 0,82 1,52 
ABCC2 0,48 2,01 0,02 1,05 0,45 0,6 2,77 
ABCC3 1,11 4,79 323,27 36,56 0 0 0 
ABCC4 1,17 1,47 0,17 I 2,03 I 1,22 1,06 3,09 
ABCC5 0,46 2,35 0,84 1,47 0,97 0,62 4,03 
ABCC6 3,43 4,25 0,71 1,5 0 3,06 
ABCC8 1940,61 6601 ,22 0 
ABCC9 2,97 
ABCC10 0,23 0,98 0,14 0,83 0,44 0,36 2,16 
ABCC11 0,08 1,68 0,64 0,14 2,68 
ABCC12 
ABCC13 
ABCD1 0,4 0,38 0,2 1,6 1,23 0,96 4,6 
ABCD2 1,02 0,82 1,16 0,35 
ABCD3 1,02 1,25 0,25 0,81 0,32 0,41 0,43 
ABCD4 0,43 1,06 0,77 1,14 0,73 0,42 3,57 
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Me14346 Me204 MeJR8 Me15888 1Melanocytes 
ADH S ADH S ADH S S ADH 
2RQ RQ RQ RQ RQ RQ RQ RQ 
ABCE1 0,55 1,23 0,44 0,89 0,45 0,48 1,29 
ABCF1 1,28 2,05 0,71 1,21 0,7 0,67 2,16 
ABCF2 0,83 2,18 2,1 1,21 0,77 0,75 0,95 
ABCF3 0,57 2,18 0,78 0,5 0,5 0,41 1,67 
ABCG1 0,18 22,16 155,9 3,32 
ABCG2 0,53 0,49 2,88 1,1 1,08 0,52 0,58 
ABCG4 0,06 1,97 1,64 8,26 5,04 1,57 1,04 
ABCG5 
ABCG8 
TAP1 0,09 0,64 0,04 0,29 0,08 0,11 1,42 
TAP2 0,28 1,58 0,05 0,7 0,24 0,27 0,89 
1: calibrator; 2: RQ values calculated using the equation RQ=2-LlLl Ct. LlLlCt values were calculated 
by subtracting the LlCt of the calibrator from the LlCt value of each target; 3: Absent genes defined as 
genes with L1Ct above 25 cycles . ° = RQ< 1 E-3. 
Overall , the MeJR8 cells appeared to be characterized by a modest modulation 
of transporter genes, and several transporters were already up-regulated in 
adherent cells. However, an interesting pattern of modulation was observed in the 
Me14346 system in which several transporters (ABCA2-3-S-7-8-9-10-11-13; 
ABCBS-7-8-10; ABCC1-2-3-S-6-8-11; ABCD4; ABCE1; ABCF1-2-3; ABCG1 -4 and 
TAP2) displayed increased expression in 14346S melanospheres as compared to 
both the corresponding adherent (Me14346ADH) cells and melanocytes (Figure 
4.4). 
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Figure 4.4. Differential expression of ABC transporters by Me14346S or Me14346ADH cells . 
Several members of ABC transporter families are differentially expressed on Me14346S (grey 
columns) with respect to their adherent counterpart (Me14346ADH. black columns). RQ values 
(calculated as indicated in Table 4.4) are reported on Y axes in logarithmic scale. Melanocytes were 
used as calibrator. 
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4.2.3 Expression of melanoma differentiation and stem-related markers on 
melanospheres and adherent cells 
All the generated melanospheres were negative for the haematopoietic marker 
CD45, while they displayed 100% positivity for MelanAlMart-1 and HMB45 
melanocyte differentiation proteins (Figure 4.5A). The expression of the melanoma 
associated markers CD146 and GD3 was variable with virtually all Me14346S cells 
staining negative for GD3 and a very low percentage staining positive for CD146 
(Figure 4.5A). Melanosphere cells did also express several embryonic stem cells 
markers and all the melanospheres behaved similarly being nearly 100% positive 
for CD9, Sox2 Oct3/4 and Nanog proteins, whereas a very low percentage of cells 
(or none at all) expressed SSEA-1 and SSEA-4. A low rate of expression was 
observed for Musashi-1, with 13-16% Me15888S and Me204S staining positive 
(Figure 4.5B). 
The expression of stem cell-related markers (CD20, CD24, CD44, CD73, 
CD133, CD166, NGFR, Nestin) identifying adult stem cells of normal and cancer 
tissues (O'Brien et ai, 2009) was examined. CD73 and CD166 were also included 
because of their expression by mesenchymal stem cells, while NGFR and Nestin 
for their association to cells of the neural crest from which melanocytes originate 
(Lee et ai, 2007). All the melanospheres were negative for CD20 and highly 
positive for CD44 and Nestin. Conversely CD24, CD73, CD166, NGFR and CD133 
markers were differently expressed in melanospheres lines. In Me15888S the large 
majority of cells were CD133+, CD166+ and CD73+ and these melanospheres 
displayed the highest percentage of NGFR positive cells (Figure 4.5C). 
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Figure 4.5. Immunophenotype of melanospheres. FACS analysis for the expression of CD45 
and melanoma associated markers Melan-AiMart-1; HMB45, CD146, GD3 (A), embryonic stem cell 
associated markers CD9, SSEA-1, SSEA-4, Sox2, Musashi-1, Oct3/4, Nanog (8) and adult stem 
cell related markers CD20, CD24, CD44, CD73, CD133, CD166, NGFR and Nestin (C) . Thin black 
histograms represent controls stained with negative isotype antibodies; filled histograms correspond 
to specific markers; numbers indicate the percentage of positive cells . Histograms are 
representative of three independent experiments. 
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The expression of the above markers was also assessed in Me204ADH, 
JR8ADH, and Me14346ADH and in seven additional pairs of adherent and 
melanosphere melanoma cell lines. Among the examined markers, only the 
expression of the stem-related protein Nanog and Oct3-4 was significantly 
enhanced in melanospheres when compared with adherent cells, and only CD146 
was significantly downregulated (Figure 4.6) 
Figure 4.6 Expression of stem cell-associated and differentiation markers on melanospheres 
and adherent cells. A) Oct3/4, Nanog, and CD146 are modulated in melanospheres when 
compared with adherent cells . The left column shows the box-and-whisker plots for the indicated 
markers. The fluorescence intensity (X mean) on the y axis equals the X mean (marker) minus the 
X mean (isotype control) . Values are calculated as the mean ± SE (Standard Error) of three 
independent experiments. Histograms of the differential expression of Oct3/4, Nanog, and CD146 in 
Me204S (black) and Me204ADH (gray) are reported . Lines and filled histograms correspond to 
isotype controls and specific antibodies, respectively (p-values evaluated with unpaired t-test). B) 
Box-and-whisker plots of analyzed markers in 11 melanoma adherent cell lines and melanospheres 
whose expression was not significantly different on melanospheres with respect to adherent cells . 
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Expression of Nanog and Oct3/4 was further analyzed by immunofluorescence, 
confirming the nuclear localization and the specific expression pattern of these 
embryonic proteins on melanosphere-derived cells (Figure 4.7). 
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Fi~ure 4.7 Expression of Oct3/4 and Nanog in Melanospheres. Me14346S were dissociated and 
10 melanoma single cells seeded onto a microscope slide by cytospin. Staining was performed 
using Oct3/4 or Nanog antibodies (green, Alexa 488) and Hoechst33342 for nuclei counterstaining 
(A) . Negative controls include staining omitting the primary antibody (B) and a complete staining on 
PBMC (Peripheral Blood Mononuclear Cell) (C) . Images at 20X (scale bar 100jJ) and 40X (scale bar 
1 OjJ) have been reported . Merge of blue and green images showed that all cells expressed Oct3/4 
or Nanog in the nucleus. White arrows indicate the few cells not displaying any positivity for the 
examined markers. 
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4.3 Melanospheres are endowed with enhanced tumorigenicity as 
compared to adherent melanoma cells 
Cancer stem cells are operationally defined as cells endowed with the ability to 
regenerate in vivo the tumour from which they were derived. Thus, the 
tumorigenicity of melanospheres was assessed by evaluating their capacity to form 
melanomas when exponentially smaller numbers of melanosphere-derived cells 
were intradermally injected in SCID mice. All the melanospheres at the dose of 104 
cells developed fast-growing tumours in 100% of injected mice in 14-48 days 
(Table 4.5 and Figure 4.8, left column). The dose of 103 melanoma cells resulted 
into 100% tumour take for Me204S, MeJR8S and Me15888S and 80% for 
Me14346S. Of note, all the melanospheres were still tumorigenic at the injecting 
dose of 100 melanoma cells per mouse. Me15888S directly obtained from a 
melanoma specimen and MeJR8S displayed 100% tumour take at this low dose 
with a median latency of 53 and 22 days respectively (Table 4.5). 
Primary tumour xenografts were serially transplanted in subsequent animal 
hosts. Secondary and tertiary tumours developed in 100% of injected mice; 
interestingly, serial tumours grew with the same kinetics or faster when compared 
to their corresponding primary engraftment (Table 4.5 and Figure 4.8, right 
column). 
Because melanospheres endowed with strong tumorigenic potential could have 
been selectea from melanoma cells adapted to growth in FCS, and because even 
the adherent melanoma cells lines had a limited but detectable in vitro self-renewal 
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capacity, Me204ADH, MeJR8ADH and Me14346ADH were inoculated in SCID 
mice to evaluate the extent to which they possess tumour-initiating capacity in vivo. 
As expected, tumour take decreased with diminishing numbers of injected cells; 
the efficiency of primary tumour formation was lower when compared with that of 
corresponding melanospheres and the latency of tumour formation was longer 
(Table 4.5). 
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Table 4.5 In vivo tumorigenicity of melanosphere forming cells (8) and adherent melanoma cells 
(AOH). 
Cell Type Cell Primary tumour Secondary tumour Tertiary tumour 
number1 formation formation formation 
Take£ Latencl Take£ Latencl Take£ Latencl 
104 5/5 22 2/2 25 2/2 18 
S 103 5/5 29 NO NO NO NO 
102 5/5 22 NO NO 2/2 35 
MeJR8 
104 5/5 22 2/2 25 2/2 30 
ADH 103 4/5 49 NO NO NO NO 
102 3/5 49 NO NO 2/2 50 
104 4/4 14 2/2 36 2/2 28 
S 103 5/5 22 NO NO NO NO 
102 2/5 39 NO NO NO NO 
Me204 105 NO NO 2/2 36 0/2 NO 
104 5/5 25 2/2 60 0/2 NO ADH 
103 5/5 67 NO NO NO NO 
102 0/5 NO NO NO NO NO 
104 5/5 48 2/2 30 NO NO 
103 4/5 92 3/3 40 2/2 30 
S 
102 3/5 123 3/3 40 3/3 40 
5x10' NO NO NO NO 3/3 57 
Me14346 
106 2/2 19 0/14 NO NO NO 
104 5/5 77 0/24 NO NO NO ADH 
103 4/5 77 NO NO NO NO 
102 3/5 123 0/24 NO NO NO 
104 5/5 33 3/3 35 3/3 35 
Me15888S S 103 5/5 33 NO NO NO NO 
102 5/5 53 NO NO NO NO 
1 Number of injected cells; 2 Number of tumours formed per number of injection; 3 Time after injection to 
tumour measurability; NO = Not Oone. Median values are reported. Observation time is 200 days.4 
Observation time is 60 days. 
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Figure 4.8. Tumorigenic potential of melanospheres. Growth curves (GC) of primary (left) or 
serially transplanted (right) human melanoma xenografts generated by intradermal injection of 
different doses of melanosphere-derived cells. Tumour mass reported on the Y axis is expressed in 
mg and calculated as the mean of the masses of the growing tumours. For details on the number of 
mice treated with each inoculating dose, see Table 4.5. 
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Primary tumour derived from adherent cells were serially transplanted in 
additional recipients. Differences in transplantability, evaluated as tumour take, 
between adherent and melanosphere-derived primary xenograft clearly emerged in 
tertiary tumour formation with Me204ADH- and Me13436ADH- derived tumours 
failing to grow. Me14346ADH xenografts showed very poor viability (Table 4.5), 
and viable tumour cells were only obtained from tumours generated by the injection 
of 106 melanoma cells. However, at the same cell dose, no serial engraftment was 
successfully established. Of note, and at variance with Me204ADH and 
Me14346ADH, MeJR8ADH showed transplantation efficiency equal to its 
autologous MeJR8S and 100% tumour take occurred with all four tumours growing 
in tertiary recipients. Moreover, once established, primary tumours generated by 
the adherent melanoma lines grew slower than the tumours generated by the 
corresponding melanosphere lines (Table 4.6). 
Table 4.6. Growth rate of tumors generate in SCID mice by melanosphere (S) or adherent 
melanoma cells (ADH). 
Primary Tumours 
Cell Type Cell dose Observation day Tumour mass (mgf 
S ADH 
MeJR8 104 42 264.1 ± 70.1 257.9 ± 67.1 
103 63 590 ± 130.4 363.8 ± 110.7 
102 85 1104.8 ± 256.5 538.8 ± 82.5 
Me204 104 105 1021 .8 ± 65.2 638.1 ± 82 
103 105 869.3 ± 150.4 256 ± 48.6 
102 83 602.5 ± 197.5 NAL 
Me14346 104 85 643.5 ± 160.8 248.2 ± 100.2 
103 120 523.9 ± 170.7 926.7 ± 178.3 
102 140 - 418.2 ± 182.3 274.3 ± 211 .8 
1 tumour mass calculated as mean ± SE (Standard Error)of the masses of the growing tumours. 
2 NA, non tumour grew in the primary recipients . 
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These quantitative differences in the in vivo behaviour of melanospheres and 
adherent melanoma cells were assessed by statistical analysis. The log-normal 
regression model yielded highly significant results for treatment (adherent vs 
melanosphere cells; p<0.0001), thus confirming the higher tumorigenic potential of 
melanospheres when compared with adherent melanoma cells. Statistically 
significant results were also obtained for cell line (p<0.0001) and dose (p<0.0001), 
indicating that both factors affected tumorigenicity. Conversely, the interactions 
between treatment and cell line (p=0.22) or inoculating dose (P=0.30) were not 
significant, demonstrating that melanospheres have higher tumorigenic potential 
that adherent melanoma cells, independently of cell line and dose. Tumour mass 
was significantly affected by treatment (adherent vs melanosphere cells; 
p<=0.0045) but not by cell line (p=0.16), and no significant interactions between 
treatment and cell line (p=0.29) or treatment and dose (p=0.79) were found (Table 
4.6). These analyses support the conclusion that, once established, tumours 
generated by melanospheres grow more aggressively, and this aggressive 
behaviour is a function of their melanosphere origin. 
Take together the in vivo results suggest that melanoma initiating cells can also 
be found in melanoma cell lines when grown as adherent cells, even if the 
frequency of self-renewing cells was relatively lower in adherent cells when 
compared to cells from melanospheres. 
To provide evidence that the melanoma xenografts generated by 
melanospheres may have a clonal origin, SCID mice were also inoculated with 
escalating dose of cells derived from melanospheres generated from a single-cell 
melanoma clone, P1 E8S. P1 E8S showed a self-renewal efficiency (20.6% ± 5.1) 
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similar to that of the JR8S spheres from which this clone had been derived (Table 
4.2). Tumour take, latency and serial tumour initiating capacity were all similar to 
those of its parental melanosphere bulk population (MeJR8S) (Table 4.7). 
Table 4.7 In vivo multipotency of the melanosphere single cell-derived clone P1 E8S. 
Cell type Cell number1 Primary tumour formation Secondary tumour formation 
Take:.! Latencl Take:.! Latencl 
104 5/5 28 2/2 26 
MeP1E8S 
103 5/5 28 ND4 
102 5/5 39 2/2 26 
1Number of injected cells; 2 Number of tumours formed per number of mice injectes; 3 Time after 
injection to tumour measurability; 4ND: not done. Median values are reported. Observation time is 
200 days; 
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4.4 Xenografts generated by melanospheres recapitulate the 
phenotypic features of the original human melanoma 
Histological evaluation confirmed that human melanoma xenografts generated in 
SCID mice by melanospheres consist of cells showing the typical morphology of 
melanoma cells: eosinophilic cytoplasm, irregular nuclei and prominent nucleoli. 
Xenografted tumours expressed the specific melanoma markers HM845, Melan-
AlMart-1 and MITF-1. Moreover, although melanospheres were found 
homogeneously positive for Melan-AlMart-1, this marker was heterogeneously 
expressed in the growing tumour mass, i.e., Melan-AIMART-1-negative melanoma 
cells could be found. In general, this heterogeneity as well as the level of MITF and 
HM845 mirrored that of the patient's original tumour (Figure 4.9A). The similarity 
between melanospheres-derived tumours and autologous patients' tumours was 
also maintained with regard to the expression of the stem cell-related markers 
CD133, CD166, NGFR and Nestin (Figure 4.98). The stem cell-related markers 
showed an elevated degree of variability in expression, with CD166 and Nestin 
expressed by the majority of cells in the tumour mass, while NGFR is found in a 
minority of clustered cells and CD133 was displayed only by very rare cells. 
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Figure 4.9. Melanospheres reproduce human melanoma in immunocompromised mice. 
Immunohistological staining of (A) melanoma-associated and (8) stem cell-related markers in 
xenograft tumours generated by intradermal injection of melanosphere-derived cells and in lymph 
node metastatic melanomas of patient 204 and patient 15888. Internal scale markers are 
indicated in each panel. For melanosphere-derived xenografts , reported images are 
representative of eight independently analyzed xenografts; for patients' tumours, images are 
representative of two non-consecutive tumour sections . Scale bar =100 um. 
A Differentiation markers 
Melan-AlMART·1 
B Stem-related markers 
(f) 
~ 
o N • 
., 
~ 
0: . 
CD133 
HMB45 
CD166 NESTIN NGFR 
Conversely, immunohistochemistry on adherent cell-derived xenografts, 
showed that the differentiation markers Melan-AIMART-1 and HM845 are 
homogenously expressed at high level and MITF transcription factor expression 
is enhanced when compared with the melanosphere-derived tumours and the 
patient's original tumours (Figure 4.10A). Adherent cell-derived xenografts 
display an expression pattern of stem cell-related markers CD133 and CD166 
comparable to that of melanosphere-derived xenografts and patient original 
tumours, while Nestin and NGFR expression seems to be slightly reduced on 
adherent-cell derived xenografts (Figure 4.108). 
These xenografts were also heavily pigmented as shown by melanin specific 
staining (Figure 4.1 ~C, left panel) evidence of a more differentiated phenotype in 
comparison to the melanosphere-derived xenografts and patients' original 
tumours. 
To further investigate the more differentiated features of adherent cell-derived 
xenografts in comparison to the melanosphere- derived ones, electron 
microscopical analysis on obtained xenografts was performed. High numbers of 
melanosomes, mostly in their terminal differentiation phase, were detected by 
electron microscopy in these adherent cell-derived tumours, whereas only a few, 
mainly immature melanosomes, were found in melanosphere-derived tumours. 
Ultrastructural analysis also revealed that several mitochondria were present on 
melanosphere-derived xenografts, but they were poorly represented in tumour 
derived from adberent cells indicating a lower metabolic activity. Finally, in the 
cytoplasm of tumour cells derived from adherent melanoma cell lines, large 
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vacuoles compatible with on-going autophagic processes were frequently 
observed. This ultra structural analysis confirms the observation that a low 
number of viable cells could have been recovered after mechanical dissociation 
of xenografts generated by adherent melanoma cells (Figure 4.1 OC, right panel). 
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Figure 4.10. Immunohistochemistry and ultrastructural analysis of xenografted tumours. 
Immunohistochemical staining of (A) melanoma-associated and (8) stem cell-related markers 
was performed on xenografts generated by intradermal injection of adherent melanoma cells 
Me204 and MeJRB. For each cell line, reported images are representative of eight independently 
analyzed xenografts . Internal scale markers are indicated in each panel. (C) Melanin staining and 
transmission electron microscopy (TEM) analysis. Fontana-Masson melanin-specific staining (C, 
left panels) and TEM (C, middle and right panels) on melanoma xenografts derived from the 
injection of Me204 melanospheres (upper panels) or Me204-adherent cells (lower panels) . M, 
melanosomes; Mt, mitochondria; N, nucleus. Scale bar=100 urn. For TEM, left panel scale bar =2 
um and right panel scale bar=500nm. 
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4.5 Expression of stem cell-related markers in human melanoma 
The analysis of the expression of stem cell-related markers was extended to 
10 primary melanoma lesions and their paired metastases. While and Nestin 
were always highly expressed (frequency of positive cells was in all the 
examined cases> 70%) NGFR and CD133 displayed different expression levels. 
In particular, NGFR expression was detected on 8/10 primary and 10/11 
related metastatic melanoma and CD133 expression on 6/10 primary and 4/11 
metastatic samples and in half of the cases analyzed NGFR expression was 
enhanced in metastases in comparison to the primary lesions (Table 4.8 and 
Figure 4.11), in line with the observation that melanoma CD271 + cells are 
endowed with high metastatic potential (Boiko et aI., 2010). 
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Table 4.8 Expression of stem cell- related markers on paired primary and metastatic melanoma. 
Primary tumours 
Patient NGFR CD133 Clark Level Thickness (mm) Ulceration Metastasis site 
1 P IV 19 Yes 
M ** Lymph node 
2 P * * IV 5,3 No 
M ** Lymph node 
M * Soft tissues 
3 P * * IV 9,6 Yes 
M * * Lymph node 
4 P * V 7,5 Yes 
M ** * Lymph node 
5 P * * IV 4,9 Yes 
M ** Lymph node 
6 P * * IV 12 Yes 
M * Lymph node 
7 P III 8 No 
M Lymph node 
8 P ** III 3,6 No 
M ** Soft tissues 
9 P ** * IV 8,2 Yes 
M ** ** Soft tissues 
10 P ** * IV >4 Yes 
M ** ** Soft tissues 
P: Primary tumours; M: Metastases; -:<5% of positive cells; *: <20% of positive cells; **: <70% of 
positive cells, ***: >70% of positive cells . Positive cells were evaluated in 10 random fields. 
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Figure 4.11. Expression level of stem-related markers differs between human melanomas. 
Immunohistological evaluation of the expression of the indicated stem cell -related markers in 
primary (left) and paired metastatic (right) melanomas. Reported images are representative of 
two independently analyzed tumour sections. Internal scale markers are indicated in each panel. 
The majority of tumour cells express (Pt3) CD166 and Nestin; rare CD133-positive cells could be 
found within the tumour mass in both primary and metastatic tumours (Pt3). (Pt1) NGFR is 
heterogeneously expressed, and in some cases enhanced, in metastatic lesions. Reported 
images are representative examples of ten primary and metastatic melanomas. Pt= Patient. 
Scale bar = 100 IJm. 
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CHAPTER 5: DISCUSSION 
Normal tissue homeostasis is assured by the balance between cell loss and 
cell renewal. This balance is indeed maintained through the ability of adult stem 
cells to undergo asymmetric division that generates a daughter cell with identical 
genetic and epigenetic content (self-renewal), and a genetically different cell 
(progenitor cell) programmed to terminal differentiation. 
The discovery of cells within the tumour mass endowed with properties similar 
to those of the stem cells of the normal tissue (indefinite proliferation, self-
renewal, ability to differentiate into a heterogeneous progeny), has led to the 
definition of "Cancer Stem Cells" (CSCs). The CSC hypothesis suggests that 
tumours are initiated and maintained by a subset of cells with stem cells 
properties. Initially, the model of CSCs was applied to haematopoietic 
malignancies and then extended to solid tumours. 
The presence, nature and frequency of CSC in human melanoma are still 
matter of investigation, but it is well known that melanoma is a tumour particularly 
resistant to conventional therapies. The current treatments can induce objective 
tumour regression only in small cohort of patients, and these responses are not 
-
durable and often not associated with improved long-term survival. In this 
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perspective, the identification of melanoma cells endowed with strict tumour 
initiating capacity is considered a big challenge for the implications this finding 
may have in the understanding of melanoma biology and in the development of 
more effective treatments. 
Two different approaches have been undertaken to show that human tumours 
contain a subpopulation of CSCs. One of these approaches directly sorted out 
putative candidate CSCs from the whole tumour mass using a combination of cell 
surface markers and the selected populations are then assayed in vivo for their 
ability to sustain tumour growth. An alternative method to isolate CSCs is based 
on the ability of stem cells to form non -adherent colonies when seeded at low 
density in a suitable culture medium. In this thesis this second approach has 
been used to investigate the presence and the nature of putative cancer stem 
cells in metastatic melanoma. 
This thesis reports evidence further supporting the notion that human 
melanomas do contain cells endowed with in vitro and in vivo features of CSCs. 
From lymph node metastatic lesions, melanoma cells were isolated that kept 
distinctive features of melanomas such as the expression of Melan-AlMart-1 and 
HMB45, but displayed the three main properties of CSCs, namely self-renewing 
capacity, multipotency and strong tumorigenic potential in immunocompromised 
mice. Moreover, the human melanoma xenografts recapitulated the original 
heterogeneity of the patient's tumours. 
The concept that CSCs should represent a rare subset in the tumour bulk has 
been recently revised and, using a syng~neic model for CSC definition, it has 
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been shown that mouse leukaemia may indeed display a higher frequency of 
tumour-initiating cells than previously thought (Kelly et ai, 2007). Further 
observation pOinted out that the frequency of CSCs in solid cancer could be 
highly variable depending on patient samples, on the histological features of the 
tumour itself, with relatively more undifferentiated tumours containing a high 
proportion of CSCs (Harris et aI., 2008). 
Data contained in this thesis are in line with the above reported observation. In 
fact, data reported here showed that melanospheres could be selected from bulk 
melanoma cells with high efficiency and that these cells displayed an elevated 
clonogenicity and a strong in vivo tumorigenic potential suggesting a high 
frequency of tumour initiating cells in melanosphere cultures (Table 4.2 and 
Figure 4.5). Thus, these results are also consistent with the recent findings of 
Morrison's studies (Quintana et aI., 2008; Quintana et aI., 2010) and sustain the 
notion that CSC may not be so rare at least in human melanoma. 
All the melanoma samples studied in this thesis were derived from lymph 
nodes or visceral metastasis and it is conceivable that metastases may be 
naturally enriched with regard to tumorigenic cells (Croker and Allan, 2008; 
Chiang and Massague, 2008); in fact, cells undergoing an epithelial-
mesenchymal transition and acquiring the ability to invade and metastasize are 
also endowed with tumorigenic properties (Mani et aI., 2008; Gupta et aI., 2009). 
It is tempting to speculate that metastases could be particularly enriched for 
tumorig~nic cells and, because it is known that melanomas are generally highly 
metastatic and endowed with a high degree of plasticity (Hendrix et aI., 2003; 
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Mourad-Zeidan et aI., 2008), this theory could explain the high frequency of 
tumorigenic cells in this particular human cancer. 
Melanospheres expressed melanoma markers Melan-AIMART-1and HMB45 
thus confirming their melanocytic origin. Two melanospheres selected for this 
study (Me204S and Me14346S) had BRAFv600E mutations while the other two 
melanospheres (MeJR8S and Me15888S) were BRAF wild type (Table 4.3). In 
these melanomas, the BRAFv600E mutation was associated with functional 
CDKN2A, while the BRAF wild type correlated with CDKN2A homozygous 
deletion. These findings are in line with general distribution of CDKN2A biallelic 
deletion in metastatic melanoma, deletion reported in about 45% of cases 
(Conway et aI., 2010, Grafstrom et aI., 2005); melanospheres do not express 
PTEN proteins, and this is correlated with a enhanced level of activated AKT 
(pAKT) (Figure 4.3). Moreover, it has been recently reported that PTEN deletion 
is found in glioma initiating cells and it was related to proliferation and self-
renewal of these cancer stem cells, independently from the expression of the 
gliomas stem cells surface CD133 (Cheng et aI., 2010). 
The most common cause of multidrug resistance (MDR) in human cancers is 
related to the expression and function of one or more ATP-binding cassette 
(ABC) transporters that efflux anticancer drugs from cells. Due to the intrinsic 
chemoresistance of stem cells it has been postulated that these transporters 
should also be amplified lover-expressed in cancer stem cells. Thus in this thesis 
the ABC' transporter expression profiles of melanospheres and adherent cell lines 
were carefully monitored. Data collected here showed that all the melanoma cells 
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express a group of ABC transporters (ABCA5, ABCB2, ABCB6, ABCD3, ABCD4, 
ABCF1, ABCF2 and ABCF3) that were previously reported as detectable at 
similar levels on cells of melanocytic origin (Heimerl et aI., 2007). Conversely, a 
subset of transporters (ABCB3, ABCB6, ABCC2, ABCC4) was found to be 
upregulated on melanospheres as compared to adherent melanoma cell lines 
and melanocytes (Table 4.4). ABCB5, proposed as a marker form melanoma 
initiating cells (Schatton et aI., 2008) was only detected in Me14346 spheres and 
adherent cells, although at a lower level of expression than in melanocytes 
(Table 4.4 and Figure 4.7). These data are in agreement with the observation 
that ABCB5 reveals a melanocyte-specific high transcript level and it is 
expressed in most melanoma cell lines, (Heimerl et aI., 2007, Chen et aI., 2005). 
The expression of a broad range of ABC transporters on cells of melanocytic 
origin may be related to the intrinsic biological features of melanocytes that 
develop a physiological resistance to toxic melanin intermediates and 
metabolites that have to be rapidly extruded from the cells. Interestingly, a model 
has been recently proposed that associates the intrinsic multidrug resistance of 
melanoma cells to the presence of immature melanosomes (Chen et aI., 2009). 
According to this model, in normal pigment-producing cells such as melanocytes, 
the ABC transporter system regulates the homeostasis of melanocytes by 
trapping cytotoxic melanin intermediates into sub-cellular organelles such as 
melanosomes. In particular, melanosomes in stage II-III of maturation are 
importaQt for the maintenance of homeostasis in melanocytic cells and should be 
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particularly enriched in ABC transporters. These physiological features could 
thus explain the high intrinsic resistance of melanoma cells to cytotoxic drugs. 
In this thesis, melanosphere phenotype was further investigated by analyzing 
the expression of an array of markers associated with both embryonic and adult 
normal stem cells. Melanospheres were uniformly positive for some embryonic 
stem cell markers (CD9, Sox2, Oct3/4, and Nanog) while they displayed 
heterogeneous expression for most of the adult normal and cancer stem cells 
associated markers analyzed (CD20, CD24, CD166, CD133, NGFR) (Figure 
4.4). Melanosphere phenotype was compared to that of adherent cells. Eleven 
paired adherent melanoma cell lines and melanospheres were included in the 
analysis. These data confirmed on a larger set of samples that the differentiation 
marker CD146 was more highly expressed in adherent melanoma cells while the 
embryonic stem cell markers Oct3/4 and Nanog displayed an enhanced 
expression in melanospheres, further endorsing the notion that melanosphere 
most likely represent a more undifferentiated, stem-like counterpart of melanoma 
cells (Figure 4.SA). Data from the literature indicate that the expression of Oct3/4 
and Nanog embryonic stem cell markers is indeed increased in cancer stem-like 
cells isolated from different human solid tumours such as glioblastoma 
(Tomuleasa et aI., 2010), lung (Leung et aI., 2010) and ovarian cancer (Guo et 
aI., 2011); moreover a role of Oct3/4 in blocking breast CSC differentiation and in 
determining resistance to chemotherapeutic drugs has been recently proved 
(Sajithla~ et aI., 2010 Honoki et aI., 2010). In addition, in human cancers the 
expression of·embryonic stem cell markers was associated with tumour 
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progression and bad prognosis (Schoenhals et aI., 2009 and Wang et aI., 2009). 
Together all this evidence further supports the immature and aggressive nature 
of melanospheres. 
Melanospheres displayed a strong in vivo tumorigenicity in SCID mice and this 
strong tumour initiating capacity was maintained over serial in vivo passages 
(Table 4.5 and Figure 4.8). However, tumorigenicity was not linked to the 
expression of a given stem cell-associated marker. Recently, studies have stress 
the role of CD133 as a cancer stem cell marker in a series of human solid 
tumours, including melanoma, (O'Brien et ai, 2009; Monzani et aI., 2007). More 
recently, NGFR (CD271) has been associated with melanoma initiating cells 
(Boiko et aI., 2010). In the present thesis it is shown that Me15888S 
melanospheres were highly positive for CD133 and they also contained a large 
subpopulation of NGFR+ cells (Figure 4.4C). However, other melanospheres, not 
expressing or expressing these markers at very low levels, exhibited similar or 
even stronger tumour initiating capacity in vivo. These findings may be 
compatible with the hypothesis that in melanoma different 'clones' of cancer stem 
cells may indeed exist. 
The data presented in this thesis reflect the complex scenario of CSC markers 
and at the moment, no definitive consensus has been reached on the CSC 
phenotype for melanoma (Fang et ai, 2005; Frank et ai, 2005; Monzani et ai, 
2007; Keshet et ai, 2008, Schatton et ai, 2008; Quintana et ai, 2008) and for 
other SGlid tumours as well (Dalerba et ai, 2007; O'Brien, 2007; Becker et aI., 
2008; Ricci-Vitani et ai, 2008; Shmelkov et ai, 2008). Moreover, some recent 
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papers suggest that phenotypic heterogeneity may be also observed within adult 
stem cells of normal tissue such as bone marrow and intestine, and cells with 
different phenotype indeed display an equally regenerative ability (Stingl et ai, 
2006; Shackleton 2006, Alison et ai, 2008; Sun et ai, 2009, Cheng et ai, 2009). 
To understand tumour heterogeneity, it has to be kept in mind that the parent-to-
progeny relationship between CSCs and tumour bulk may not necessarily reflect 
the well conserved and predictable rules operating in normal tissue development. 
Conversely, tumour generation more likely represents an aberrant and highly 
unstable differentiation program due to the intrinsic genetic and epigenetic 
instability of cancer cells Thus tumour heterogeneity is likely to be the result of 
multifaceted mechanisms; among them variability of frequency, phenotype and 
even functional features of CSCs may be a relevant factor. Furthermore, the 
genetic and epigenetic instability that are characteristic features of tumour 
biology can induce cellular heterogeneity within the stem and the non stem cell 
population of the tumour, suggesting that cancer stem cells may be more 
dynamically regulated than hitherto suspected. Moreover new evidence proposes 
that cancer stem cell properties could be a functional state induced by 
environmental factors as recently shown for colon cancer and glioblastoma 
cancer stem cells (Vermeulen et aI., 2010; Heddleston et ai, 2009). Thus in line 
with this observation, the considerable phenotypic heterogeneity of 
melanospheres shown in this thesis might be a reflection of melanoma metastatic 
stem ceH diversity that increases with genetic instability as tumours progress and 
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may indeed be the result of the emergence of distinct clones with melanoma 
initiating potential that better respond to different environmental signals. 
The histological features of xenografts generated by melanospheres used in 
this study clearly resembled features of human melanomas thus recapitulating 
the original tumour heterogeneity. In particular, although melanospheres were 
found to be homogenously positive for Melan-AlMart-1, this marker showed a 
heterogeneous expression in melanoma xenografts and in general the 
expression patterns of melanoma-associated markers and stem-related markers 
mirrored those of the patient's original tumour. In particular, very few cells could 
be found to be positively stained for CD133 and scattered cell nests positive for 
NGFR were detected in xenografts as well as in the original human tumours 
(Figure 4.98). These patterns of staining were also found in a panel of primary 
and metastatic paired melanomas confirming that this heterogeneity is a rule in 
human melanomas. CD166, CD133 and Nestin have been reported to be 
expressed by a greater number of cells in human melanoma (Klein et aI., 2007) 
as compared to nevi with no clear difference between primary and metastatic 
lesions although Nestin staining in early (I and II) stage melanomas has been 
shown to predict poor survival (Piras et aI., 2010). Data reported in this thesis are 
in line with this observation with Nestin and CD166 are highly expressed in most 
of the cells composing the tumour mass (Table 4.8). Data in this thesis showed 
that in the analysed specimens, CD133 expression was detected both in primary 
and metastatic melanomas, with a similar expression pattern. Although CD133+ 
-
cells are increased in melanomas compared to nevi (Klein et aI., 2007; Sharma 
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et aI., 2010), its prognostic significance and its association with progression in 
metastatic melanoma still remain to be established (Klein et aI., 2007; Piras etal., 
2010). 
CD271 (NGFR) has been recently reported as a marker for the identification of 
melanoma cells strongly endowed with tumour initiating capacity and strong 
metastatic potential (Soiko et aI., 2010). In the cases analyzed in this thesis, half 
of the metastatic lesions show an enhanced percentage of cells positive for 
NGFR with respect to the corresponding primary tumours (Table 4.8). Although 
NGFR seems to be crucial for the diagnosis of rare melanoma subtypes including 
desmoplastic melanoma (Lazova et aI., 2010) and to specifically identify 
perineural invasion in malignant melanomas (MMs) (Chan and Tahan, 2010), the 
role of this receptor in melanomas is yet to be fully elucidated. 
One additional important finding of this thesis is the clear observation that the 
ability to form tumours in immunocompromised mice is not a unique feature of 
melanospheres. In agreement with data from the literature (Rodolfo 1988), in this 
thesis it has also been shown that melanoma cells grown as adherent cells in 
medium containing FCS form tumours in SCID mice. However it is also 
nevertheless clearly demonstrated that the efficiency in tumour formation is 
higher for melanospheres as compared to adherent melanoma cells. 
The in vivo experiments using immunocompromised mice, clearly suggest a 
higher enrichment in tumorigenic cells in melanospheres with respect to adherent 
cells. Indeed, tumour take and latency of xenografts generated in primary 
recipients by melanospheres and adherent melanoma cells are different with a 
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high statistical significance (P<0.0001) as evaluated by an accurate multiple 
regression model. Moreover, as far as the xenografts serially transplanted into 
subsequent hosts are considered, the difference in tumour take between the two 
groups emerges even more clearly, with efficiency in tumour formation for 
melanospheres being 100% while being 52% for adherent cells (Table 4.5). 
These data, together with the evidence that melanospheres could have been 
generated from their corresponding adherent melanoma cells, strongly suggest 
that putative melanoma stem cells are likely contained both among 
melanospheres and adherent melanoma populations. Nevertheless, because of 
the absence of molecular marker(s) or lineage tracing in vivo, our data did not 
definitively address the issue of the relative frequency of CSCs in melanosphere 
and adherent melanoma cells. 
In agreement with these quantitative differences, xenografts derived from 
adherent melanoma cells qualitatively diverged from xenografts generated by 
melanospheres. In general, adherent cell-derived tumours displayed a highly 
differentiated phenotype, with a uniform expression of Melan-AlMart-1 and an 
enhanced level of MITF expression, which correlates with a decrease invasive 
potential of melanoma cells (Carreira et aI., 2008) (Fgiure 4.1 OA). Ultrastructural 
analysis through electron microscopy revealed that tumours generated from 
adherent cells do contain highly differentiated melanoma cells, enriched in 
mature melanomsomes in comparison to melanosphere-derived xenograft 
tumours that are characterized by the presence of more immature melanosomes; 
moreover adherent cells are enriched in intra cellular vacuoles, characteristic of 
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cells possibly undergoing to autophagic processes that are almost absent in 
sphere-derived tumours (Figure 4.1 DC). 
This scenario could indeed be also compatible with the hypothesis that 
melanoma adherent cells are mainly finally differentiated cells that, while still 
maintaining proliferation potential, may form tumours in vivo, but these tumours 
display strong features of differentiation and are endowed with very limited 
transplantability capacity in subsequent animal hosts. 
In conclusion, the present data provide further evidence that human 
melanoma is a heterogeneous cancer, composed by cells with different 
characteristics. We further show that melanoma cells selected by their ability to 
form melanosphere cells in stem cell culture medium retain the ability to 
efficiently regenerate human melanoma in a mouse model, which is the crucial 
characteristic that functionally defines CSC. 
Moreover, results presented in this thesis add to the existing evidence that 
human melanoma is a heterogeneous cancer composed of cells with different 
characteristics and suggest that melanospheres and their corresponding tumours 
in immunocompromised mice represent a reliable model to analyze melanoma 
biology. A better understanding of the fate of melanosphere-derived cells 
inoculated in vivo, and their response to stimuli derived from the tumour stroma, 
will offer the possibility to better understand the mechanisms driving melanoma 
formation and progression. This new knowledge will be instrumental in designing 
novel, more efficient therapies targeting CSCs in human melanoma. 
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CHAPTER 6: MELANOMA STEM CELLS AND THEIR 
CROSS-TALK WITH THE IMMUNE SYSTEM 
6.1 Introduction 
The previous parts of this thesis were focused on the identification and in vitro 
isolation of melanoma cells with sternness properties and strong tumour initiation 
capacity in vivo. Studies reported in this chapter were aimed at investigating the 
immunological properties of melanoma stem cells. 
According to the CSC theory, tumour microenvironment acquires novel 
significance and it is likely to provide the "niche" influencing CSCs fate. Thus, 
considering that melanoma is an immunogenic tumour, with the final aim of 
designing immune-based intervention targeting CSCs, it was of particular 
interest to define the reciprocal interaction of melanoma initiating cells with the 
immune system. 
It is well known that malignant melanomas produce and express receptors for 
different cytokines, chemokines and growth factors which, through autocrine and 
paracrine mechanisms of action, enable melanoma cells to growth autonomously 
and to acquire metastatic phenotype. Autocrine production of IL-8 and 
sometimes IL-6 and IL-10 stimulated melanoma proliferation, while growth 
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factors such as IL-1 and TGF-~1 either produced by melanoma cells or by 
stromal cells, modulate tumour microenvironment to promote tumour growth and 
invasion (Ikushima and Miyazono, 2010). Furthermore, many chemokines such 
as CXCL 1-2, CXCL5-8, CCL2, CCL5, CCL21 and CCL27 are known to sustain 
melanoma growth and progression (Richmond et aI., 2009) and other 
chemokines (CCL2-4, CXCL9, CXCL 10) are associated with the recruitment of 
cells of the immune system, such as pro-tumorigenic macrophages (Harlin et aI., 
2009). 
From an immunological point of view, evidence has been provided for a 
favourable prognostic role of the immune system in cancer patients. However, 
despite significant progresses in tumour immunology, current immuno-based 
therapies targeting antigens highly expressed in cancer cells failed to induce 
clinically effective anti-cancer responses. This breakdown can be due to the 
immune-suppressive mechanisms active in cancer patients; this suppressive 
environment selectively might protect CSCs from immune effectors cells. Indeed, 
induction of tolerance is a key feature of normal mesenchymal stem cells that 
display immunosuppressive properties (Spaggiari et aI., 2009; Oi Ianni et aI., 
2008). Moreover, neural stem cells, through the release of soluble mediators, 
exert immunomodulatory effect on peripheral T cells by suppressing their 
activation and proliferation (Kim et aI., 2009). These 'physiological' mechanisms 
parallel mechanisms of immune evasion relevant to neoplastic development and 
progression (Le Blanc and Ringden, 2007). In a tumour setting, glioblastoma 
multiform CSCs show low immunogenicity and high suppressive activity 
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suggesting that the low differentiation stage of CSCs could be associated with a 
weaker expression of molecules that are crucial for T cells and NK recognition 
(Oi Tomaso et aI., 2010). 
Secretion activity of stem cells has been proved to be extensive and to playa 
relevant role in regulating proliferation and differentiation processes. In particular, 
the autocrine production of IL-4 plays an important role in increasing self-renewal 
and survival of colon CSCs (Todaro et aI., 2007; IL-6 is involved in Notch-
mediated signalling that is crucial for breast SC maintenance (Sansone et aI., 
2007) and is known to contribute to haematopoietic stem cell maintenance (Kang 
et aI., 2007). 
Based on these evidences, this part of the thesis explored the immune-related 
phenotype of melanoma initiating cells with the aim of assessing their possible 
interaction with the immune system in term of susceptibility to recognition and/or 
ability to negatively modulate the anti-tumour response, as recently suggested for 
ABCBS+ melanoma stem cells (Schatton et aI., 2010). The expression of class I 
and II HLA (Human Leukocytesa Antigen) as well as that of the immune 
regulatory molecules CTLA-4 (Cytotoxic T-Lymphocytes Antigen-4), PO-1 
(Programmed Oeath-1) and their ligands was analysed in melanospheres and in 
their corresponding adherent melanoma cells. Moreover, melanospheres were 
also assessed for their secretion profile both at mRNA and protein level. 
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6.2 Results 
6.2.1 Expression of cell surface immune-related molecules by melanospheres 
Phenotypical analysis by flow cytometry revealed that HLA class I (are 
expressed by all the melanospheres, while only a limited expression for HLA-
class II (Major Histocompatibility Class II, MHC II) could be detected in 
Me14346S and Me15888S. Of note, although all the cells within melanospheres 
and adherent cells express HLA class I (Figure 6.1A), the fluorescence intensity 
is slightly lower on melanospheres, suggesting that these cells express lower 
level of HLA class I in comparison to their corresponding adherent cells, 
confirming in melanoma data previously reported for glioblastoma SCs (Oi 
Tomaso et aI., 2010). 
The expression of molecules involved in the modulation of the activation status 
of T cells was also examined. Results reported in figure 6.1 B showed that PO-1 
and its ligand PO-L 1 are expressed by the samples tested with no major 
differences between melanospheres and adherent cells. Conversely, the 
expression of CTLA- 4, an additional inhibitory molecule, is expressed at higher 
level in melanospheres as in comparison to adherent cells. Notably this 
difference is even more pronounced when the expression of CTLA-4 is examined 
without previous cell permeabilization indicating that CTLA-4 molecules are 
exposed directly on the cell surface and available for functional triggering. 
Although at low level, the CTLA-4 ligand' C086 is detectable on all the analysed 
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samples suggesting the possibility of autocrine activation. No C080 expression 
was evidenced. 
Figure 6.1 . Expression of immune related molecules on melanospheres and adherent cells. 
Black line represents Isotype controls; gray filled histograms represent the specific antibody. 
Numbers indicate the percentage of positive cells . 
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6.2.2 Expression of immune-related genes 
To better define which soluble factors could be crucial for the interaction 
between melanoma stem cells and tumour microenvironment, the secretion 
profile of melanospheres was analysed taking advantage of real-time PCR 
arrays. Cultured melanocytes were also examined and used as calibrator for data 
analysis (Table 6.1). Upregulated immune related genes are reported in red, 
while genes downregulated in melanospheres in comparison to melanocytes are 
reported in blue. Il-8, TGF~1, SMAD7 and TNF mRNA expression was 
enhanced in all melanospheres (green boxed), while eClS, eSF-1, IKBK, 
BCl2l1, BAX, FAS, SKI, FN-1, HMOX-1 were expressed at lower level on 
melanospheres compared with melanocytes (yellow boxed). Most of the mRNA 
genes are differently expressed by the various melanospheres, with some of 
them expressed only by one sample analyzed such as Il-10 (pink boxed). These 
differences remains to be fully addressed but it is likely to speculate that this 
different array of factors might be related to the different stages of functional 
differentiation of each melanosphere. 
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Table 6.1. Expression of immune-related genes on melanospheres. Melanocytes are used as 
calibrator. 
2RQ 
Gene Me14346S Me204S MeJR8S Me1S888S 'Melanocytes 
IL-1~ 3 77.29 
IL-6 1 
IL-7 1.39 1.37 0.07 1 
I 'L-8 17.49 19.01 13.66 1
11
.
62 11 
IL-10 1-382 .9 
IL-12a 135.26 6.64 
IL-18 132.18 
CCL2 0.33 0.02 1.81 1 
CCL3 122.33 12.89 
CCLS 0.73 0.23 0.07 0.55 1 
CCR4 
CXCL10 0.21 1 
CXCL11 0.85 1 
CSF1 0.19 0.14 0.02 0.21 1 
CTLA-4 0.18 11 .72 1 
CYP7A-1 
AGTR2 
STAT3 0.17 1.22 0.19 0.50 
NFKB 0.43 4 .59 1.03 0.78 1 
IKBK 0.54 0.30 0.16 0.59 
I TGF~1 I ~ 1.95 145.59 117.84 110.68 I 1 
C03E 10.82 
C04 1.31 0.50 1 
C040 0.03 11 .98 1.06 1 
C038 1 
C068 0.56 7.19 3.50 
C080 132.02 
C086 1 
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2RQ 
Gene Me14346S Me204S MeJR8S Me15888S 'Melanocytes 
HLADRA - 0.04 0 0 1 
HLADR B -
PTGS2 0.06 0.11 0.13 1 
COL45A 26.96 3.29 
VEGF 0.60 1.81 0.55 0.90 1 
C3 0.02 2.31 2.72 1 
ACE 1 
ICOS 7.37 
NOS2a 4.15 29.5 
BCL2 1.68 0.36 0.16 1.06 1 
BCL2L1 0.26 0.69 0.14 0.67 1 
BAX 0.48 0.54 0.12 0.69 
FAS 0.08 0.05 0.01 0.64 1 
SMAD3 1.91 2.55 0.31 1.98 1 
I SMAD7 11.79 118.99 13.97 12.69 11 
SKI 0.58 2.24 0.48 0.63 1 
FN-1 0.26 0.52 0.10 0.94 1 
1 TNF 162.42 142.66 120 .29 1251 .77 1 -
ICAM-1 0.70 13.35 2.29 1.73 1 
HMOX-1 0.26 0.65 0.11 0.38 
LRP-2 3694.87 
ECE1 1.07 6.08 1.58 0.84 1 
1: calibrator; 2: RQ values calculated using the equation RQ=2-L1L1 Ct. L1L1Ct values were calculated 
by subtracting the L1C t of the calibrator from the L1C t value of each target; 3: Absent genes defined 
as genes with L1Ct above 25 cycles . 0 = RQ< 1 E-3. 
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6.2.3 Secretion profile of melanoma stem cells 
After this initial evaluation, quantitative analysis of cytokines and chemokines 
released by melanospheres in culture supernatants was performed by flow 
cytometry through Cytokine Beads Array (CBA). The secretion profile of 
melanospheres was compared to that of adherent melanoma cells and 
melanocytes. The secretion level of each cytokine and chemokine is reported in 
Table 6.2. 
Data confirmed at the protein level the profile obtained with mRNA analysis; all 
the melanospheres produced IL-8 and CCL-2 while IL-10 is exclusively released 
by Me15888S. Conversely, IL-6 and IL-4 were not detected in any of the 
melanosphere-cond itioned su pernatant. 
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Table 6.2. Cytokines and chemokines secretion level. 
[pg/ml]1 
Me14346 Me204 Me15888 Melanocytes 
ADH S ADH S S ADH 
Cytokines IL-1 f3 11.5 2 1.85 
IL-2 
IL-4 
IL-5 
IL-6 1950.59 3127.56 430.66 
IL-8 1450.22 231 .220 2119.73 150.02 20.11 2515.00 
IL-10 6.45 116.92 
IL-12p70 
TNFa. 4.01 1.53 
TNFf3 
INFy 
Chemokines G-CSF 
MCP-1 (CCL2) 23262.633 72.41 428.13 17.97 323.48 
MIP1a. 102.97 17.91 
MIP1 f3 12.58 
MIG 412.71 
1: pg/ml: pg of released molecule for ml of culture supernatants normalized for 0.5E6 cells . Values 
reported are mean of two rerlicates obtain after subtraction of the values detected in the 
unconditioned culture medium. : undetected . 3: out of range of calibrator curve. 
In this analysis, melanocyte and adherent cell-conditioned media were also 
considered . Interestingly, in comparison to melanospheres, these cells product 
IL-8 and CCL-2 at higher level. The same trend was detected for IL-6. This 
cytokine was produced by melanoma adherent cells and melanocytes while it 
was undetectable in melanosphere-conditioned supernatants (Table 6.2 and 
Figure 6.2). These data are in line with published findings reporting that 
advanced melanomas produce high level of IL-6 known to exert both autocrine 
and paracrine roles in melanoma biology (Lazar-Molnar et aI., 2000). 
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Figure 6.2. Cytokines and Chemokines secretion levels. Melanospheres produce lower level 
of IL-6 and CCL-2 with respect to adherent melanoma cells and melanocytes. IL-6 is exclusively 
produced from melanoma adherent cells and IL-10 is only produced by Me15888S. On the X 
axes are reported name of the analyzed samples; on the Y axes are reported pg/ml of released 
cytokines normalized for O.5E6 cells after subtraction of the values detected in the unconditioned 
culture medium. 
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receptors, specific for the cytokines/chemokines released by melanospheres or 
by more differentiated melanoma cells, here represented by melanoma cells 
growth as adherent monolayer, was also examined. Data are reported in Figure 
6.4. The high affinity IL-8 receptor CXCR2 was expressed in all the analyzed 
samples with the exception of Me204ADH, while only a fraction of Me14346S 
and Me204S was positive for CXCR1. The CCL-2 receptor (CCR-2) is expressed 
both on melanospheres and adherent cells with an enhanced expression by 
Me204S and Me14346 S in comparison to adherent cells. 
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Me15888S, that produced IL-10, expressed enhanced level of IL 10Ra thus 
suggesting a possible autocrine role of IL-10 in influencing melanospheres 
biology. IL-6 receptor is composed by the a subunit, responsible for IL-6 specific 
binding (IL-6Ra), and by the gp130, representing the traducing subunit. All the 
samples analysed expressed gp130, while the high affinity IL-6Ra could be 
detected at significant level only on melanospheres (Figure 6.3) suggesting a 
possible role of IL-6 in the regulation of melanosphere properties. Of note, IL-6 
was not produced by melanospheres but released by their differentiated 
counterpart, namely by adherent cells. 
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Figure 6.3. Expression of Cytokines and Chemokines receptor. Black lines represent Isotype 
controls; gray filled histograms represent the specific antibodies. % of positive cells is reported in 
each histogram. 
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6.3 Discussion 
Data reported in this last session of the thesis provide an initial 
characterization of the immune-related phenotype of melanospheres. Whenever 
possible, comparisons have been made with the phenotype of corresponding 
adherent cells and with in vitro cultured melanocytes. Although heterogeneity did 
exist within melanospheres, nevertheless their immune-related profile was 
different from their corresponding adherent cells and melanocytes. 
In comparison to adherent melanoma cells and melanocyte, melanospheres 
displayed significantly enhanced expression of TGF~ (Tab 6.1). This finding is in 
agreement with the differential role that TGF~ exerts on melanocytes and on 
melanoma cells. It is in fact known that while this cytokine limits the proliferation 
of normal melanocytes, it switches from a paracrine inhibitory to an autocrine 
stimulatory function in advanced stage of metastatic melanomas (Vetterlein et aI., 
1995). Furthermore, TGF~ also promotes tumour angiogenesis in vivo and 
increases the angiogenic action of bFGF (Moretti et aI., 1997). In stem cell 
biology, TGF~ is a known signalling molecule mediating dormancy of 
haematopoietic stem cells (Yamazaki et aI., 2009). In human tumours, this 
cytokine is involved in the maintenance of stemness in glioma CSCs (Penuelas 
et aI., 2009; Ikushima et aI., 2009), while the role of TGF~ in breast CSCs is still 
controversial (Tang et aI., 2007; Mani et aI., 2008). In comparison to 
melanocytes, melanospheres displayed also enhanced expression of SMAD7 
transcript as compared to melanocytes, in accordance to the observation that 
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SMAD7 regulates neural stem/progenitor cell proliferation in a TGF~-independent 
manner (Krampert et aI., 2010). 
In the 6.2.3 section, data obtained by mRNA expression analysis have been 
confirmed at protein level and assessment of the quantity of 
cytokines/chemokines in the melanoma-conditioned media was obtained taking 
advantage of a flow cytometry based assay, known as CSA. Interestingly 
melanospheres displayed a secretion profile distinct from that of the adherent 
melanoma cells and melanocytes. Differences were evident for those cytokines 
whose role in melanoma progression has been previously reported (Lazar-
Molnar et aI., 2000). In particular, IL-8 and CCL-2 (also known as macrophage 
chemoatactic protein 1 MCP-1), were produced at considerably lower level by 
melanospheres than adherent cells (Table 6.2 and Figure 6.2). 
The differential expression of CCL-2 between melanospheres, displaying a 
more aggressive behaviour in vivo (see chapter 4), and adherent cells, is in line 
with the observation that higher amount of CCL2 is secreted by melanoma cell 
lines with lower metastatic and invasive potential. These in vitro data mirror the in 
vivo situation in which expression of CCL-2 mRNA is higher in melanoma in situ 
and decreases in more invasive tumours (Varney et aI., 2005). Moreover, it has 
been observed that CCL-2 in melanoma exerts different functions depending on 
its secretion level and it works as chemo-attractant for pro-tumorigenic 
macrephages when secreted at low level by tumour cells. Low level of CCL-2 
production by melanospheres may thus be associated with the capacity of 
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melanoma initiating cells to generate a tumour promoting microenvironment 
(Nesbit et aI., 2001). 
IL-8 exerts an autocrine role in sustaining melanoma proliferation, through 
interaction with its receptors (CXCR1 and CXCR2), that are expressed at high 
level on melanoma cells and melanocytes (Varney et aI., 2003). Recent 
evidences also showed that IL-8 receptors are upregulated under hypoxic 
conditions and have a role in tumour angiogenesis. CXCR2 is also involved in 
melanoma cell migration and invasion (Gabellini et aI., 2009) and data of this 
thesis showed that CXCR2 was expressed on all the analysed melanospheres 
while CXCR1 was present on a subpopulation of cells within melanospheres, 
with the exception of Me15888S (Figure 6.3). A role of IL-8 and CCL-2 in 
modulating normal or cancer stem cell biology has not been yet addressed 
although IL-8 receptor CXCR1 has been proposed as marker for the definition of 
the breast cancer stem cells subpopulation within the ALDH+ cells (Ginestier et 
al.,2010). 
IL-6 could not be detected in melanosphere supernatants while it was highly 
produced by adherent cells and cultured melanocytes. A function of IL-6 and IL-
10 in influencing stem ness properties has been clearly demonstrated in the 
literature. Exogenous added IL-6 was shown to induce neural and glial 
differentiation of murine neural stem cells (Islam et aI., 2008) and it has been 
recently demonstrated that IL-6, secreted by differentiated astrocytes, induced 
specific neuronal differentiation of rat neural hyppocampal progenitor cells (Oh et 
aI., 2010). Analogously, IL-6 produced by human microglia negatively influenced 
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neurosphere self-renewal (Balasubramaniam et aI., 2009). As concern 
melanomas, the role of IL-6 is once more controversial when early or late stage 
melanomas are considered. In particular, the growth of early stage melanomas 
are inhibited by IL-6 released by fibroblasts, conversely, metastatically 
competent, advanced stage melanomas are resistant to this anti-proliferative 
function (Sun et aI., 1992; Silvani et aI., 1995). Furthermore, IL-6 sustains 
proliferation of differentiated melanoma while is not necessary for early 
melanoma replication (Lu et aI., 1992). These recent evidences favour the 
hypothesis that IL-6 may have a role in supporting differentiated cells and being 
melanospheres likely composed by undifferentiated melanoma cells they did not 
require this cytokine for their survival. Nevertheless data of this thesis indicated 
that melanospheres express IL-6 receptor but the biological significance of this 
expression remains to be addressed. IL-6, interacting with Notch signalling, 
affects self-renewal in beast CSCs (Sansone et aI., 2007) and thus, also in 
melanoma model, IL-6 produced by the differentiated melanoma cells or by 
tumour stroma may act in a paracrine way and influence stemness properties of 
melanoma stem cells in accordance to the recent discussed hypothesis that 
cancer stem cells could be dynamically regulated by tumour microenvironment 
(Heddelston et al.j 2009). 
IL-10 was detected in sera of patient with advance stage malignant melanoma. 
IL-10 is a well known immunosuppressive cytokine that affects the expression of 
HLA class I on different cells type including antigen presenting cells. Most of the 
melanoma cell lines express IL-10 receptor and its expression is associated with 
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a pronounced down-regulation of the HLA class I molecule (Yue et aI., 1997) and 
of MHC class I chain-related proteins A (MICA). These IL-10 mediated effects 
directly protect melanoma cells from recognition by both T and NK cells. 
The involvement of IL-10 in stimulating self-renewal of haematopoietic stem 
cells has been recently suggested (Kang et aI., 2007). Furthermore, glioma stem 
cells expressed enhanced level of IL-10 mRNA in comparison to the 
correspondent adherent glioma cell lines, with a correlation between the level of 
IL-10 mRNA expression and the pathological grade of gliomas (Qiu et aI., 2010). 
Adipose derived stem cells (ASCs) isolated from breast cancer patients display 
significantly higher level of IL-10 and TGF~ mRNA than ASCs isolated form 
normal individuals and the culture supernatant of ASCs induces in vitro 
regulatory T cells (Razmkhah et aI., 2010). 
Results presented in sections 6.2.3 show that IL-1 ORa was expressed both on 
melanospheres and adherent cells, and was strongly upregulated on Me15888S 
that uniquely produced significant amount of IL-10. This phenotype suggests a 
possible autocrine role of IL-10 in Me15888S maintenance and also a possible a 
paracrine role of this cytokine in influencing melanoma behaviour. 
Immunotherapy has a long history with striking but limited success in patient 
with melanoma. The limitations of melanoma immunotherapy stem from tumour-
induced mechanisms of immune evasion that cause the host to be tolerant to 
tumour antigens. For instance, melanoma inhibits the maturation of antigen-
presenting c(311s, thus preventing full T-cell activation and diminishing the effector 
antitumour immune response. New immunotherapy, targeting critically regulatory 
173 
elements of the immune system, may overcome tolerance, leading to a more 
effective antitumour response. These include monoclonal antibody that blocks 
CTLA-4 thus preventing inhibitory signals that down-regulate T-cell activation. 
Moreover, since the T-cell proliferation and cytokine production can be inhibited 
also by the interaction of PO-1 with its ligand PO-L 1 and by the interaction of po-
L 1 with C080, the simultaneous blockade of CTLA-4 and PO-1 has been shown 
to be more than twice effective in promoting the rejection of melanoma in in vivo 
murine models (Curran et aI., 2010). Interestingly, CTLA-4 and also the co-
stimulatory molecules PO-1, PO-L 1 and C086 are expressed by the 
melanospheres and adherent cells here analyzed, with membrane CTLA4 and 
C086 prevalently expressed on melanospheres (Figure 6.1A and 6.1B). These 
observations are in line with the phenotype reported for ABCB5+ melanoma 
initiating cells endowed with stronger ability to inhibit peripheral blood 
mononuclear cell (PBMC) proliferation and enhancing T regulatory cells induction 
via C086 (Schatton et aI., 2010). Analogous immunosuppressive properties are 
displayed by mesenchymal stem cells (Oi Ianni et aI., 2008) and by gliomacancer 
initiating cells that, inhibit T-cell proliferation and activation thorough PO-L 1. 
Interestingly, exposure of glioma initiating cells to differentiation stimuli causes 
the lost of their immunosuppressive properties (Wei et aI., 2010). 
Taken together the data presented in this part of the thesis underline a strong 
relation between the immune system and the putative melanoma stem cells. This 
relationship indicates that CSCs are indeed well equipped to evade immune-
recognition and able to exploit immune-related factors for improving their stem 
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cell-related functions. Thus, immunotherapy approaches should consider 
strategies targeting CSC subpopulation. In addition, it will be mandatory to 
combine novel treatments efficient against CSCs with the most recent therapies 
targeting the immunoregulatory molecules CTL-4, and PO-1 although the precise 
role of these two molecules and that of COB6 and PO-L 1 expressed on CSCs 
remains to be identified. 
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CHAPTER 7: FUTUREPERSPECnVES 
Future experiments will be aimed at defining the reciprocal interaction between 
melanoma initiating cells and the tumour microenvironment, stroma and the 
immune system, with particular attention to the ability of soluble factors in 
regulating melanoma heterogeneity, plasticity and tumour maintenance. To this 
aim, the following lines of research will be pursued: 
1. To elucidate the functional role of the identified chemokines/cytokines in 
affecting self-renewal and differentiation of melanoma stem cells. 
Experiments will be performed in vitro and in vivo taking advantage of 
neutralizing antibodies directed against each cytokine and using 
agonist/antagonist antibodies directed to the cytokine receptors of interest. 
Experiments with siRNA will be also designed. 
2. ConSidering that melanospheres display a heterogeneous phenotype, the 
possibility to identify different subpopulations of cells within melanospheres 
will b~ explored. Starting from the observation that as in breast 
mammospheres (Pece et aI., 2010,) also melanospheres contain a slow 
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cycling fraction of cells (Roesch et aI., 2010), the differential response of 
these two populations to modulating cytokines/chemokines will be carefully 
explored. 
3. Interaction with stromal cells is crucially important for tumour development. 
The influence of keratinocytes or fibroblast, in modulating the properties of 
the different subpopulation of melanospheres will be investigated. 
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ORIGINAL ARTICLE 
Heterogeneous Phenotype of Human Melanoma Cells 
with In Vitro and In Vivo Features of Tumor-Initiating 
Cells 
Michela Perego\ Monica Tortoreto1, Gabrina Tragni2 , Luigi M ari ani3 , Paola Deho1, Antonino Carbone2, 
Mario Santinami 4 , Roberto Patuzzo4 , Pamela Della Minas, Antonello Villas, Graziell a Prates i1 , Giacomo 
Cossa 1, Pao la Peregol, Mari a G. Daidone1, Malco lm R. Ali son6, G iorgio Parmiani 1,?, Li cia Ri vo ltini 1 and 
Chi ara Castelli 1 
M elanospheres, t he m elanoma ce ll s th at grow as nonadherent co lo ni es and th at show in vitro self-renewin g 
capacity and mult i po tency, w ere se lected fro m m elanoma specimens or from m elano ma ce ll l ines. M elano-
spheres w ere highl y tumorigenic, and intrad ermal injection s in severe combined immuno deficient (SClD) mice 
of as few as 100 ce lls generated t umo rs t hat maintained tum o ri genic potenti al into subsequent recipients. 
Primary and se ri ally transplanted xe nografts recapitulated the phenotypic features of th e o ri g inal melanoma of 
the patient. M elano m a ce lls cultu red in t he presence of fetal ca lf se rum (FCS) w ere al so tumo rigenic in SCiD 
ll1ice, altho ugh w ith lower effi ciency; t hese xenografts showed a ho m o geneous phenotype fo r th e express ion o f 
ll1elanoma-associated markers, M elan-NM art-1, HMB45, and MITF, and contain ed ce ll s w ith features of fully 
differentiated ce ll s. M elanosphe res w ere heterogeneous for th e expression of stem ce ll markers and showed a 
Significantly enhanced express io n of the Nanog and O ct3/4 transcription factors when compared with adherent 
ll1elanoma ce ll s. No direct and unique co rre lation between any o f th e examined stem ce ll markers and in vivo 
tumorigenic ity was fo und. Taken togeth er, o ur data provide furth er evidence on the heterogeneous nature of 
~uman melano m as and show that melanospheres and th eir co rresponding tumors, w hich are generated in vivo 
In immunocomp ro mised mice, represent a mo d el to investi gate m elano ma biology. 
JOurnal of Investigative Derma tology advance on line publica tion, 8 April 2010; doi:1 0. 1 038/jid.2010.69 
INTRODUCTION 
T!le cancer stem ce ll theory proposes that tu mors can be 
viewed as the result of an anomalous differentiation program 
of putative cancer stem cells (CSCs). Although probably 
representing a minor populat ion of the whole tumor mass, 
CSCs are believed to constitute a unique ce ll subset 
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responsible for tumor maintenance and growth (Reya et al., 
2001; Lee and Herl yn, 2007; Aill es and Weissman, 2007) . 
However, the parent-to-progeny relationship between CSCs 
and the tu mor bulk population does not necessaril y reflect 
the well -conserved and predictable ru les operating in normal 
tissue organization. Instead, beca use of the intri nsic genetic 
and epigenetic instabi lity of ca ncer ce ll s, it is more likely that 
tumor generation represents an aberrant and highly unstable 
differentiation program (Adams and Strasser, 2008; O doux 
et al. , 2008). Moreover, recent data suggest that tumor 
heterogeneity ca n result from variabi lity in the frequency, 
phenotype, and functional features of CSCs (Pi ccirill o et al., 
2009). 
Although there is no defi nitive consensus on the pheno-
type and frequency of CSCs in the majority of human tumors, 
much experi mental evidence supports the contentions that 
many tumors of both epithelia l and nonepithelial origin have 
operationall y defined CSCs (cell s able to propagate tu mors in 
immunodeficient mice) and that the presence of these CSCs 
affects tumor bio logy (AI ison et al., 2008; Dick, 2009; Jordan, 
2009) . 
Melanoma, one of the most aggress ive human cancers 
w ith metastatic les ions resistant to conventional therapies, is 
highl y heterogeneous and shows a high degree of plasticity 
w"''' .pdonline.org 
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(Hendri x et al., 2003; Mourad-Zeidan et al., 2008). Recent 
ev idence indicates that human melanomas contain different 
cell populations endowed w ith intrinsic chemores istance 
(Frank et al., 2005). Moreover, it has been shown that stem-
associated markers such as C01 33, C0166, and nestin are 
expressed by human melanomas (Klein et al., 2007). 
Although the nature and frequency of CSCs in melanoma is 
Controversial, it is li kely that the CSC model ca n be applied to 
human melanoma, and different surface markers have been 
proposed to define melanoma ce ll s with tumor- initiat ing 
potential (Fang et al., 2005; Monzani et al., 2007; Keshet 
et al., 2008; Schatton et al., 2008). A recent study using 
non obese diabetidsevere combined immunodeficient (SClO) 
112ry- l- mice for an in vivo assay of tumor init iation 
Suggested a very high frequency of CSCs in melanoma; 
moreover, an analysis of a large panel of melanoma-related 
markers fa iled to find any correlation between a specific 
phenotype and tumor- initi ating capacity in vivo (Quintana 
et al., 2008). Thus, stem cells in melanoma are worthy of 
investigation, and our study eva luated the presence of cell s 
~howi ng in vitro and in vivo features of tu mor-i ni t iating cell s 
In human metastatic melanomas. 
RESULTS 
Anchorage-independent, self-renewing melanospheres variably 
express stem-associated markers 
Stem ce ll med ium (SCM) supported the se lection of ce ll s 
growing as melanospheres in 8 of the 18 lymph node 
n1elanoma metastases used in this study (44% success rate). A 
si mil ar percentage of melanosphere forma tion (32%) was 
achieved by starting from melanoma ce ll l ines previously 
establi shed as adherent ce ll s in medium supp lemented w ith 
fetal ca lf serum (FCS). MejR8S and Me204S, derived from the 
adherent melanoma ce ll I ines, and Me15888S and 
Me14346S, derived directly from lymph node metastasis, 
were used th roughout thi s study. The se lf-renewing capacity 
of tumor spheres was assayed by sphere formation and 
clonogenic assays. Both tests gave cons istent results, showing 
that all of the melanospheres showed a higher frequency of 
se lf-renewing ce lls than adherent melanomas (Table 1). 
Melanospheres were cultu red in differentiating media for 
Cells of the mesenchymal lineage: chondrocytes, osteocytes, 
and ad ipocytes. Me204S was able to differentiate into all 
three ce ll types w ith similar effic iencies (Supplementary 
Figure Sl on line). Melan-NMART-1 expression, a marker of 
l11elanocyte differentiation, was eva luated after growi ng 
l11elanosphere-derived cell s in the presence of 10% FCS. I~e corresponding adherent melanoma ce ll line Me204AOH 
did not show differentiation ca pability and maintained a high 
eXpression of Melan-NMART-1. Similar differentiation rates 
were obta ined for MejR8S, Me15888S, and Me14346S (data 
nOt shown). 
h All of the generated melanospheres were negative for the 
enlatopoietic marker C045 . Conversely, all of them were 
1 ?O% pos itive for Melan-A:lMART-1 and HMB45 melanocyte 
differentiation prote ins (Figure 1 a). The expression of C0146 
and G0 3 was variable, w ith virtually all Me14346S cell s 
Stai ning negat ive for G03 and a very low percentage sta ining 
JOurnal of Investigative Dermato logy 
Table 1. Self-renewal of melanospheres (S) and 
melanoma-adherent cells (ADH) 
% of melanospheres 
Cell type 
Me204 
5 
ADH 
MeJR8 
5 
AOH 
Me14346 
5 
AOH 
Me 15888"' 
5 
SFA' 
54 ± 7.1 53 
10.7 ± 8.2 
25 .6± 1.1 
8.2 ± 3.8 
26.9±4.1 
0.9± 1.1 
14 ±8.2 
Abbreviation: SFA, Sphere Formation Assay. 
1 Percentage of melanospheres per 100 cel ls. 
2Percentage of clones per total si ngle cells seeded. 
Clonogenic assay2 
52.7 ± 5.6 
4.4 ± 0.3 
18.5 ±2.1 
6.4 ± 0.2 
11 .8±4.2 
o 
5.8± 1.8 
3Mea n ± SO calcu lated on the bases of three independent experiments. 
"Fresh melanoma ce ll suspension derived from lymph node melanoma 
metastas is no. 15888 failed to establish an adherent melanoma ce ll line, 
and thus the adherent cou nterpart of Me15888S is not avai lable for 
analysis. 
positive for C0146 (Figure 1 a). Melanosphere ce lls also 
expressed severa l embryonic stem ce ll markers, and all four 
of the melanosphere lines were almost 100% pos itive for 
C09, SOX2 Oct3/4, and Nanog proteins whereas a very low 
percentage of ce ll s (or none at all ) expressed SSEA-1 and 
SSEA-4. A low rate of expression was observed for Musashi -1, 
w ith 13- 16% of Me15888S and Me204S ce ll s staining 
pos itive (Figure 1 b and Supplementary Figure S2 online) . 
The expression of stem-related markers used to identify adult 
stem ce lls of normal and mal ignant tissue (C020, C024, 
C044, C073, C0133, C0166, nerve growth factor receptor 
(NG FR), and nestin) was examined (O'Brien et al., 2009). 
NGFR and nestin were included because of their express ion 
in c lis of the neural crest (Lee et al. , 2007). A ll the 
melanosphere lines were negative for C020 and positive for 
C044 and nestin. Converse ly, C024, C073, C0166, NGFR, 
and C0133 markers were expressed in different percentages 
of ce ll s in all the melanosphere li nes. In Me15888S, a 
majority of ce lls were C0133 -, C0166- , and C073 +, and 
this melanosphere line had the highest percentage of NGFR-
positi ve ce ll s (Figure 1 c) . 
The expression of all the above markers was also assessed 
in Me204AOH, jR8AOH, and Me14346AOH and in seven 
add itiona l pairs of adherent and me lanosphere melanoma 
lines. Among the examined markers, on ly the express ion of 
the stem-related proteins Nanog and Oct4 was signi ficant ly 
a 
b 
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;gure 2. O c13/4, Nanog, and C0146 are modulated in melanospheres when compared with adherent cells. The left co lumn shows the box-a nd-whisker 
Pats for the markers that were di ffe rentially expressed in melanospheres w hen compared w ith adherent ce ll s. The fluorescence intensity (X mean) on the yaxis 
~~ua l s the X mean (marker) minus the X mea n (isotype control). Va lues are ca lcu lated as the mean of three independent exper iments. Histograms of the 
c ferentlal expression of Oct3/4, Nanog, and CD146 in Me204S (black) and Me2 04ADH (gray) are reported. Lines and filled histograms correspond to isotype 
\ antrals and specifi c antibodies, respective ly (P-values eva luated wit h unpa ired I-test). In all , 11 melanoma adherent ce ll l ines and 11 melanospheres 
vere analyzed. 
enhanced in melanospheres when compared with adherent 
~~li s, and on Iy CD146 was significa nt ly downregulated 
Igure 2). 
AS Rea l-time PCR clearly show ed that ABCB 1, ABCB5, and 
Of CC2 genes were expressed by melanocytes. Moreover, all 
ASthe melanosphere and adherent ce ll lines were pos itive for 
(S CC2, whereas they variably expressed ABCB 1 and ABCB5 
Upplementary Table Sl online) . 
~~lanosPheres are endowed with enhanced tumorigenicity 
Ih en compared with adherent melanoma cells 
e e tumor igeni city of melanospheres was assessed by ~alu at ing their ca pacity to form melanomas when intrader-
thal ly injected into SCiD mice. At a dose of 104 ce lls, all of 
lOe nlelanosphere lines generated fast-growing tumors in 
i)) 0% of injected mice w ithin 14--4B days. Notabl y, all of the 
c ~ I a nosphere lines coulq form tumors w hen as few as 100 
a
e Is were injected per mouse, and two of them (Me15BBBS I~d MeJRBS) formed tumors in 100% of mice even at thi s 
\Iv dose. Pri mary xenografts were then seri ally transpl anted 
IQ~ r 
nal of Invest lgdtlve Dermatology 
into subsequent animal hosts. Secondary and terti ary 
tumors developed in 100% of injected mice; interestingly, 
serial tumors grew as fast or faster than their corresponding 
primary engraftment (Tabl e 2 and Supplementary Figure S3 
online). 
To prov ide evidence that the melanoma xenografts 
generated by melanospheres may have had a clonal ori gin, 
SCiD mice were inoculated with esca lat ing doses of ce ll s 
derived from melanospheres generated from a single mela-
noma cl one, P1 EBS. Tumor take, latency, and secondary 
tumor formation were all sim ilar to those of the parenta l 
melanosphere bu lk populati on URBS) from w hich the clone 
was generated (Supplementary Tabl e S2 online). 
Beca use melanospheres endowed with strong tumorigeni c 
potential could have been se lected from melanoma cell s 
adapted to grow in FCS, and because even the adherent 
melanoma lines had a limited but detectable in vitro 
se lf-renewal capacity, Me2 04ADH, MeJRBADH, and 
Me14346ADH ce ll s were inoculated in SCi D mice to 
eva luate the extent to w hich they possess tumor-initi ating 
Table 2. In vivo tumorigenicity of melanosphere-
forming cells (5) and adherent melanoma cells (ADH ) 
Primary Secondary Tertiary 
tumor formation tumor formation tumor formation 
Cell Ce ll 
type number' Take2 Latencyl Take2 Latency3 Take2 Latency3 
MejR8 
5 
Me204 
5 10' 
103 
102 
515 
515 
515 
515 
4/5 
3/5 
AO H 105 
4/4 
SIS 
2/5 
NO 
515 
SIS 
0/5 
M e14346 
5 104 SIS 
103 4/5 
102 3/5 
5x 10' NO 
AO H 106 212 
104 515 
103 4/5 
102 3/5 
Me 1588a5 
5 515 
515 
515 
22 
29 
22 
22 
49 
49 
14 
22 
39 
NO 
25 
67 
NO 
48 
92 
123 
NO 
19 
77 
77 
123 
33 
33 
53 
Abbreviat ion: NO, not done. 
' Number of injected cells. 
2/2 
NO 
NO 
2/2 
N O 
NO 
2/2 
NO 
NO 
2/2 
2/2 
NO 
NO 
2/2 
3/3 
3/3 
NO 
011 4 
0/24 
NO 
0/24 
3/3 
NO 
NO 
25 
NO 
NO 
25 
NO 
NO 
36 
NO 
NO 
36 
60 
NO 
NO 
30 
40 
40 
NO 
NO 
NO 
NO 
NO 
35 
NO 
NO 
2/2 
NO 
2/2 
2/2 
2/2 
2/2 
NO 
NO 
0/2 
0/2 
NO 
NO 
NO 
2/2 
3/3 
3/3 
NO 
NO 
NO 
N O 
3/3 
NO 
NO 
18 
NO 
35 
30 
50 
28 
NO 
NO 
NO 
NO 
NO 
NO 
NO 
30 
40 
57 
NO 
NO 
NO 
NO 
35 
NO 
NO 
2Number of tumors fo rmed per number of injections. 
3Time from injection to tumor measurabili ty. Median va lues are reported. 
Observation time is 200 days. 
40 bservation ti me is 60 days. 
5Fresh melanoma ce ll suspension deri ved from lymph node melanoma 
metastas is no. 15888 fai led to establish an ad herent melanoma ce ll line, 
ana th us the adherent counterpart of Me15888S is not avai lable for 
ana lys is. 
capac ity in vivo. As expected, tumor take decreased with 
dimini shing numbers of injected ce ll s; the efficiency of 
primary tumor fo rmation was lower when compared with 
M Perego et al. 
Cancer Stem Cells in Human Melanoma 
that of the corresponding melanospheres, and the latency of 
tumor formation was longer (Tab le 2). Moreover, once 
established, the pri mary tumors generated by the adherent 
melanoma lines grew slower than the tumors generated by 
the corresponding melanosphere lines (Supp lementary Tab le 
S3 online). 
These quantitative diffe rences in the in vivo behavior of 
melanospheres and adherent me lanoma ce ll s were assessed 
by statist ica l ana lys is. The log-normal regression model 
yielded highl y signi ficant resu lts for treatment (adherent vs. 
melanosphere ce ll s; P<O.OOO l ), thus confirmi ng the higher 
tumorigenic potential of melanospheres when compared w ith 
adherent melanoma ce ll s. Statistica ll y significant resul ts were 
also obtai ned for ce ll li ne (P<O.OOO1) and dose (P<O .OOOl), 
indicating that both factors affected tumor igenicity. Con-
versely, the interactions between treatment and ce ll li ne 
(P= 0.22) or inocu lating dose (P= 0.30) were not significant, 
indicating that melanospheres have a higher tumorigenic 
potential than adherent melanoma ce lls, independent of ce ll 
line and dose. Tumor mass was sign ificantly affected by 
treatment (adherent vs. me lanosphere ce ll s; P= 0.0045) but 
not by ce ll li ne (P=0. 16) or dose (P= 0.35), and no 
significa nt interact ions between treatment and ce ll line 
(P= 0.29) or treatment and dose (P= 0.79) were found. 
These analyses support the concl usion that, once estab li shed, 
tumors generated by melanospheres grow more aggress ive ly, 
and that thi s aggress ive behavior is a funct ion of their 
melanosphere origin . 
Primary tUmors deri ved from adherent ce ll s were seriall y 
transplanted in addi tiona l recip ients. Differences in trans lat-
ability, eva luated as tumor take, between adherent and 
melanosphere-deri ved pri mary xenografts emerged in tert iary 
tumor format ion w ith Me204ADH- and Me14346ADH-
derived tumors fa i ling to grow. Me14346ADH xenografts 
showed very poor v iabili ty (Tab le 2), and viab le tumor ce ll s 
were onl y obta ined from tumors generated by the injection of 
106 melanoma ce ll s. However, at the same ce ll dose, no 
serial engraftment was successfu ll y established. Of note and 
at difference from Me204ADH and Me14346ADH, Me) 
RBADH showed transplantation efficiency equa l to its 
auto logous MeJRBS, and 100% tumor take occurred w ith 
all four tumors growing in tert iary recipients . 
Xenografts generated by melanospheres recapi tulate the 
phenotypic features of the original human melanoma 
Histologica l eva luation confi rmed that human melanoma 
xenografts generated in SCi D mice by melanospheres 
consisted of ce ll s showing the typ ica l morphology of 
melanoma ce ll s: eosinophili c cytoplasm, irregular nuclei, 
and prominent nucleo li. Xenografted tumors expressed the 
spec ific melanoma markers HMB45, Melan-NMart-l, and 
MITF-l . Moreover, although melanospheres were homoge-
neously positive for Melan-NMART-l, this marker was 
heterogeneous ly expressed in the growing tumor mass; i .e., 
Melan-NMart-l -negati ve melanoma ce lls could be found. 
In general, thi s heterogeneity, as we ll as the levels of 
MITF and HMB45, mirrored that of the patient's original 
tumor (F igure 3a). Furthermore, the sim ilarity between the 
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Figure 3 Mclanospheres are tumorige~ i c and reproduce human melanoma in immunocompromi cd mice. Immunohistological staining of (a) melanoma-associated 
and (b) stem-related markers in xenograft tumors generated by intradermal inject ion of melanosphere-derived ce lls and in lymph node metastatic melanomas of 
patient 204 and patient 15888. Internal sca le markers are indicated in each panel. For m lanosphere-derived xenografts, reported images are representati ve of eight 
independently analyzed xenograft s; for patients' tumors, images are representative of two non-consecutive tumor sections. Sca le bar = 100 J.lm. 
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melanosphere-derived tumors and the patient's ori gi nal 
tumor was also maintained with regard to the express ion of 
the stem-related markers C0133, C01 66, NGFR, and nestin 
(F igure 3b). 
The stem-related markers showed an elevated degree of 
variability in express ion, w ith C0166 and nestin expressed 
by the majority of cell s in the tUlllor mass, and C0133 
expressed by very few tumor ce ll s. This distribution was 
confirmed by the analysis of 10 primary melanoma les ions 
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and their paired metastases (Supplementary Table 54 and 
Figure 54 online). 
Conversely, immunohistochemistry showed that adherent 
ce ll-derived xenografts uniformly expressed the differentia-
t ion markers, Melan-NMART-1 and HMB4S, and had an 
elevated level of the transcription factor MITF w hen 
compared w ith the melanosphere-derived tumors and the 
patient's original tUlllor (Figure 4a). These xenografts were 
also heavily pigmented, as shown by melanin-specific 
MITF 
NESTIN NGFR 
TEM 
Figure 4 Immunohistochemistry and ultrastructural analysis oT xenografted tumors. Immunohistochemica l staining of (a) melanoma-associa ted and 
(b) stem-related markers was performed on xenografts generated by intradermal injection of adherent melanoma ce lls Me204 and MeJRB. For each ce ll line, 
reported images are representati ve of eight independentl y analyzed xenografts. Internal sca le markers are indi cated in each panel. (c) Melanin staining 
and transmi ss ion electron microscopy (TEM) analys is. Fontana-Masson melanin-specifi c staining (c, left panels) and TEM (c, middle and right panels) on 
melanoma xenografts deri ved from the injection of M e204 melanospheres (upper panels) o r Me204-adherent cells (lower panels). M, melanosomes; 
IvIt, mitochondria; N, nucleus. Sca le bar = , 00 ~lm. For TEM, left panel sca le bar = 2 J.lm and ri ght panel sca le bar = 500 nm. 
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stai ning (Figure 4c, left panel). High numbers of melano-
somes, mostl y in the ir terminal differentiation phase, were 
detected by electron microscopy in these adherent ce ll -
derived tumors, whereas only a few, mainly immature 
melanosomes, were found in melanosphere-deri ved tumors 
(Figure 4c, ri ght panel). 
DISCUSSION 
In this study we show that from lymph node metastatic 
les ions we iso lated, by se lective in vitro culture, 
melanoma ce lls growing as melanospheres, which had 
distinctive featu res of melanomas such as the express ion 
of Melan-NMart-1 and HMB45 and that showed 
in vitro se lf-renew ing capacity, multi potency, and strong 
tumorigenic potential in immunocompromised mice. 
Moreover, the human melanoma xenografts, generated in 
immunocompromi sed mice by the inj ection of melano-
spheres, recapitulated the original heterogeneity of the 
patient's tumors. 
Our data show that melanospheres can be se lected 
with high efficiency from bulk melanoma ce ll s and 
from estab li shed adherent melanoma ce ll li nes, and that 
these ce ll s show a high clonogen icity and a strong in vivo 
tumorigenicity, suggesting a high frequency of ce ll s endowed 
With or acqu iring tumorigenic potenti al once inj ected in vivo. 
All the melanoma samples that we studied were derived 
from lymph nodes or visceral metastasis and it is conceivable 
that metastases may be naturall y enriched with regard to 
tumorigenic ce ll s (Croker and Al lan, 200B; Chiang and 
Massague, 200B); in fact, ce lls undergoing an epithelial-
mesenchymal transition and acquiring the abi li ty to invade 
and metastas ize are also endowed w ith tumorigenic 
properties (Mani et al., 200B; Gupta et al. , 2009) . It is 
tempting to specu late that metastases could be parti cularl y 
enri ched for tumorigenic ce lls and, because it is know n that 
melanomas are generall y highl y metastatic and endowed 
w ith a high degree of plasticity (Hendrix et al. , 2003; 
Mourad-Zeidan et al. , 200B), this theory could exp lain 
the high frequen y of tumorigen ic ce ll s in this particular 
human cancer. 
The melanosphere phenotype confirmed their melanocy-
ti c origin, was heterogeneous with rega rd to stem-associated 
markers, and tumorigenic ity was not linked w ith any 
parti cular phenotyp ic profi Ie. Recently, studies have stressed 
the ro le of C0133 as a cancer stem ce ll marker in a set of 
human so lid tumors, incl uding melanoma (Monzani et al., 
2007; O/Brien et al., 2007). In this study we show that 
melanospheres homogeneously expressi ng C0133 were 
endowed with the same tumorigen icity as melanospheres 
With only a lim ited percentage of C0133 + ce ll s. Sim ilarly, 
We did not detect any specifi c enrichment of C020 + ce lls in 
rnelanospheres. These data para llel the complexity of 
characteriz ing CSC markers, and currently no definitive 
consensus has b en reached on the CSC phenotype for 
melanoma (Fang et al., 2005;, Frank et al. , 2005; Monzani 
et al. , 2007; Keshet et al., 200B; Schatton et al., 200B; 
Quintana et al. , 200B) or indeed for other so lid tumors or 
nOrmal t issues (Oalerba et al., 2007; O'Brien et al. , 2007; 
JOurnal of Investigative Dermato log 
Ri cc i-Vitian i et al., 2007; Becker et al. , 200B; Shmelkov et al., 
200B; Cheng et al., 2009; Sun et al. , 2009 ). 
The histo logica l features of the xenografts generated by 
melanospheres clearly resembled those of human 
melanomas, thus recapitulating the ori gi nal tumor hetero-
geneity. Although the melanospheres were homogenously 
positive for Melan-N MART-1, this marker was heteroge-
neously expressed in melanoma xenografts, and in 
general, the express ion patterns of melanoma-associated 
markers and stem-related markers mirrored those of the 
patient's original tumors. In parti cular, very few ce ll s 
were C01 33 + / and scattered NGFR + ce ll nests were 
detected in the xenografts as we ll as in the ori ginal 
human tumors. These patterns of staining were also found 
in a panel of primary and metastati c pai red melanomas, 
confirming that thi s heterogeneity is a general trait of human 
melanomas. 
In vitro se lf-renewa l, defined as the ability of the ce ll s to 
grow in SCM when seeded at clonogenic density, and the 
abili ty to form tumors in immunocompromised mice 
were not onl y unique features of melanospheres but they 
were also detected in adherent melanoma ce lls . In agreement 
with the literature (Rodo lfo et al. , 19BBL we found that 
melanoma ce lls grown as adherent ce lls in medi um contain-
ing FCS also formed tumors in SCiO mice. However, the 
efficiency of tumor formation was lower for adherent 
ce ll s w hen compared with the corresponding melanospheres, 
and the latency of tumor growth was delayed in the 
group of tumors derived from adherent melanoma ce ll s. In 
agreement with these quantitat ive d ifferences, xenografts 
derived from adherent melanoma ce ll s qualitatively 
diverged from xenografts generated by melanospheres and, 
in general, adherent ce ll-derived tumors showed a highl y 
differentiated phenotype, as ev idenced by ultrastructural 
analysis. 
Of note, we found that the melanoma ce ll li ne 
MeJRBAOH, derived from visceral metastas is (stage IV 
melanoma), showed over seri al in vivo passages equa l tumor 
take to its melanosphere counterpart . These data, together 
w ith the evidence that melanospheres could have been 
generated from their correspond ing adherent melanoma 
ce ll s, strongly suggest that putative melanoma stem ce ll s 
are li kely contained both among melanospheres and adher-
ent melanoma populations. Neverthel ess, because of the 
absence of molecular marker(s) or lineage tracing in vivo, our 
data did not definitively address the issue of the presence and 
relative frequency of CSCs in melanosphere and adherent 
melanoma ce lls. 
Taken together, our data add to the ex isting evidence that 
human melanoma is a heterogeneous cancer composed of 
ce ll s w ith different characteristi cs and suggest that melano-
spheres and their corresponding tumors in immunocompro-
mised mice represent a reli able model to analyze melanoma 
biology. A better understanding of the fate of melanospheres 
inoculated in vivo, and their response to stimuli deriving from 
the tumor stroma, wi ll offer the possib ili ty to better under-
stand the mechanisms driving melanoma formation and 
progress ion. 
MATERIALS AND METHODS 
Melanoma cell cultures 
Lymph node melanoma metastases were collected upon pati ents' 
informed w ritten consent. The melanoma adherent cel l lines 
Me204ADH and Me14346ADH were establi shed as reported 
(Vallacchi et al., 200S) . The melanoma cell line jRSADH, deri ved 
from a melanoma lung metastas is, was kindly provided by Dott G. 
Zuppi, Istitu to Regina Elena, Rome. Fresh melanoma cel l suspension 
derived from lymph node melanoma metastas is no. 1 5SSS failed to 
establish an adherent melanoma ce ll line. To generate Me15SSSS 
and Me1 4346S melanospheres, fresh melanoma cell s were seeded at 
cl onal density (2,500-5,000 cells cm-'2) in 75-cm2 flasks in SCM 
consisting of DMEMlF-12 (Lonza, Valais, Switzerl and), supplemen-
ted w ith N2 supplement (Inv itrogen, Carlsbad, CAl . Melanospheres 
Me2 04S and jRSS were derived by plating melanoma ce ll s grown as 
a monolayer (Me204ADH and MejRSADH) in SCM. Clone P1 ES5 
was deri ved by plating primary melanospheres of jRSS at clonal 
density (1 ce ll per well ) in SCM. The study was conducted according 
to the Dec larati on of Helsinki Principles. 
Sphere formation assay and clonogenic assay 
For the sphere formation assay, 100 single, viable melanoma cells 
were plated in 500 III of SCM in poIY-L- lys ine (Sigma, St Loui s, MO), 
coated overnight in a 4S-well plate and melanospheres were counted 
after 5-8 days. For the clonogenic assay, 100 III of SCM containing 
2.5 cell s ml-1 was seeded in 96-well plate. After 2-4 hours, wells were 
examined under the microscope and we lls containing a single cell 
were followed for sphere formation over the fo llow ing days. 
Flow cytometry 
The primary antibodies, anti-human CD24, CD44, CD73, CD1 46, 
CD166, and NGFR (CD271) were all from Becton Dickinson (Franklin 
Lakers, NJ). In addition, anti-human CD133 (clone C293; Mi ltenyi, 
Bergisch Gladback, Germany); anti-human Nestin (R&D, Minneapolis, 
MN); anti-human Melanosome (HMB45, Dako, Glostrup, Denmark) and 
anti-human Melan-NMART-1 (clone M2-7; Kawakami et aI. , 1997); and 
anti-human Musashi-1, Sox2, Oct3/4, and Nanog (R&D) were used. For 
intracellular staining, CytofixlCytoperm and PermlWash buffer (Bedon 
Dickinson) were used; nuclear antigens were analyzed in cells fixed with 
4% parafonna ldehyde and permeabi lized with TX-1oo 0.1 % in 
phosphate-buffered saline for 30 minutes at room temperature. Data 
were acquired by FACScalibur (Bedon Dickinson) and analyzed using 
Flowjo, V S.5.2, Tree Star, Ashland, OR. 
Real-time peR 
RNA extracti on and digestion with DNase were ca rri ed out using the 
RNAqueous-4PCR Kit (Ambion, Carl sbad, CAl . Complementary 
DNA synthes is was performed w ith the High-Capacity complemen-
tary DNA Reverse Transcripti on Kit (Applied Biosystems, Carlsbad, 
CAl . The rea l-t ime PCR rea tion was performed w ith inventoried 
assays, using the ABI 7900HT instrument (Applied Biosystems) . 
In vivo tumorigenicity 
SOD mice 7 weeks old, were intradermall y injected w ith 
illelanoma ~e ll s, resuspended in ' phosphate-buffered sa line, and 
illi xed w ith Matrigel (Becton Dick inson) in a 1:1 ratio (Charles Ri ver, 
Wilmington, MA). Viabi li ty of the injected cell s was determined 
Using the Trypan blue exclusion test. To perform serial engraftments, 
M Perego et al. 
Cancer Stem Cells in Human Melanoma 
mice bearing tumors of approx imately 500 mg were kil led, their 
tumors were dissoc iated, and viable single cell s were re-inj ected into 
SCiD mice . The experiments were approved by the Eth ics 
Committee for Animal Experimentati on of the Istituto Nazionale 
Tumori of Milan, according to the institut ional guidelines. 
Immunohistochemistry 
Formalin-fixed, paraffin -embedded tissue secti ons (1-2 Ilm) were 
stained according to the standard procedures (Vallacchi et al., 200S; 
Kl ein et al., 2007) w ith the following primary mouse anti -human 
antibodies: anti -melanosome, 1 :50 (HMB45, Dako); anti-Melan-A, 
1 :50 (Dako clone A 103); anti-M ITF, 1 :200 (clone 34CA5; Novocas-
tra Laborator ies, New Castle, UK); anti-nestin, 1 :200 (Chemicon 
International, Bi lerica, MA); anti -CD166, 1 :40 (clone MOG/07; 
Novocastra Laborator ies); anti-NGFR, 1 :50 (Novocastra Labora-
tori es); and anti -CD133, 1 :25 (clone AC133; Mil tenyi). Stained 
sections were analyzed by opti ca l microscope (N ikon Eclipse 600, 
Nikon, Tokyo, japan). Fontana-Masson silver staining w as performed 
on 6-llm deparaffini zed and hydrated secti ons according to the 
standard procedures . 
Transmission electron microscopy analysis 
Tumors were fi xed w ith 4% paraformaldehyde and 2% gluta ralde-
hyde in 0.12 M phosphate buffer. All samples were post-fixed w ith 
1 % OS04 in cacodylate buffer, dehydrated in ethanol, and 
embedded in epoxy resin. U ltra thin sections (60 nm), obtained with 
an ultra microtome (Ultracut E; Reichert-jung, Depew, V), were 
doubly stained w ith uranyl acetate and lead citrate and then 
examined by transmiss ion electron microscope CM 10 Philips (FEI, 
Eindhoven, The Netherlands). 
Statistical analyses 
The differences in tumorigenicity (tumor take and latency) and in the 
tumor mass of the xenografts generated by melanospheres and 
adherent ce lls were stati stica ll y evaluated. For all the analyses, 
mu ltip le regress ion models were used: a log-normal model for 
" time-to-event" data to eva luate di fferences in the tumorigenicity, 
and a generali zed linear model for normal data in the case of tumor 
mass. The stati stica l assumptions were verifi ed, and the log-normal 
model was chosen as being the best fit among a number of 
parametri c alternati ves (exponential, Weibul l, and log- logistic 
models). The model predictors were trea tment (melanospheres and 
adherent melanoma ce ll s), ce ll l ine (Me204, MejRS, and Me14346), 
and dose (104, 103, and 102) . When treatment was the factor of 
experimental interest, ce ll line and dose represented study design-
re lated covari ates. All these factors were categor ica l, and thus coded 
w ithin the models by indicator (0- 1) dummy variables. A search for 
interactions between treatment and cell li ne or dose was also 
performed. Analyses were performed with SAS (Cary, NC); two-sided 
P-va lues of < 0.05 were considered stati sti ca ll y signi ficant. Row 
outputs of the analyses are included in the Supplementa ry Material. 
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melanoma cells (ADH) evaluated by Real Time PCR 
Cell t~~e Trans~orters 
ABCB1 ABCB5 ABCG2 
'AC l 2RQ 'ACt 2RQ 'ACt 2RQ 
Me204 S 12,96 0,66 3 0,00 11,17 1,10 
ADH 14,07 0,30 3 0,00 9,78 2,88 
MeJR8 S 3 0,00 3 0,00 12,25 0,52 
ADH 17,25 0,03 18,01 0,00 11,21 1,08 
Me14346 S 15,70 0,10 8,48 0,22 12,34 0,49 
ADH 11,72 1,56 11,98 0,02 12,22 0,53 
Me158884 S 5,61 107,35 3 0,00 12,09 0,58 
Melanocytes 12,36 1,00 6,27 1,00 11,31 1,00 
I l!C I values calculated as [C I (target gene)- C I (GAPDH RNA)] 
2 RQ values calculated using the equation RQ=2-Mc,. l!l!C I values were calculated by 
subctracting the l!C lof the calibrator from the l!C I value of each target. 
3 Absent genes defined as genes with l!C I above 25 cycles. 
4 Fresh melanoma cell suspension derived from lymph node melanoma metastasis #15888 failed 
to establish an adherent melanoma cell line, thus the adherent counterpart of Me15888S is not 
available for analysis 
Table 25 In vivo tumorigenicity of the melanosphere clone P1 E8 S. 
Cell primary tumor secondary tumor 
Cell ty~e Number) formation formation 
Take2 Latencyl Take2 Latencyl 
104 5/5 28 2/2 26 
MeP1E8S 10
3 5/5 28 nd 
102 5/5 39 2/2 29 
) Number of injected cells. 
2 Number of tumours formed I number of injections. 
3 Time from injection to tumour measurability. Median values are reported. Experiments were 
followed up to 200 days. 
nd not done. 
Table 35. Growth rate of tumors generated in 8CID mice by melanosphere (8) or 
adherent melanoma cells (ADH). 
Primary Tumors 
Cell Observation 
Tumor Mass (mg)l Cell type 
dose day 
S ADH 
MeJR8 104 42 264,1 ± 70,1 257,9 ± 67,1 
103 63 590 ± 130,4 363,8 ± 110,7 
102 85 1104,8 ± 256,5 538,8 ± 82,5 
Me204 104 105 1021,8 ± 65,2 638,1 ± 82 
103 105 869,3 ± 150,4 256 ± 48,6 
102 83 602,5 ± 197,5 NA2 
Me14346 104 85 643,5 ± 160,8 248,2 ± 100,2 
103 120 523,9 ± 170,7 926,7 ± 178,3 
102 140 418,2 ± 182,3 274,3 ± 211,8 
1Tumor mass calculated as mean ± SE of the masses of the growing tumors. 
2NA, no tumors grew in the primary recipients 
Table 4s. Expression of stem cell markers on paired primary and metastatic melanoma 
Primary tumors 
Patient NGFR CD133 Clark Level Thickness Ulceration Metastasis site 
P IV 19mm yes 
1 
M ** Lymph node 
P * * IV 5,3mm no 
2 M ** Lymph node 
M * Soft tissues 
P * * IV 9,6mm yes 
3 
M * * Soft tissues 
P * V 7,5mm yes 
4 
M ** * Lymph node 
P * * IV 4,9mm yes 5 
M ** Lymph node 
P * * IV 12mm yes 6 
M * Lymph node 
P III Smm no 
7 
M Lymph node 
P ** III 3,6mm no 
8 
M ** Soft tissues 
P ** * IV S,2mm yes 
9 
M ** ** Soft tissues 
P ** * IV >4mm yes 
10 
M ** ** Soft tissues 
P: Primary tumors; M: Metastasis; -:<5%; *:<20% of positive cells; **:<70% of positive cells; ***: 
> 70% of positive cells. Positive cells were evaluated in 10 random fields. 
Legends to the supplementary figures 
Figure 15. Mesenchymal differentiation of melanospheres and melanoma adherent 
cells. (A) and (8) Me204S and Me204ADH cells were induced to differentiate in 
osteogenic, adipogenic chondrogenic media as indicated in the Human Mesenchymal 
Stem Cell Functional Identification Kit (R&D). Differentiated cells were then stained for 
osteocalcin (green, Alexa 488), FA8P4 (red, TRITC) or Aggrecan (red, TRITC), and with 
Hoechst33342 (upper and lower row in A and 8). After washing, cover slips were 
mounted with 20% Mowiol (Sigma) and cells were analyzed by fluorescence microscopy 
with a Nikon Eclipse 600 (Nikon, Dusseldorf, Germany). No expression of any of the 
differentiation markers was detected in adherent cells. Melan-AiMART-1 staining was 
also performed after culturing Me204S and Me204ADH in medium with serum. (C) 
Histogram shows the percentage of Me204S (grey columns) and Me204ADH (black 
column) cells expressing the indicated differentiation marker counted in ten 20X random 
fields. Three independent experiments were performed and each experiment was 
performed in triplicate. Scale bar = 100 jJm. 
Figure 25. Expression of Oct3/4 and Nanog in Me14346S. Me14346S were dissociated 
and 105 melanoma single cells seeded on microscope slide by cytospin. Staining was 
performed using Oct3/4 or Nanog antibodies (green, Alexa 488) and Hoechst33342, 
according to protocol indicated in the "Embryonic Stem Cell Markers Antibody Panel 
Plus" (R&D). After washing, cover slips were mounted with 20% Mowiol (Sigma) and 
cells were analyzed by fluorescence microscopy with a Nikon Eclipse 600 (Nikon) 
Images at 20X (scale bar 100jJ) and 40X (scale bar 10jJ) have been reported. Merge of 
blue and green images showed that nearly the totality of cells expressed Oct3/4 or 
Nanog in the nucleus. White arrows indicate the few cells not displaying any positivity for 
the examined markers. Staining only with the secondary antibody has been shown as 
control. 
Figure 38. Tumorigenic potential of melanospheres. Growth curves (GC) of primary 
(left) or serially transplanted (right) human melanoma xenografts generated by 
intradermal injection of different doses of melanosphere-derived cells. Tumor mass is 
expressed in mg and calculated as the mean ± SE of the masses of the growing tumors. 
For details on the number of mice treated with each inoculating dose, see Table 2. 
Figure 48. Expression level of stem-related markers differs between human 
melanomas. Immunohistological evaluation of the expression of the indicated stem-
related markers in primary and paired metastatic melanomas. Reported images are 
representative of two independently analyzed tumor sections. Internal scale markers are 
indicated in each panel. The majority of tumor cells express (Pt3) CD166 and Nestin; 
rare CD133-positive cells could be found within the tumor mass in both primary and 
metastatic tumors. (Pt1) NGFR is heterogeneously expressed, and in some cases 
enhanced, in metastatic lesions. Images are representative examples of twelve primary 
and metastatic melanomas. Scale bar = 100 !-1m. 
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Statistic Report 
Number of tumors 
dose treatment Somma 
JR8 2 ADH 3 
S 5 
3 ADH 4 
S 5 
4 ADH 5 
S 5 
T14346 2 ADH 2 
S 3 
3 ADH 3 
S 4 
4 ADH 5 
S 5 
T204 2 ADH 0 
S 2 
3 ADH 5 
S 5 
4 ADH 5 
S 4 
Mass (mean, SE) by cell type, dose and treatment 
Cell type dose treatment Media Err std 
JR8 2 ADH 538.8 82.5 
S 1104.8 256.5 
3 ADH 363.8 110.7 
S 590.0 130.4 
4 ADH 257.9 67.1 
S 264.1 70.1 
T14346 2 ADH 274.3 211. 8 
S 418.2 182.3 
3 ADH 926.7 178.3 
S 523.9 170.7 
4 ADH 248.2 100.2 
S 643.5 160.8 
T204 2 ADH 
S 602.5 197.5 
3 ADH 256.0 48.6 
S 869.3 150.4 
4 ADH 638.1 82.0 
S 1021. 8 65.2 
Analysis of tumor mass by cell type, dose and treatment 
Dependent Variable: mass 
Origine DF 
treatment 1 
Cell_type 2 
dose 2 
Parameter Stima 
treatment ADH -252.0495879 
Least Squares Means 
treatment 
ADH 
S 
Note: 
mass LSMEAN 
450.087234 
702.136822 
Type III SS 
1082269.243 
474602.540 
265403.926 
Errore 
standard 
85.5393090 
Media 
quadratica 
1082269.243 
237301. 270 
132701.963 
Valore t 
-2.95 
Val ore 
F 
8.68 
1. 90 
1. 06 
Pr > It I 
0.0045 
P(treatment*Cell_type)=0.2948, P(treatment*dose)=0.7864 
Analysis of tumor latency by cell type, dose and treatment 
Type III Analysis of Effects 
Wald 
Effect DF Chi-Square Pr > ChiSq 
treatment 1 16.6024 <.0001 
Cell type 2 43.4657 <.0001 
dose 2 73.2576 <.0001 
Analysis of Parameter Estimates 
Errore 95% Confidence 
Parameter DF Stima standard Limits 
Intercept 1 3.0149 0.2007 2.6215 3.4084 
treatment ADH 1 0.6242 0.1532 0.3240 0.9245 
S (reference) 
Cell_type . JR8 1 -0.1803 0.1985 -0.5694 0.2088 
T14346 1 0.9845 0.2084 0.5761 1. 3929 
T204 (reference) 
dose 2 1 1. 8486 0.2187 1.4200 2.277l 
3 1 0.7657 0.1714 0.4298 1.1016 
4 (reference) 
Scale 1 0.6276 0.0570 0.5253 0.7499 
Weibull Shape 1 1. 5933 0.1447 1.3335 1. 9038 
Note: 
Pr > F 
0.0045 
0.1574 
0.3509 
Chi-
quadrato Pr 
225.55 
16.60 
0.82 
22.32 
71. 47 
19.96 
p(Scale)<.OOOl, P(treatment*Cell_type)=0.4659, p(treatment*dose)=0.3564 
> ChiSq 
<.0001 
<.0001 
0.3638 
<.0001 
<.0001 
<.0001 
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LETTER TO THE EDITOR 
Spheres of Influence in Cancer Stem Cell Biology 
Journal of Investigative Dermatology advance onli ne publication, 21 October 2010; doi:1 0.1 038/jid.20 1 0.305 
TO THE EDITOR 
We read w ith great interest the Com-
mentary by Schatton and Frank (2010) 
that appea red in the July issue of 
Journal of In vestigative Dermatology. 
They highlight one of the major findings 
of our articl e, published in the same 
issue of the Journal (Perego et al., 
2010): that malignant melanoma- initi-
ating cel ls (MMIC) can also be found in 
melanoma ce ll lines when grown as 
adherent ce ll s. We found that melano-
spheres could be derived from both 
melanoma single-cell suspensions ob-
tained from fresh tumor specimens, 
and from melanoma ce lls previously 
adapted to grow as adherent ce ll s. 
However, it should be noted that we 
found the frequency of se lf-renewing 
ce lls was relative ly low in adherent 
ce lls when compared w ith ce lls from 
melanospheres. 
These in vitro quantitative differ-
ences were also reflected in the results 
from the in vivo tumorigenic assays 
using immunocompromised mice, 
clearly suggest ing a greater enrichment 
of tumorigeni c ce ll s in melanospheres 
compared w ith adherent ce lls. More-
over the latency of xenografts generated 
in primary recipients by melanosphere 
ce lls was much shorter than that ob-
served with adherent melanoma cell s. 
Likewi se, when xenografts were serially 
transplanted into secondary and tert iary 
hosts, the difference in successful tumor 
graft ing between the two groups be-
ca me even more appa rent. Thus, for 
these reasons we bel ieve the differences 
must reflect a bio logica l difference in 
the two populati ons, although in our 
study the lack of a true limiting di lution 
analysis in vivo prec luded any numer-
ica l quantification of MMIC in melano-
spheres and adherent melanoma ce ll s, 
hence we cannot assess to w hat extent 
melanospheres are enriched in MMIC 
as compared with adherent melanoma 
ce ll s. 
© 2010 The Society for Invest igat ive Dermatology 
O n the other hand, it is accepted 
that spheres are not composed entirely 
of stem ce ll s, as high I ighted by two 
recent articles expl oring heterogeneity 
in mammospheres and melanospheres 
(Pece et ai. , 2010; Roesch et al., 2010). 
Although we agree with Schatton and 
Frank, w ho advi se caution in consider-
ing sphere format ion as the definitive 
methodology for identifying cancer 
stem ce ll s, these latest papers never-
theless stress the utility of sphere 
cultures to investigate ca ncer stem cell 
biology, including the fa ct that ca ncer 
stem ce ll s may be more dynamical ly 
regulated than hitherto suspected 
(Heddleston et ai, 2009; Vermeu len 
et al., 2010)-and thus not stri ctly adher-
ing to a hierarchica l system. The con-
siderable phenotypic heterogeneity that 
we found in our melanospheres can be 
ascribed to the relatively poor enrichment 
in melanoma stem cells, a view favored 
by Schatton and Frank, though equally 
well heterogeneity may be a refiection of 
MMIC diversity that increases w ith genetic 
instability as tumors progress (Piccirillo 
et ai, 2009; Greaves 2010). 
Rega rding the prospective iso lation 
of ca ncer stem ce ll s from melanoma, a 
confusi ng array of markers have 
been proposed, rangi ng from none at 
all (Quintana et al., 2008) to C0133 
(M onzani et al., 2007), ABCB5 
(Schatton et al. , 2008), C0 27 1 (Boiko 
et al. , 2010), and JARIOl B (Roesch 
et al. , 201 0). The emergence of geneti-
ca lly distinct clones w ith metastatic 
melanoma- in itiating capacity may be 
behind this plethora of markers. 
On the other hand, using the same 
methods (FACS iso lation and sphere 
formation) has lead to the identi fication 
of a population of tumor-initiating ce lls 
expressing C01 33 across a surpri sing 
range of tumor types, including co lo-
recta l ca ncer, Ewi ng's sarcoma, and 
hepatoce llul ar carcinoma (O 'Bri en 
et al., 2009). Thus, although these 
analytical approaches have limitations 
Uensen and Parmar, 2006; Rosen and 
Jordan, 2009; Alexander et al. , 2009), 
they do seem useful for ident ifyi ng 
tumor-initiating ce ll s that are the same 
as ca ncer stem ce ll s. Of note, one of 
our melanospheres, Me15888S, was 
highly enriched in ce ll s express ing two 
ce ll-surface markers found to be asso-
ciated with MMIC, namely C0133 and 
C0271 (M onza ni et al., 2007; Boiko 
et al., 20 10). 
In conclusion, the field of ca ncer 
stem ce lls, especiall y in so lid tumors, is 
sti ll in its infancy. Several methodo-
logica l issues still remain, most notably 
a ca reful assessment of the va lidity and 
limi tations of the vari ous analyt ica l 
approaches. However, as highli ghted 
by the authors of the Commentary, the 
'must' that shou ld always be kept in 
mind when eva luat ing any new data is 
indeed its relevance for patients and 
clinica l transferab ility. 
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